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Abstract 
Infection with HIV results in a chronic infection that progressively impairs the 
immune system.  Although depletion of CD4+ T cells is frequently used to explain the 
deterioration in immune function, the combination of the chronicity of infection and 
progressive loss of CD4+ T cells are not sufficient to fully account for the immune 
dysregulation that occurs during the progression to AIDS. 
Arginase-induced L-arginine deprivation is emerging as a key mechanism for the 
downregulation of immune responses.  In this thesis it is shown that PBMC arginase 
activity increases with disease severity in HIV seropositive patients. PBMC arginase 
activity was found to be associated with both CD4+ T cell count and plasma viral 
load.  However, these associations were not found in the cohort of patients that were 
taking highly active antiretroviral therapy.  HIV seropositive patients with high 
PBMC arginase activity were also found to have decreased levels of CD3! protein by 
western blot, a marker of T cell dysregulation caused by arginase mediated L-arginine 
depletion. 
The arginase1+ cells in the PBMC fraction were identified as CD15+ CD14- 
granulocytes and therefore named low-density granulocytes (LDGs).  The percentage 
of LDGs was found to be associated with PBMC arginase activity.  LDGs were found 
to be phenotypically different from neutrophils that co-purify with erythrocytes after 
density gradient centrifugation (normal density granulocytes – NDGs). LDGs have an 
increased size, increased expression of the activation markers CD63 and CD66b and a 
decreased expression of arginase 1 compared to NDGs.  This suggests that the LDGs 
may be a population of activated neutrophils that have degranulated releasing arginase 
1.  As it has been shown that T cells have an absolute requirement for L-arginine in 
order to proliferate and express CD3! the results presented in this thesis suggest that 
arginase-induced L-arginine deprivation might contribute to T cell dysfunction in HIV 
infection.   
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Layout of thesis: 
The introduction (Chapter I) of this thesis describes the metabolism of L-arginine by 
arginase and the role of arginase mediated L-arginine depletion in immune regulation.  
This thesis focuses on this mechanism of immune regulation in the context of HIV 
infection.   HIV infection is an ideal read-out system for arginase mediated L-arginine 
depletion because: i) it is possible to recruit a cohort of patients at St Mary’s Hospital; 
ii) it is a progressive disease with well validated markers of disease severity with 
which to compare arginase activity to and iii) T cell function decreases with disease 
progression – a phenomenom which I hypothesise that arginase mediated L-arginine 
depletion is contributing to.  The second half of the introduction focuses on HIV 
infection, introducing the structure of the HIV virion, and the epidemiology, clinical 
course and immune dysfunction that occurs in HIV infection.   
Chapter II, Materials and Methods, contains details of protocols and reagents used. 
In Chapter III, the impact of the absence of L-arginine on proliferation and CD3! 
expression is measured in human T cells.  These are important proof of principal 
experiments and establish that human T cells have an absolute requirement for L-
arginine in order to be optimally activated. 
Chapter IV shows that PBMC arginase activity is associated with HIV disease 
progression in anti-retroviral naïve patients.  The data in Chapter IV has been 
published in 2010:  
Cloke, T. E. et al., Increased level of arginase activity correlates with disease 
severity in HIV-seropositive patients. J Infect Dis 202 (3), 374. (Chapter X: 
Publications arising from this thesis, page 268) 
Cloke, T. E. et al., Antiretroviral therapy abrogates association between 
arginase activity and HIV disease severity. Trans R Soc Trop Med Hyg 104 
(11), 746. (Chapter X: Publications arising from this thesis, page 268) 
Finally, in chapter V, the arginase expressing cells in the PBMC fraction of HIV+ 
patients are identified.  These cells are found in the PBMC fraction following density 
gradient centrifugation, so they are called low density granulocytes (LDGs). The 
phenotype of LDGs and neutrophil found in the erythrocyte fraction (called normal 
density granulocytes (NDGs) is compared.  
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Chapter I: Introduction 
 
“…untune that string, And, hark! what discord follows!”    
 
Troilus and Cressida  Act i. Sc. 3, Shakespeare, 1602  
   
 
A functioning immune system is much like a finely tuned instrument.  In the same 
way the pitch of an instrument can become sharp or flat, so too the response of the 
immune system can be excessive or inadequate and the discord that follows can be 
damaging, or even fatal, to the host.  For this reason, regulation of the immune system 
is vital to maintain homeostasis.  Excessive activation of the cellular immune 
response is manifested as immunopathology in the form of allergy, autoimmunity and 
inflammation.  However, excessive downregulation of the cellular immune response 
results in immunodeficiency and increased susceptibility to infection and sepsis. The 
co-evolution of the immune system in the presence of physical and pathological insult 
has meant it has developed mechanisms of immune regulation, which endeavor to 
prevent damage by a response that is excessive or inadequate.  I believe that these 
mechanisms of immune homeostasis are likely to function initially at a local level 
before systemic immune regulation is apparent.   These mechanisms do not always 
benefit the host. The balance between escalation and suppression of the immune 
response can become dysregulated, particularly when acute inflammation fails to clear 
the source of pathology.  This can result in chronic antigenic stimulation as in the case 
of HIV. Here, I propose that counter regulatory mechanisms that would usually 
prevent immune pathology may be aberrantly upregulated and lead to 
immunodeficiency.  In this thesis it is investigated whether one such mechanism of 
immune regulation, arginase mediated L-arginine metabolism, is dysfunctional in 
HIV infection and whether this contributes to the pathology observed.   
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1.1.  L-arginine  
L-arginine was first isolated from lupin seedlings in 1886 (Schulze and Steiger, 1886).  
Since then much progress has been made in understanding the role of this amino acid, 
its metabolism and its impact on the immune response (see figure 1.1).  An overview 
of L-arginine metabolism is shown in figure 1.2.   
 
Under normal physiological conditions, dietary uptake of L-arginine and endogenous 
synthesis (via de novo synthesis from citrulline (Dhanakoti et al., 1990, Castillo et al., 
1996, Wu et al., 2009)) provide sufficient amounts of L-arginine to meet metabolic 
demands.  However, requirements can exceed endogenous supply if metabolic 
demand is increased or production is decreased.  This occurs in infants (Wu et al., 
2004) and growing children or in adults undergoing catabolic or cellular stress  (sepsis 
(Luiking et al., 2004), tissue trauma (Bernard et al., 2001)) or when there is a 
reduction in endogenous synthesis due to dysfunction of the kidneys or small intestine 
(Wakabayashi et al., 1995).  Consequently, L-arginine is classified as a semi-essential 
amino acid (Barbul, 1986, Flynn et al., 2002, Morris, 2004, Morris, 2006).  
 
Serum L-arginine levels in healthy human adults is reported to be between 40-150!M 
L-arginine (Cynober, 2002, Rodriguez and Ochoa, 2008, Schwedhelm et al., 2008).  
This free L-arginine pool is derived from diet, endogenous synthesis and protein 
turnover (Morris, 2006).  
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Figure 1.1: L-arginine timeline
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Figure 1.2:  Overview of L-arginine metabolism 
 
 
 
 
Enzymes that use arginine as substrate are:  
a. arginyl-tRNA synthetase  
b. NO synthases 
c. arginases 
d. arginine:glycine amidinotransferase 
e. arginine decarboxylase 
 
Abbreviations:  
ADMA: asymmetric dimethyl-L-arginine 
SDMA:  symmetric dimethyl-L-arginine 
NMMA: NG-monomethyl-L-arginine 
 
Figure and legend from:  
Morris, S. M., Jr., Recent advances in arginine metabolism: roles and regulation of the 
arginases. Br J Pharmacol 157 (6), 922 (2009) 
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1.1.1.  Dietary L-arginine intake 
The average western diet contains 4.4g/day of L-arginine (King et al., 2008).  Food 
which has a high content of L-arginine includes: seafood; watermelon juice; nuts; 
seeds; algae; meats; rice protein concentrate and soy protein isolate (Wu et al., 2009).  
However, 40% of the ingested L-arginine is degraded by first pass metabolism in the 
small intestines so never enters systemic circulation (Castillo et al., 1993b, Wu, 
1998).  The reliance on sources of L-arginine other than diet is highlighted in the 
fasting state when approximately 85% of free L-arginine comes from protein turnover 
and 15% from de novo synthesis (Wu and Morris, 1998). 
 
1.1.2.  Endogenous synthesis of L-arginine 
The majority of de novo synthesis of L-arginine occurs in a metabolic collaboration 
between the small intestine and kidney (Wu and Morris, 1998, Morris, 2006).  In the 
small intestine, citrulline is synthesised from glutamine, glutamate and proline in the 
mitochondria of enterocytes (Wu et al., 2009) (see figure 1.2).  Citrulline is primarily 
taken up by the kidney, where it is metabolised in a two-step process; first, by 
arginosuccinate synthase and, then, arginosuccinate lysase into L-arginine (Wu and 
Morris, 1998).  The magnitude of endogenous synthesis means, that in a healthy adult, 
L-arginine is not an essential amino acid (Morris, 2006).  
 
1.1.3.  L-arginine transport  
L-arginine needs to be transported from the extracellular milieu into cells in order to 
be metabolised.  By affecting both intracellular and extracellular L-arginine 
concentration, L-arginine transporters may regulate the rate of L-arginine 
metabolising enzymes.    
L-arginine transport involves a combination of y+, b0,+, B0,+, and y+L transporters.  The 
y+ system is mediated by cationic amino acid transport (CAT) proteins. The CAT 
proteins form a subfamily of the solute carrier family 7 (SLC7) that consists of four 
confirmed transport proteins for cationic amino acids: CAT-1, CAT-2A, CAT-2B and 
CAT-3 (Closs et al., 2006).  These CATs have different substrate affinity, pH 
dependency and cellular expression.   
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1.1.3.1.  CAT-1 
CAT-1 is expressed ubiquitously (except in the liver), it is located in the plasma 
membrane and its activity is pH independent (Closs et al., 2006).  
 
1.1.3.2.  CAT-2A 
CAT-2A is expressed in the liver and has a dependence for moderate pH (Closs et al., 
2004).  It is hypothesised that expression of CAT-2A in the liver may limit L-arginine 
absorption and metabolism by arginase (Grillo and Colombatto, 2004).  Its role is 
likely to be the removal of excess amino acids from portal circulation (Closs et al., 
1993).   
 
1.1.3.3.  CAT-2B 
CAT-2B has a higher affinity for L-arginine than CAT-2A (Grillo and Colombatto, 
2004). However, its activity reduces at pH levels lower than 7.5 (Closs et al., 2006).  
CAT-2B is constitutively expressed at low levels and upregulated upon murine 
macrophage activation by cytokines or LPS, alone or in combination (LPS, LPS/IFN%, 
IL-4 or IL-4/IL-10) (Closs et al., 2004, Yeramian et al., 2006).  The expression of 
arginase 1 and iNOS coincides with the expression of CAT2B in murine macrophages 
and this is associated with the concomitant depletion of L-arginine from the 
microenvironment (Kakuda et al., 1999, Rodriguez et al., 2003).  The induction of L-
arginine metabolising enzymes was found to be independent of the expression of 
CAT-2B as CAT-2B deficient mice were still able to upregulate iNOS and arginase 1 
(Yeramian et al., 2006).  
 
1.1.3.4.  CAT-3  
CAT-3 is a high affinity transporter of L-arginine, that is pH independent between pH 
5.5-8 and is widely expressed during embryonic development but seems to be 
confined to the central nervous system of adult mice (Ito and Groudine, 1997, Closs et 
al., 2004).  In humans, it is found:  at high levels in the thymus; at moderate levels in 
the uterus, testis, mammary glands and brain and at low levels in the ovary and 
stomach (Vekony et al., 2001).  The specific function of CAT-3 is not known (Closs 
et al., 2004).  
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There are still several unanswered questions about L-arginine transport. Importantly, 
the L-arginine transporter on human T cells is yet to be identified.  
 
1.1.4.  L-arginine homeostasis  
The regulation of L-arginine homoeostasis depends on: dietary L-arginine intake; 
whole-body protein turnover; L-arginine synthesis and catabolism (see figure 1.2).  
By using stable isotopes, it was possible to show that the rate of endogenous L-
arginine synthesis is independent of L-arginine intake and, therefore, that L-arginine 
homeostasis is achieved largely by modulating L-arginine dietary intake and/or the 
net rate of L-arginine degradation (Castillo et al., 1993a).  This suggests that L-
arginine homeostasis is achieved principally by regulating L-arginine catabolism 
(Morris, 2006). 
 
1.2.  L-arginine metabolism 
L-arginine is catabolised by five sets of enzymes leading to the synthesis of protein, 
ornithine, urea, citrulline, nitric oxide, polyamines, proline, glutamate, creatine and 
agmatine (see figure 1.2 for overview and appendix figure 9.1 for detailed diagram of 
L-arginine metabolism) (Morris, 2009).   
In mammalian cells, the two principal metabolic fates of L-arginine involve the 
enzymes: nitric oxide synthase and arginase (Morris, 2004, Morris, 2006).   
 
1.2.1.  Nitric oxide synthase 
There are three distinct isoforms of the enzyme nitric oxide synthase (NOS) expressed 
in mammals (Alderton et al., 2001). The isoforms are:  
o NOS1, also know as neuronal NOS (nNOS) as it is constitutively expressed in 
neuronal tissue (Bredt et al., 1991) 
o NOS2, also known as inducible NOS (iNOS) as it is induced in multiple cell 
types including vascular endothelium, dendritic cells and macrophages (Xie et 
al., 1992) 
o NOS3, also known as endothelial NOS (eNOS) as it is constitutively 
expressed in endothelial cells (Lamas et al., 1992)  
NOS1 and NOS3 are both Ca2+-calmodulin dependent and are constitutively 
expressed at low levels.  In contrast, iNOS is an inducible enzyme and its induction is 
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not dependent on the elevation of intracellular Ca2+, however, when it is expressed, it 
produces a high output of nitric oxide (Xie et al., 1992, Alderton et al., 2001).  
The metabolism of L-arginine by NOS is a two-step process consisting of two 
sequential mono-oxygenase reactions.  One molecule of L-arginine is oxidised at the 
guanidino nitrogen to produce N!-hydroxy-L-arginine (NOHA) intermediate. NOHA 
acts as an endogenous inhibitor of arginase (Grillo and Colombatto, 2004, Morris, 
2004). 
NOHA is further oxidized to yield one molecule of nitric oxide (NO) and L-citrulline 
(see figure 1.3).    
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Figure 1.3: The products of L-arginine metabolism by arginase 1 and inducible 
nitric oxide synthase 
 
 
Abbreviations: 
NOHA  N! -hydroxy-L-arginine  
OAT  ornithine aminotransferase 
ODC  ornithine decarboxylase  
RNOS  reactive nitrogen-oxide species. 
 
Figure from: 
Bronte, Vincenzo and Zanovello, Paola, Regulation of immune responses by L-
arginine metabolism. Nat Rev Immunol 5 (8), 641 (2005).  
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1.2.1.1.  Nitric oxide (NO)  
Nitric oxide is a colourless radical gas that is soluble in lipids and water (MacMicking 
et al., 1997).  In the absence of oxygen it is very stable (Moncada and Higgs, 1993).  
In water it reacts with oxygen to yield: (i) other radicals (e.g. NO2); (ii) moderately 
stable anions (NO2-); (iii) very stable anions (NO3-); (iv) unstable higher 
oxides (e.g. N2O3) and (v) unstable peroxides (e.g. ONOO&) (MacMicking et al., 
1997).  In plasma NO is oxidised to nitrite however in whole blood this is rapidly 
converted to nitrate (Moncada and Higgs, 1993). 
 
1.2.1.1.1.  Functions of nitric oxide 
The known functions of nitric oxide are ever growing.  These include: vasodilatation; 
neurotransmission and immune responses.   
 
1.2.1.1.1.1.  Vasodilatation 
NO is involved in regulating blood vessel tone and consequently blood pressure due 
to its activity as a vasodilator (Furchgott and Zawadzki, 1980, Palmer et al., 1988). 
NO, generated by eNOS in endothelial cells, diffuses into the smooth muscle cells 
where it causes relaxation and consequently vasodilatation (Waldman and Murad, 
1988).  
 
1.2.1.1.1.2.  The nervous system 
The L-arginine-nitric oxide pathway exists in the central nervous system where it has 
been detected in varying amounts in all parts of the brain (Moncada and Higgs, 1993).  
It is a mediator of glutamate induced neuronal activity (Garthwaite, 1991).   Nitric 
oxide is also found in the peripheral nervous system where it is thought to contribute 
to sensory transmission and be a neurotransmitter or modulator of nonadrenergic and 
noncholinergic nerves (Rand, 1992, Moncada and Higgs, 1993).  It is thought that NO 
delivered by these nerves may contribute to regulating gastrointestinal (GI) tract tone, 
tracheal tone and vascular tone (Moncada and Higgs, 1993).  
 
1.2.1.1.1.3.  Role of nitric oxide in the immune response  
Nitric oxide plays an important and multifaceted role in the immune response.  It can 
have both protective and toxic effects and contribute to both the control and 
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pathogenesis of infectious diseases, tumours, autoimmune processes and chronic 
degenerative diseases (Bogdan, 2001).  
 
1.2.1.1.1.3.1.  Cytostatic, cytotoxic and antimicrobial roles of NO  
NO has been shown to bind to iron-sulphur centres, zinc fingers and haem groups of 
key enzymes within the respiratory cycle and in the synthesis of DNA causing their 
inactivation (Moncada and Higgs, 1993, Bogdan, 2001).  Aditionally, it can cause: 
mutation of DNA; inhibition of DNA repair and synthesis; inhibition of protein 
synthesis; alteration of S-nitrosylation, ADP-ribosome or tyrosine nitration; and 
peroxidation of membrane lipids (Bogdan, 2001).   These are the principal direct 
mechanisms by which NO causes cytotoxicity of infected or tumour cells and 
pathogens.  In addition, when NO reacts with reactive oxygen intermediates, it forms 
peroxynitrite (ONOO-), which then decomposes to become an extremely potent 
oxidizing agent that has antimicrobial properties (Bogdan, 2001).  Furthermore, NOS 
may have an indirect effect on pathogen survival by utilising L-arginine: it prevents 
pathogens being able to use L-arginine via arginase to generate polyamines which are 
required for their proliferation (Bogdan, 2001).  
However, iNOS expression is not always beneficial to the host as the same 
mechanisms operating to kill pathogens and infected cells cause cytotoxicity and 
tissue damage to healthy tissue.  
 
1.2.1.1.1.3.2.  Effect of NO on T cells 
It has been shown that NO can regulate T cell signalling and proliferation (Macphail 
et al., 2003). NO-mediated T cell suppression occurs as it interacts with the IL-2 
signalling, which is required for T cell activation (Bronte and Zanovello, 2005).   NO 
blocks the phosphorylation of signal transduction molecules that are downstream of 
the IL-2R and affects the stability of IL-2 mRNA and its release from activated 
lymphocytes (Bronte and Zanovello, 2005).   
When arginase is active within the cell, there is a reduction in the level of L-arginine.  
When there are low levels of L-arginine, iNOS activity favours the generation of 
superoxide (O2-) ions (Xia et al., 1996, Bronte et al., 2003).  The superoxide ions react 
with NO and water to generate peroxynitrites (ONOO–) and hydrogen peroxide 
(H2O2) (Bronte and Zanovello, 2005).   These reactive nitrogen and oxygen 
intermediates induce T cell dysfunction and apoptosis (Bronte and Zanovello, 2005). 
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1.2.2.  Arginase 
Arginase is a binuclear manganese metalloenzyme that catalyses the hydrolytic 
cleavage of the guanidine group from the end of L-arginine, creating ornithine and 
urea (Kossel and Dakin, 1904, Kim et al., 2002, Das et al., 2010).  There are two 
isoenzymes of mammalian arginase: they are designated arginase I and II.  Although 
they catalyse the same biochemical reaction, they differ in cellular expression, 
regulation and subcellular location (Jenkinson et al., 1996).   
Arginase I is a 37 kDa, 322-amino acid, trimeric, cytosolic protein that is 
predominantly expressed in periportal hepatocytes as one of the enzymes of the urea 
cycle.  As the final enzyme of the hepatic urea/ornithine cycle, arginase 1 is required 
for the detoxification of waste nitrogen.  The urea cycle is essential for the conversion 
of highly toxic ammonium ions to urea (Jenkinson et al., 1996).  A deficiency of any 
of the urea cycle enzymes, except arginase, presents in neonates with 
hyperammonemia causing encephalopathy, coma and death (Brusillow and Horwich, 
1995).  However, deficiency of arginase I leads to a milder clinical picture as patients 
have near-normal blood urea levels (Jenkinson et al., 1996, Iyer et al., 1998). 
Arginase 1 deficiency usually presents in the second year of life with progressive 
dementia and spasticity, short stature, with episodes of irritability, vomiting and 
lethargy (Iyer et al., 1998).  Arginase 1 deficiency is rarely fatal (Iyer et al., 1998) 
because it is partially compensated by elevated arginase II in the kidney (Spector et 
al., 1983, Grody et al., 1989, Wu and Morris, 1998).   
Arginase activity has been found in numerous organs and tissues where there is no 
functioning urea cycle (Cederbaum et al., 2004).  Due to this, the possibility of two 
arginase isoenzymes was suggested (Glass and Knox, 1973, Kaysen and Strecker, 
1973).  Arginase II is a 36kDa, trimeric, mitochondrial protein that is expressed in 
virtually all extrahepatic cells (including neuronal, renal, vascular and muscle cells) 
(Wu et al., 2009, Das et al., 2010).  
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1.2.2.1.  Expression of arginase in cells of the immune system  
Arginase is inducible in murine macrophages and other murine myeloid cells 
including dendritic cells (Munder et al., 1999, Mayer et al., 2008, Liu et al., 2009b) 
and granulocytes (Munder et al., 2005). 
In humans, monocytes, monocyte derived macrophages and dendritic cells do not 
express arginase activity when in a resting state or when stimulated with Th2 
cytokines (Munder et al., 2005).  However, arginase I is constitutively expressed in 
polymorphonuclear granulocytes (Munder et al., 2005).  In contrast to murine myeloid 
cells, treatment of human PMN with pro- or anti-inflammatory stimuli does not 
modulate arginase activity (Munder et al., 2005). 
In certain pathologies, particularly cancer, immature myeloid cells that express 
arginase and suppress T cell function have been described and named myeloid derived 
suppressor cells (MDSCs).  Furthermore, L-arginine metabolising tumour associated 
macrophages (TAMs) are found in the tumour microenvironment.  These cells will be 
described in more detail in section 1.2.6.2.2.  
 
1.2.2.2.  Products of L-arginine metabolism by arginase 
When L-arginine is metabolised by arginase it forms ornithine and urea.  Ornithine 
can be further metabolised by: i) ornithine decarboxylase (ODC) to form the 
polyamines putrescine, spermidine and spermine or ii) ornithine aminotransferase 
(OAT) to form L-proline (see figure 1.3).  As ODC and OAT are located in different 
subcellular compartments (the cytosol and mitochondria, respectively), ornithine 
produced by cytosolic arginase I or mitochondrial arginase II probably have differing 
metabolic fates (Wu and Morris, 1998).   
 
1.2.2.2.1.  Polyamines 
Polyamines have a variety of functions including modulation of gene expression, cell 
signalling, proliferation and differentiation (Pegg, 1986, Igarashi and Kashiwagi, 
2000). Polyamines are positively charged molecules which means they function by 
binding to negatively charged molecules including RNA, DNA, nucleotide 
triphosphate, and proteins (Flynn et al., 2002).  This gives them a plethora of 
functions including regulation of gene expression, signal transduction, ion channel 
formation, DNA and protein synthesis, apoptosis and N-methyl-D-asparate (NMDA) 
receptor activity (Igarashi and Kashiwagi, 2000).  After stimulation with growth 
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hormone, polyamines are produced and induce DNA replication and protein synthesis, 
showing their importance in the process of cell proliferation (Flynn et al., 2002). In 
addition, polyamines are antioxidants and so help to protect cells against oxidant 
damage (Igarashi and Kashiwagi, 2000). 
 
1.2.2.2.2.  Proline  
Proline is an important precursor in the synthesis of collagen (Albina et al., 1990) 
therefore is important in wound healing and fibrosis (Bansal and Ochoa, 2003). 
 
1.2.3.  Regulation of iNOS and arginase in myeloid cells  
The regulation of L-arginine metabolising enzymes in myeloid cells has mainly been 
described in murine studies.  Much less is known about their induction and regulation 
in human cells. 
In murine myeloid cells L-arginine metabolism is regulated by many factors 
including: cytokines; endotoxins; hormones (glucocorticoids, growth hormone and 
leptin); dietary components (lysine, manganese, n-3 fatty acids) and endogenously 
generated substances (creatine, lactate, ornithine and methylarginine) (Wu et al., 
2009).  These are shown in figure 1.4. 
 
1.2.3.1.  Cytokines and endotoxin 
The induction of iNOS or arginase I in murine macrophages has been used as an 
important parameter for discriminating between classically activated or alternatively 
activated macrophages (Gordon, 2003, Gordon and Martinez, 2010). The expression 
of iNOS and arginase I in murine macrophages is regulated by T cell cytokines.  
When macrophages are exposed to the Th1 cytokine, IFN-%, in the presence of TNF# 
iNOS is induced (Nathan and Xie, 1994, Mosser and Edwards, 2008).  Alternatively, 
when murine macrophages are exposed to Th2 cytokines IL-4 or IL-13, arginase is 
induced (Corraliza et al., 1995, Munder et al., 1998, Louis et al., 1999, Munder et al., 
1999, Gordon, 2003, Bronte and Zanovello, 2005).  This dichotomy in macrophage 
differentiation is enhanced by the reciprocal suppression of the L-arginine 
metabolising enzyme induced by Th1 or Th2 cytokines, respectively and the 
downstream products of metabolism (Munder et al., 1998, Bronte and Zanovello, 
2005).   
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There are other factors that upregulate L-arginine metabolising enzymes in murine 
macrophages.  Other than IFN-%, iNOS expression is also upregulated following 
exposure to the cytokines IL-1#, IL-1', IFN-#, IFN-#, IFN-' and LPS (Munder et al., 
1999, Gordon, 2003, Kleinert et al., 2003, Bronte and Zanovello, 2005).   Arginase 
expression as part of alternative activation is further increased when cells are cultured 
in the presence of both IL-4 and IL-10 (Munder et al., 1999).  A similar synergistic 
response occurs when IL-4 and IL-10 are combined with transforming growth factor 
(TGF)' (Boutard et al., 1995, Jost et al., 2003).   
LPS can induce both ARG1 and iNOS (Sonoki et al., 1997, Salimuddin et al., 1999) 
suggesting that in certain circumstances both enzymes can work in the same cellular 
environment (Bronte and Zanovello, 2005).  Indeed it has been suggested that the 
cytokines that induce classically or alternatively activated phenotypes should be 
considered separate to the direct effects of microbial stimuli, like LPS, which induce 
innate macrophage activation, often by signalling through Toll-like receptors (Gordon 
and Martinez, 2010).  In addition, Mosser et al. suggest that macrophages are a very 
heterogeneous population that display functional and phenotypic plasticity depending 
on signals received from the tissue environment (Mosser and Edwards, 2008).  
Together this suggests that murine macrophages may be able to adapt to the signals 
around them and switch between expressing iNOS or arginase I or even both enzymes 
simultaneously and that their level of activation may be determined by their 
recognition of innate danger signals.   
 
1.2.3.2.  Hormones 
Glucocorticoids, such as dexamethasone, have been shown to induce arginase 
expression possibly due to the presence of a transcription response element that is 
sensitive to dexamethasone in the 5’ flanking region of the mouse ARG1 gene 
(Morris, 2002, Flynn et al., 2009).  In addition, glucocorticoids have been shown to 
suppress NOS expression and synthesis of its co-factor tetrahydrobiopterin (BH4) 
thereby reducing nitric oxide production (Shi et al., 2004, Wu et al., 2009).  
 
1.2.3.3.  Dietary components 
Levels of lysine are important as lysine competes with L-arginine for entry to the cells 
because it uses the same cationic amino acid transporters (Wu and Morris, 1998).  
Therefore, high levels of lysine will reduce L-arginine influx into the cell, resulting in 
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low intracellular L-arginine levels. This has been reported to halt translation of iNOS 
therefore reducing its activity (El-Gayar et al., 2003, Lee et al., 2003a).  Low levels of 
intracellular L-arginine could also be due to increased metabolism by arginase, low 
extracellular L-arginine concentration in addition to reduced capacity to transport L-
arginine into the cell.  
 
1.2.3.4.  Endogenously generated substances 
The products of L-arginine metabolism can also alter the metabolic fate of L-arginine 
by interacting with the enzymes and transporters of L-arginine: 
1. Strong proinflammatory signals cause intense macrophage iNOS activity 
leading to the release of NOHA, which inhibits arginase 1 and stimulates 
further release of NO by iNOS (Hecker et al., 1995, Wu and Morris, 1998) 
2. NO also causes S-nitrosylation of the cysteine residue in the active site of 
ornithine decarboxylase which inhibits its function and prevents polyamine 
production (Buga et al., 1998)  
3. Polyamines are inhibitors of iNOS (Blachier et al., 1997) 
 
In addition, factors that interact with L-arginine transport, such as L-ornithine and 
eosinophil-derived cationic proteins (e.g. major basic protein (MBP) and its analogue 
poly L-arginine), reduce L-arginine’s entry into the cell having an effect on iNOS and 
arginase 1 metabolism (Bronte and Zanovello, 2005). 
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Figure 1.4:  Cytokine-dependent and metabolic regulatory circuits that affect the 
inducible enzymes arginase 1 and nitric-oxide synthase 2  
 
 
 
 
 
 
 
Abbreviations: 
ONOO–  peroxynitrite 
STAT    signal transducer and activator of transcription 
 
Figure from:  
Bronte, Vincenzo and Zanovello, Paola, Regulation of immune responses by L-
arginine metabolism. Nat Rev Immunol 5 (8), 641 (2005). 
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1.2.4.  Enzyme kinetics of arginase and inducible nitric oxide synthase 
Arginase and iNOS both compete for the common substrate L-arginine.  The 
Michaelis constant (Km) is the substrate concentration at which the reaction rate 
reaches its half-maximum value. iNOS has a greater affinity for L-arginine as its Km is 
approximately 2-20µM whereas the Km for arginase is in the millimolar range (( 2-
20mM) (Bansal and Ochoa, 2003).  The maximum rate of the reaction (Vmax) occurs at 
the enzyme concentration when all of the enzyme is binding to a substrate. The Vmax 
for arginase (1400 µM/min per mg) is approximately 1000 times greater than that of 
iNOS (1 µM/min per mg) (Bansal and Ochoa, 2003).  Therefore, the rate of substrate 
usage is approximately the same and both enzymes compete for L-arginine (Fligger et 
al., 1999).  
 
1.2.5.  L-arginine Paradox 
L-arginine is the only substrate for NOS and as such affects NO production.  The 
intracellular L-arginine concentration is approximately 1-2 mmol/L in freshly isolated 
endothelial cells, which is much greater than the Km of iNOS at 2-20µmol/L.  
Therefore the enzyme should be saturated and an increase in extracellular L-arginine 
should not have an impact on the rate of NO synthesis.  However, there is a 
dependence on the concentration of extracellular L-arginine in the rate of intracellular 
NO synthesis. This phenomenon constitutes the “L-arginine paradox” (Kurz and 
Harrison, 1997, Lee et al., 2003a). 
Many explanations have been suggested for the L-arginine paradox involving eNOS 
in endothelial cells including: i) the co-localisation of arginine transporters and eNOS 
in membrane-associated caveolae; ii) the intracellular compartmentalisation of L-
arginine; iii) interaction between L-arginine and glutamine; iv) alterations in eNOS 
dimerisation; v) competitive inhibition of eNOS by endogenous inhibitors such as 
asymmetric dimethylarginine; vi) the intracellular location of the enzyme arginase 
leading to local L-arginine deficiency in certain intracellular compartments (Tousoulis 
et al., 2002, Tousoulis et al., 2007).     
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1.2.6.  Role of L-arginine metabolism by arginase in the immune response 
Before the notion of arginase mediated L-arginine depletion causing T cell 
dysfunction was understood, arginase was implicated in regulating the immune 
response in different ways: 
1. By substrate competition; this is limiting NO production and cytotoxicity  
2. By committing L-arginine to the production of ornithine; this enhances proline 
availability for collagen synthesis and fibrosis  
3. By generating polyamines; this enhances cell proliferation.    
 
1.2.6.1.  Arginase mediated L-arginine depletion 
The mechanism by which arginase depletes L-arginine thereby causing T cell 
hyporesponsiveness is a topic of ongoing research.  To date two principal mechanisms 
have been described: 
1. Intracellular L-arginine metabolism: 
o High arginase activity coincides with the transport of extracellular L-
arginine into the cells by CAT2B, thereby causing a reduction in the level 
of L-arginine in the microenvironment (see figure 1.5) 
2. By reducing free L-arginine availability in the extracellular environment: 
o Following activation or cell death, arginase 1 is released from myeloid 
cells into the micro-milieu where it binds L-arginine and thereby reduces 
the level of free L-arginine available to T cells (see figure 1.6) (Munder et 
al., 2005, Munder et al., 2006, Muller et al., 2009). 
 
However, it is not yet clear whether these are the only mechanisms or whether they 
are species specific – indeed there may be a degree of redundancy with more than one 
mechanism occurring simultaneously.   
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Figure 1.5: Diagrammatic representation of intracellular L-arginine uptake and 
metabolism by arginase expressing myeloid cells  
 
 
Figure 1.6: Diagrammatic representation of the role of extracellular arginase in T 
cell hyporesponsiveness  
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The reduction in the bioavailability of L-arginine results in impaired T cell responses 
in both murine and human studies, characterised by reduced CD3! (the main 
signalling molecule of the T cell receptor (TCR)) expression, down-regulation of T 
cell proliferation and cytokine production (Bronte and Zanovello, 2005).  
Rodriguez et al. showed that, in the absence of L-arginine, activated T cells cannot 
upregulate cyclin D3 and cdk4 leading to G0-G1 cell cycle arrest (Rodriguez et al., 
2007).  It was shown that the regulation of cyclin D3 and cdk4 by L-arginine 
starvation occurs at both the transcriptional and post-transcriptional levels (Rodriguez 
et al., 2007).  It was also found that L-arginine starvation triggered signalling through 
the stress kinase, general control non-derepressible-2 (GCN2) (Rodriguez et al., 
2007).  The mechanism by which GCN2 senses L-arginine depletion and causes T cell 
dysfunction will be discussed in section 1.3.3.1.   
 
1.2.6.2.  Role of L-arginine metabolism by arginase in physiological and 
pathological conditions 
Arginase-mediated L-arginine deprivation has been shown to be involved in the 
physiology or pathophysiology of a variety of conditions ranging from cancer, 
infectious disease, pulmonary disease and vascular disease. This is detailed below. 
 
1.2.6.2.1.  Arginase activity as a fungicide 
In human neutrophils, arginase has been shown to have fungicidal properties by 
depleting L-arginine within the phagosome (Munder et al., 2005).  
 
1.2.6.2.2.  Arginase activity in cancer  
In cancer immunology, tumour cells evade the host immune response by inducing 
mechanisms that cause a state of anergy or tolerance allowing malignant cells to 
proliferate and metastasise (Smyth et al., 2001, Rabinovich et al., 2007). Induction of 
T cell anergy by modulating the availability of L-arginine has been proposed as one of 
the main causes of the failure of immune surveillance seen in cancer (Sica and Bronte, 
2007, Rodriguez and Ochoa, 2008). 
Myeloid cells which express arginase I and suppress T cell responses have been called 
myeloid derived suppressor cells (MDSC) (Gabrilovich et al., 2007).  MDSCs have 
been extensively described in mouse and human cancer.  MDSCs are a heterogeneous 
population of myeloid cells that share a: 
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"lack or reduced expression of markers of mature myeloid cells, expression of both 
Gr-1 and CD11b molecules in mice, inability to differentiate into mature myeloid cells 
in the presence of tumour-derived factors, high levels of reactive oxygen species, and 
activation of arginase I" (Gabrilovich et al., 2007) 
 
Tumour-associated macrophages (TAMs) are another population of L-arginine 
metabolising cells found locally at the site of the tumour.  TAMs differentiate from 
circulating blood monocytes and MDSCs that have infiltrated the tumour 
microenvironment (Gabrilovich and Nagaraj, 2009).  TAMs can be distinguished 
from MDSCs as they are F4/80+ Gr1- and unlike MDSCs, at a population level have 
only been found to express arginase1 or iNOS and not both enzymes at the same time 
(Mantovani et al., 2002, Gabrilovich and Nagaraj, 2009). The level of iNOS and 
arginase1 activity is much higher in TAMs than it is in peripheral blood MDSCs 
(Gabrilovich and Nagaraj, 2009). 
 
1.2.6.2.2.1. Myeloid derived suppressor cells in murine cancer 
In mice, MDSCs comprise both monocytic-like cells and low density PMN-like cells 
at different stages of maturation (Movahedi et al., 2008).  This depends on the cancer 
model being investigated; for example, in C26 colon carcinoma there are 
inflammatory monocytic MDSCs (Gallina et al., 2006); in DA-3 mammary carcinoma 
granulocytic MDSCs exist (Ilkovitch and Lopez, 2009) and in the 3LL lung 
carcinoma model, mature granulocytic GR-1-, CD11b+, CD14- are dominant. 
What causes the induction, activation and accumulation of MDSCs is a matter of 
active research.  Gabrilovich et al. suggested that MDSCs are generated from bone 
marrow haematopoietic precursors in response to tumour derived cytokines such as 
GM-CSF, IL-3, and VEGF (Gabrilovich, 2004).  However, mechanisms by which 
MDSCs upregulate arginase I remain unclear.  Recently, murine tumour models have 
shown that tumour cells express high levels of COX-2 resulting in the production of 
prostanoids (especially PGE2) that stimulate arginase I and CAT-2 expression in 
MDSC.  Genetic and pharmacological inhibition of COX-2 prevented upregulation of 
arginase activity (Rodriguez et al., 2005).   
The tumour microenvironment also plays a crucial role in inducing arginase 
expression.  Corzo et al. demonstrated that MDSCs in the periphery only suppressed 
antigen-specific T cell activity, however, locally at the tumour site both antigen 
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specific and non-specific T cell activity were suppressed (Corzo et al., 2010). They 
provided strong evidence to suggest that hypoxia at the tumour site was responsible 
for this phenomenon (Corzo et al., 2010).   The relationship between TAMs and 
MDSCs is unclear, however, it has been shown that both populations of cells suppress 
T cells in an antigen non-specific manner within the tumour and it is reported that 
hypoxia signalling via HIF-1# rapidly induces MDSCs to differentiate into TAMs 
(Corzo et al., 2010).     
 
1.2.6.2.2.2.  Arginase activity in human cancer 
Increased arginase activity has been found in patients with many forms of cancer 
including: prostate (Harris et al., 1983, Keskinege et al., 2001, Gannon et al., 2010); 
breast (Porembska et al., 2003); gallbladder (Shukla et al., 2009); colon (Leu and 
Wang, 1992); lung (Suer Gokmen et al., 1999, Rodriguez et al., 2004, Rotondo et al., 
2009); renal cell (Zea et al., 2005, Rodriguez et al., 2009); stomach (Wu et al., 1987, 
Wu et al., 1996) and skin (Gokmen et al., 2001).  In addition, arginase activity has 
been shown to be associated with disease severity in certain cancers (Harris et al., 
1983, Pretlow et al., 1985, Leu and Wang, 1992, Shukla et al., 2009).   Increased 
arginase activity, as well as low levels of L-arginine and high levels of ornithine, have 
also been associated with reduced T cell function (Rodriguez et al., 2004, Zea et al., 
2005).   
MDSCs in human cancer have a heterogeneous phenotype expressing CD11b and 
CD33 with low or undetectable expression of HLA-DR (Greten et al., 2011).  There 
have been attempts to divide them into monocytic CD14+ or granulocytic CD15+ 
subsets (Greten et al., 2011).  However, it is too early to know if all MDSCs will fall 
into these categories or whether they will be of any functional significance.   In renal 
cell carcinoma, arginase producing MDSCs were identified as activated granulocytes 
(Zea et al., 2005, Rodriguez et al., 2009).  
What causes an induction and/or activation of MDSCs in humans remains largely an 
unanswered question.  Recently, a role for IL-8 has been suggested in non-small cell 
lung carcinoma (NSCLC). IL-8 is found to be expressed by cells from patients with 
NSCLC and shown to induce the exocytosis of arginase 1 from PMNs (Rotondo et al., 
2009).  
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1.2.6.2.3.  Role of arginase in Trauma 
It has been found that, after trauma, there is immune dysfunction, as shown by:  
1. A reduction in the expression of T cell CD3! (Ichihara et al., 1999).  
2. A decrease in T cell proliferation in response to mitogens coupled with a 
decreased production of IL-2 and IFN-% and an increased production of IL-4, 
IL-10 and TGF-' (Miller-Graziano et al., 1991, Decker et al., 1996, Ochoa et 
al., 2001).   
Trauma led to an increase in arginase expression and activity compared to control 
subjects and a decrease in the level of plasma L-arginine (Ochoa et al., 2001).  
Interestingly, arginase activity was associated with the severity and outcome of the 
trauma as measured by: the Champion Trauma score; the Glasgow Coma scale; length 
of stay in an intensive care unit and serum lactic acid levels (Ochoa et al., 2001).   
Recently, the arginase producing cells within the PBMC fraction in trauma patients 
were identified as a subset of activated granulocytes (Bryk et al., 2010).  They are 
CD16+ granulocytes which expressed the markers of activation CD11b and CD66b 
(Bryk et al., 2010).  In addition, morphologically, these hypodense neutrophils are 
more swollen and degranulated than non-contaminating granulocytes.  
 
1.2.6.2.4.  Arginase activity in pregnancy 
Upregulation of arginase activity occurs physiologically during pregnancy (Kropf et 
al., 2007).  It has been shown that in uncomplicated pregnancies, the placenta has high 
arginase activity that induces a localised down-regulation of T cell functions (Kropf et 
al., 2007).  Although the highest arginase activity is found locally in the placenta, 
arginase activity in PBMCs from peripheral blood was elevated in pregnant women 
compared to age and sex matched controls (Kropf et al., 2007).  In addition, the 
arginase activity of the maternal PBMC returns to normal levels after parturition (I. 
Müller, T. Cloke, P Kropf personal communication). 
 
1.2.6.2.5.  Arginase activity in Leishmania infection   
One of the main immunological characteristics of nonhealing human leishmaniasis is 
the inability of PBMCs to mount an efficient immune response, as shown by their 
impaired capacity to proliferate or produce IFN-% in response to the Leishmania 
antigen in vitro (Petersen et al., 1982, Haldar et al., 1983, Modlin et al., 1985, Barral 
et al., 1986, Sacks et al., 1987, Castes et al., 1988, Pirmez et al., 1993, Bomfim et al., 
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1996).  The mechanisms leading to this suppression are not fully identified however, 
in an experimental model of leishmaniasis, it has been shown that high arginase 
activity, a hallmark of nonhealing leishmaniasis, is associated with a localised 
depletion of L-arginine. This impairs the effector functions of T cells at the site of 
pathology-the footpad lesion (Modolell et al., 2009).  
To determine whether this experimental model translates to human disease, a study 
was undertaken to investigate the role of arginase in human leishmaniasis.  Initial 
results show that PBMC arginase activity is similar in patients with cutaneous 
leishmaniasis and in uninfected controls. However, biopsies from patients with 
cutaneous leishmaniasis have high arginase activity while biopsies from uninfected 
controls do not express arginase.  Furthermore, the levels of arginase activity in the 
PBMCs from patients with visceral leishmaniasis are higher than in cutaneous 
leishmaniasis patients or controls (P Kropf, I Muller, T Abebe, T Cloke personal 
communication). 
These preliminary results suggest that high arginase activity might contribute to T cell 
hyporesponsiveness in patients with leishmaniasis. 
 
1.2.6.2.6.  Role of arginase in mycobacterium tuberculosis (MTB) infection 
In patients with tuberculosis T cell dysfunctions are observed: diminished responses 
to mycobacterial antigens (Toossi, 1986, Kleinhenz and Ellner, 1987) and decreased 
expression of CD3! at the site of mycobacterial infection in the granuloma (Seitzer et 
al., 2001).   The level of PBMC arginase activity was found to be high in patients with 
active pulmonary tuberculosis compared to latently infected patients or uninfected 
controls (Zea et al., 2006).  High PBMC arginase activity was associated with low 
CD3! expression (Zea et al., 2006).   
It can be hypothesised that high arginase activity causes low levels of L-arginine 
leading to dysfunctional T cell response in patients with MTB.  Furthermore, by 
decreasing L-arginine, high arginase activity may lead to decreased NO production by 
macrophages and consequently decreased MTB killing (Chan et al., 1995, Rich et al., 
1997, Ralph et al., 2008).  In addition, low non-toxic levels of NO have been shown 
to drive MTB into a dormant phase of inhibited metabolism. This results in a lack of 
efficacy of anti-TB drugs in the killing of MTB and therefore, a latent TB infection 
(Voskuil et al., 2003, Ralph et al., 2008).   
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1.2.6.2.7.  Role of arginase in asthma 
In 2003 Zimmermann et al. found that there was a marked upregulation in arginase I, 
arginase II and cationic amino acid transporter 2 in two experimental models of 
asthma (Zimmermann et al., 2003).  In addition, bronchoalveolar lavage fluid from 
patients with asthma had an increase in the percentage of arginase expressing cells 
compared to control subjects (Zimmermann et al., 2003).  In a separate study, the 
level of L-arginine was reduced and the arginase activity increased in the serum of 
asthmatic patients experiencing an exacerbation compared to healthy controls (Morris 
et al., 2004).   
There are many theories as to how arginase activity is implicated in the pathogenesis 
of asthma: 
1. By depleting L-arginine, arginase activity: 
a. reduces NO production and consequently bronchodilation leading to 
airway hyperresponsiveness (Meurs et al., 2000).   
b. causes an increase in the production of superoxide by macrophages 
expressing iNOS (Xia et al., 1996) that lead to the formation of 
peroxynitrite.  Peroxynitrite causes inflammation, cellular cytotoxicity 
and enhanced contractility, which are all involved in the pathogenesis 
of asthma (Meurs et al., 2003).   
2. Increased arginase activity causes increased production of L-proline and 
polyamines.   
a. L-proline is often the rate limiting substrate for collagen synthesis, 
which is important in airway remodelling (Zimmermann et al., 2003).   
b. Polyamines cause an increase in cellular proliferation, which may be 
partly responsible for the fibroblast and smooth muscle cell 
hyperplasia seen in chronic asthma (Ito et al., 2002, Meurs et al., 
2003).   
 
1.2.6.2.8.  Role of arginase in hepatitis B virus (HBV) infection  
Patients with HBV have a reduced CD3! expression on CD8+ T cells, both in the 
periphery and in the liver, compared to healthy controls (Das et al., 2008).  The 
expression of CD3! is lower in the liver than in the periphery and it is also associated 
with disease severity as it is associated with viral load, HBeAg status and alanine 
transaminase (ALT) (Das et al., 2008). The level of L-arginine was measured in the 
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serum and it was found that patients with a high level of liver inflammation (ALT > 
100 IU/L) had significantly reduced levels of L-arginine in their serum.  The serum 
arginase activity of two patients was studied longitudinally and it was found that 
arginase activity fluctuated over the course of time, however, it was found that its 
peaks correlated to flares in disease severity, as measured by HBV DNA and ALT 
levels (Das et al., 2008).  This suggests that arginase induced L-arginine depletion 
may contribute to the suppression of CD8+ T cell responses found during disease 
flares.  
 
1.2.6.2.9.  Role of arginase in Helicobacter pylori infection  
Helicobacter pylori infection induces chronic inflammation of the underlying mucosa 
and is a co-factor in the development of three important upper gastrointestinal 
diseases: duodenal or gastric ulcers; gastric cancer; and gastric mucosa-associated 
lymphoid-tissue (MALT) lymphoma (McColl, 2010).  H. pylori produces the enzyme 
arginase that leads to the production of carbon dioxide and alkaline ammonia. This in 
turn allows H. pylori to occupy the hostile acidic niche in the stomach (McColl, 
2010).  In addition, it has been shown that H. pylori arginase activity also affects T 
cell function by depleting L-arginine (Zabaleta et al., 2004).  T cells co-cultured with 
H. pylori sonicate had decreased proliferation and CD3! expression (Zabaleta et al., 
2004). It has also been suggested that H. pylori arginase activity increases its 
resistance to macrophage mediated killing by reducing the L-arginine available for the 
production of toxic NO (Gobert et al., 2001).   
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1.3  Immune regulation by amino acid metabolism  
Amino acid starvation is increasingly recognised as a potent mechanism of 
immunoregulation (Li et al., 2007).  Amino acid deficiency results in activation of the 
integrated stress response (ISR) causing T cell dysfunction. An ISR has been defined 
by Scheu et al. as:  
“a general stress-response program conserved from yeast to mammals, is 
known to modulate protein biosynthesis by integrating various types of stress 
signals, including endoplasmic reticulum stress, amino acid deprivation, 
infection with double-stranded RNA viruses, heme deficiency and oxidative 
stress” (Scheu et al., 2006).   
Immune regulation by amino acid metabolism has been demonstrated for several 
different amino acids particularly L-arginine and L-tryptophan and to a lesser extent 
L-cysteine, L-glutamine and L-histidine (Grohmann and Bronte, 2010).    
 
1.3.1.  L-tryptophan metabolism 
L-tryptophan is metabolised by indoleamine 2,3 dioxygenase (IDO) in the kynurenine 
pathway which is shown in figure 1.7. 
 
IDO is expressed in many different tissue types: 
o it is basally expressed in the gut, lung, epididymis, brain, and thymus 
(Grohmann and Bronte, 2010) 
o it is inducible in APCs, such as DCs, in response to type I (IFN-# and IFN-') 
and type II (IFN-%) IFNs (Grohmann et al., 2003, Mellor and Munn, 2004a).  
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Figure 1.7:  Schematic representation of tryptophan catabolism along the 
kynurenine pathway 
 
 
Indoleamine-2,3-dioxygenase (IDO) induces both tryptophan starvation and 
kynurenine production. L-Trp, L-tryptophan; KYN, L-kynurenine; 3-HK, 3-
hydroxykynurenine; KYNA, kynurenic acid; AA, anthranilic acid; 3-HAA, 3-
hydroxyanthranilic acid; QUIN, quinolinic acid. 
 
Figure and legend from:  
Grohmann, Ursula and Bronte, Vincenzo, Control of immune response by amino acid 
metabolism. Immunological reviews 236 (1), 243 (2010).  
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1.3.1.1.  Immune regulation by IDO mediated L-tryptophan depletion 
IDO metabolism of L-tryptophan has been shown to be a potent mechanism of 
peripheral tolerance due to the fact that it:  
1. Causes L-tryptophan depletion  
2. Generates immunoregulatory kyneurenines  
3. Can generate and increase the number of regulatory T cells  
It has been shown that L-tryptophan depletion induces a state of anergy in mouse 
CD8+ T cells (Munn et al., 2005, Fallarino et al., 2006).  T cell anergy due to L–
tryptophan is dependent on the GCN2 activation – this mechanism will be described 
in section 1.3.3.1. 
The immune suppression generated by IDO activity is not just down to L-tryptophan 
depletion, the kynurenines produced when IDO metabolises L-tryptophan have been 
shown to have immunoregulatory effects such as: selective apoptosis of murine 
thymocytes and Th1 cells in vitro (Grohmann et al., 2003); inhibition of the 
proliferation of T lymphocytes (Terness et al., 2002) and to block NK cell 
proliferation (Frumento et al., 2002) 
Extended activation of IDO leading to both L-tryptophan depletion and generation of 
downstream kynurenines causes naive CD4+ CD25& T cells to become Foxp3+, 
CD25+, CD69&, CTLA-4+ functional IL-10 producing induced regulatory T cells 
(Fallarino et al., 2006, Puccetti and Fallarino, 2008).  
 
1.3.2.  L-cysteine metabolism 
L-cysteine is another amino acid that is required for T cell proliferation (Grohmann 
and Bronte, 2010).  L-cysteine depletion leads to cell-cycle arrest in human T cells 
due to intracellular glutathione reduction and altered redox regulation (Sido et al., 
2000).  T cells are unable to produce L-cysteine and are reliant on uptake from local 
accessory cells (Gmünder et al., 1990, Sido et al., 2000).  This mechanism of 
immunoregulation is important physiologically in the intestinal mucosa.   Lamina 
propria T cell (LP-T) reactivity is regulated by the ability of local macrophages to 
secrete L-cysteine.  Lamina propria macrophages (LP-M) from the normal gut do not 
secrete L-cysteine, resulting in a low glutathione content in LP-T (Sido et al., 2008).  
Consequently, LP-T are not activated by the luminal contents (Sido et al., 2008).  
However, in inflammatory bowel disease LP-M secrete substantial amounts of L-
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cysteine resulting in increased LP-T cell reactivity resulting in tissue inflammation 
(Sido et al., 2008).  
 
1.3.3.  Endogenous mechanisms of immunosuppression caused by amino acid 
depletion 
The endogenous mechanisms that transduce amino acid deficiency into T cell 
dysfunction are an area of active research.  The work produced so far provides 
potential steps in the mechanism, but as yet, the complete pathway is still to be 
defined.  However, it appears that when cells detect amino acid depletion, pathways 
that control the translation of proteins are affected. To date research has focused on 
the GCN2 and mTOR pathways. 
 
1.3.3.1. General Control Non-Derepressible-2 (GCN2) pathway  
L-arginine and L-tryptophan starvation results in GCN2 activation which causes 
disruption in protein translation (Mellor and Munn, 2004a, Munn et al., 2005, 
Rodriguez et al., 2007).  The GCN2 pathway will now be described in the context of 
L-arginine depletion as this is the focus of this thesis; however, the same processes 
are applicable to L-tryptophan depletion.  
The depletion of L-arginine is sensed by T cells due to the accumulation of empty 
uncharged tRNAs (Munn et al., 2005).  This activates GCN2 kinase, which 
phosphorylates the serine residue at position 51 of the #-subunit of eukaryotic 
initiation factor 2# (eIF2#) (Munn et al., 2005).  This results in eIF2# having an 
increased binding affinity to eIF2', preventing eIF2' exchanging GTP for GDP.  
Consequently, the eIF2 complex prevents methionine aminoacyl tRNA accessing the 
ribosome thereby inhibiting translation initiation (Hinnebusch, 1994, Lee et al., 
2003a, Bronte and Zanovello, 2005). This is shown in figure 1.8.
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Figure 1.8: Control of translation by eIF2! 
 
 
Multiple signals can trigger the phosphorylation of eIF2#, including nutrient 
starvation (GCN2), dsRNA (PKN), unfolded proteins (PERK), and oxidative stress 
(HRI). Phospho-eIF2# binds to the IF2' complex, preventing its translocation and 
inhibiting translation. 
 
Figure and legend from:  
Rodriguez, P. C. and Ochoa, A. C., Arginine regulation by myeloid derived 
suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. 
Immunological reviews 222, 180 (2008). 
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1.3.3.1.2.  mRNA stability in the absence of L-arginine; the role of the RNA 
binding protein HuR 
Rodriguez et al. also showed that the absence of L-arginine caused a reduction in 
cyclin D3 mRNA stability (Rodriguez et al., 2007) that was dependent on the RNA-
binding protein HuR (Rodriguez et al., 2010).  HuR binds to response elements in the 
3’-untranslated region of cyclin D3 in in vitro activated T cells, increasing mRNA 
stability (Rodriguez et al., 2010). It was found that in the absence of L-arginine, there 
was a reduction in HuR protein expression as part of a global arrest in the de novo 
protein synthesis that was dependent on the expression of GCN2 (Rodriguez et al., 
2010). Therefore, L-arginine starvation activates GCN2. This directly impairs global 
cell translation and, in particular, impairs cyclin D3 mRNA stability via a reduction in 
HuR production (Rodriguez et al., 2010).  
 
Modification of the GCN2 pathway is not the only mechanism by which amino acid 
starvation causes T cell dysfunction.  It has been shown that GCN2 is not involved in 
the suppression of: i) human NK cell function caused by L-arginine starvation 
(Oberlies et al., 2009) or ii) murine T cell proliferation after depletion of a variety of 
essential amino acids (Cobbold et al., 2009).  In both of these cases it has been 
demonstrated that the depletion of amino acids is having an impact by inhibiting the 
mammalian target of rapamycin (mTOR).  
 
1.3.3.2.  Mammalian target of rapamycin (mTOR) pathway 
mTOR exerts its effects by controlling the initiation step of translation when mRNA 
is recruited to the ribosome.   For translation to proceed, the ribosome must recognise 
the 5) cap structure of the mRNA. This is controlled by the eukaryotic initiation factor 
4F (eIF4F), whose eIF4E subunit binds to the 5) cap (Gingras et al., 1999). The 
assembly of eIF4F is blocked by 4E-binding proteins (4E-BPs) (Pause et al., 1994, 
Lin et al., 1995).  The mTOR complex 1 (mTORC1) controls the initiation of 
translation by phosphorylating 4E-BPs.  The hyperphosphorylation of 4E-BPs causes 
them to dissociate from eIF4E allowing eIF4 to bind to the 5) cap structure of the 
mRNA and translation to commence (see figure 1.9). 
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Figure 1.9:  The role of mTOR in control of cell translation 
 
A. 
 
Mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation of 
4E-BPs releases the 4E-BP from eIF4E, resulting in the recruitment of eIF4G to the 5' 
cap, and thereby allowing translation initiation to proceed. 
 
B. 
 
Rag proteins respond to the presence of amino acids and serve to control the 
subcellular localisation of mTORC1 
 
Figure from:  
Ma, X. M. and Blenis, J., Molecular mechanisms of mTOR-mediated translational 
control. Nat Rev Mol Cell Biol 10 (5), 307 (2009). 
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Amino acid deprivation can turn off the signal pathways controlled by mTOR.  This is 
thought to occur because Rag proteins respond to the presence of amino acids and 
serve to control the subcellular localisation of mTORC1 (Sancak et al., 2008, 
Goberdhan et al., 2009, Ma and Blenis, 2009): 
o In the abence of amino acids mTOR is distributed throughout the cytoplasm 
and is not activated. 
o In the presence of amino acids mTOR localises to the same intracellular 
compartment that contains RHEB, which is required for mTOR activation  
However, it is currently unknown how amino acids regulate the GTPase activity and 
cellular distribution of the Rag proteins. 
Studies on mice have demonstrated that inhibition of mTOR activity suppresses the 
induction of cyclin A and the activation of Cdk1 and Cdk2 which causes a G1-S cell 
cycle arrest in antigen-stimulated T cells (Song et al., 2007).  
It has been shown that inhibition of mTOR signalling via amino acid depletion 
induces de novo expression of FOXP3 in the presence of TGF-' in mouse T cells 
(Cobbold et al., 2009).  Therefore, induction of Tregs does not just occur in the absence 
of L-tryptophan but can also occur in the absence of other amino acids, including L-
arginine, via inhibition of mTOR (Cobbold et al., 2009).  This suggests that the 
concept of ‘infectious tolerance’ outlined with respect to L-tryptophan depletion and 
GCN2 signalling might be a common feature of amino acid depletion.  
 
Therefore, it is likely that amino acid starvation signals through both GCN2 and 
mTOR with a degree of functional redundancy. However, it could also be that the 
different pathways have different effects due to: 
1. Downstream metabolites i.e. L-ornithine and polyamines and kynurenines; 
2. The cell type affected; 
3. The environment in which amino acid depletion occurs. 
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1.4  The challenge viruses pose to the immune response  
Viruses are obligate intracellular pathogens. This means that they do not possess the 
machinery required to replicate and are dependent on infecting a host cell for survival 
and transmission.   Once viruses have gained entry into a host cell they compete for 
cellular resources, hijack cellular machinery and may cause cellular damage. By 
mediating cellular damage and destruction, viruses cause pathology and by 
stimulating host immune responses, viruses can trigger excessive immune responses 
leading to immunopathology. As a result, it is not in the interest of the infected cell to 
be a host for the virus, however, viruses have an absolute requirement on host cells to 
survive and replicate.  This divergence in requirements for survival and replication for 
both host and virus governs host-virus interaction dynamics, which ultimately 
determines if a viral infection is cleared or persists.  Due to their co-evolution, viruses 
and their hosts have both exerted a selection pressure upon each other.  This has led 
viruses to develop a multitude of evasion strategies to subvert the host’s immune 
response.  However, the host has adapted to counteract the pathology caused by the 
virus and to co-ordinate a targeted immune response against the virus in an attempt to 
block viral entry and to suppress viral replication and damage.                                                                                                                                                                                                                                                                                                                    
As Polly Matzinger proposed in the danger model, immune responses are initiated 
because of the perceived presence of danger by the host (Matzinger, 1994).  Viruses 
contain pathogen associated molecular patterns (PAMPS), which are detected by toll 
like receptors and other pathogen recognition receptors (PRRs) (Kanneganti, Kawai 
and Akira, 2006).  This triggers an innate immune response mediated by: natural 
killer cells; macrophages; dendritic cells and neutrophils, which are rapidly recruited 
to the site of infection. Here, they engage in cytolysis of infected cells, secretion of 
proinflammatory and anti-viral mediators, such as type I interferons, and phagocytosis 
of virus particles (Kershaw et al., 2005).  Viral control also occurs through 
intracellular anti-viral restriction factors such as the proteins from the APOBEC 
(Apolipoprotein B mRNA-editing, catalytic polypeptide) and TRIM (tripartite motif) 
families (Harris and Liddament, 2004, Ozato et al., 2008).  Professional antigen 
presenting cells (dendritic cells and macrophages) take up virus particles and present 
antigenic peptides in the context of MHC class II molecules to cells of the adaptive 
immune response in lymphoid tissue (Zinkernagel and Doherty, 1974).  This provides 
the link between the innate and adaptive immune response.  Virus specific T and B 
cells are activated, proliferate and are recruited to the site of infection.  CD4+ T cells 
 65 
provide help for the generation of neutralising antibodies and cytotoxic CD8+ T cells, 
which attempt to clear free virus and infected cells (Kershaw et al., 2005).  
This description of an immune response to a viral infection is an overview. It is 
apparent that the innate and adaptive immune responses occur simultaneously and 
there is cross talk between them which shapes the overall immune response.  
However, the question of why some individual’s immune response controls viral 
infections and others cannot remains unanswered.  Especially in the setting of chronic 
viral infection, like HIV, the cause of immune dysfunction needs to be studied. 
 
1.5.  Introduction to HIV 
In the late 1970s and early 1980s a new disease, that was characterised by 
immunological dysfunction, was found in men who have sex with men in both the 
United States of America and in Europe (Centers for Disease Control, 1981c, Centers 
for Disease Control, 1981b, Centers for Disease Control, 1981a, Gottlieb et al., 1981). 
It emerged that this immunological deficiency was also present in other groups 
including: patients with haemophilia; blood transfusion recipients; Haitian 
immigrants; sexual partners or children of these groups and injecting drug users (Chin 
and Mann, 1989, Knipe et al., 2007).  A marked depletion of the CD4+ T cell subset in 
the peripheral blood was a universal finding in affected individuals (Knipe et al., 
2007). The disease was associated with opportunistic infections such as Pneumocystis 
jiroveci (formerly P. carinii) pneumonia, cytomegalovirus-associated retinitis, 
cryptococcal meningitis, and a number of unusual cancers e.g. Kaposi Sarcoma 
(Knipe et al., 2007).  In 1981, the Center for Disease Control (CDC) described this 
syndrome of a CD4+ T cell count below 200 cells/µL and the presence of a CDC 
category C infection and called it the Acquired Immunodeficiency Syndrome (AIDS) 
(Centers for Disease Control, 1981c, Centers for Disease Control, 1981b, Centers for 
Disease Control, 1981a).  The epidemiological pattern of the populations affected 
suggested that the disease was transmitted through blood or sexual intercourse (Knipe 
et al., 2007). 
 
In 1983 the aetiological agent was identified as human immunodeficiency virus type 1 
called LAV in France and HTLV-III in USA (Barré-Sinoussi et al., 1983, Broder and 
Gallo, 1984, Gallo et al., 1984).  In 1986 a related human retrovirus called HIV-2 was 
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discovered (Clavel et al., 1986).  HIV-1 and HIV-2 are complex cytopathic 
retroviruses belonging to the genus Lentivirus. 
 
1.5.1.  HIV/AIDS epidemiology  
Since the initial description of AIDS in 1981, it is estimated that 60 million people 
have become infected and more than 30 million people have died (UNAIDS, 2010) 
making HIV responsible for one of the worst pandemics in human history.  With more 
than 7000 new infections and 4900 deaths each day in 2009, the pandemic is still very 
active (UNAIDS, 2010). Since 2000, the global percentage of people living with HIV 
has stabilised, but at an unacceptably high level (UNAIDS, 2010).  However, the 
overall number of people living with HIV has increased due to incident infections and 
a reduction in mortality resulting from an increase in the availability of antiretroviral 
therapy.  
At the last survey in 2009, UNAIDS estimated that globally there are 33.3 million 
people living with HIV (see figure 1.10A) with 2.6 million new infections in 2009 
(UNAIDS, 2010).   Despite being once thought of as a disease of homosexual men, 
globally women make up half of all infections (UNAIDS/ WHO).  Sub-Saharan 
Africa is the world’s most heavily infected region, home to 68% of all people living 
with HIV and where the prevalence rate is, in parts, as high as 25.9% (UNAIDS, 
2010) (see figure 1.10B).  The rates of new HIV infection vary depending on the 
region of the world. In Sub-Saharan Africa the rate has stabilised or is decreasing, 
however, there are parts of Eastern Europe and Central Asia where the rates of new 
infection have increased by over 25% between 2001-2009 (UNAIDS, 2010).  
With increased survival, it is important to consider the morbidity caused by 
HIV/AIDS. This can be defined in terms of disability adjusted life years (DALY).  
The DALY represents a weighted measure of deaths and morbidity and more 
accurately reflects the true socio-economic and health impact of a given disease.  
HIV/AIDS accounted for 58.5 million disability adjusted life years  (3.8% of total 
DALY lost) at the last estimate in 2004 (WHO).  
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Figure 1.10:  Global burden of HIV infection  
 
A.  Adults and children estimated to be living with HIV in 2009 
 
Source: UNAIDS 
 
B.  Global prevalence of HIV infection in 2009  
 
Source: UNAIDS 
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1.5.2.  Human immunodeficiency virus  
Retroviruses are a class of enveloped RNA virus that are distinguished by their 
requirement for reverse transcription of their RNA genome by a viral reverse 
transcriptase enzyme to form a cDNA intermediate, which is then integrated into the 
host chromosomal DNA.  Lentiviruses are a subset of retrovirus - distinguished by the 
presence of numerous accessory proteins (Harris and Liddament, 2004).   
 
1.5.2.1.  Genomic organisation of HIV 
The HIV genome consists of two strands of +RNA.  The HIV genome is 9.7-kb long 
and contains nine open reading frames, which encode: (See figure 1.11A) 
1) Group-specific antigen (Gag) polyprotein that is processed into matrix (MA), 
capsid (CA), nucleocapsid (NC) and p7, which make up the inner core of the 
viral particle; 
2) Envelope protein (Env) that encodes gp120 surface envelope protein (SU) and 
gp41 transmembrane envelope protein (TM), which form the outer membrane 
proteins of the virus; 
3) Polymerase (Pol) polyprotein that encodes viral enzymes protease (PR), 
reverse transcriptase (RT) and integrase (IN), which are encapsulated in the 
core of the inner particle; 
4) Four accessory proteins (Nef, Vif, Vpr and Vpu);  
5) Two regulatory proteins (Tat and Rev).  
 
1.5.2.2.  The HIV virion 
The HIV virion is 100-120nm in diameter (Knipe et al., 2007). It contains a cone-
shaped, cylindrical core or nucleoid in which the two strands of  positive RNA are 
associated with reverse transcriptase (RT) and integrase (INT) molecules.  These 
elements, plus the nucleocapsid protein p9 and the viral protease (PR), are surrounded 
by a capsid made up of p24 protein. The capsid is nestled in a matrix of p17 protein. 
The matrix also contains the accessory proteins Nef, Vpr, Vif, and Vpu. The matrix is 
surrounded by a lipid bilayer envelope containing the viral envelope spike. See figure 
1.11B.  
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Figure 1.11:  The HIV genome and the structure of the HIV virion  
 
A: 
 
 
B: 
 
Abbreviations:  
Rev, regulatory protein; Gag, group-specific antigen; PR, viral enzymes protease; IN, 
integrase; CA, p24 capsid protein; Env, envelope protein; LTR, long terminal repeat; 
MA, p17 matrix protein; NC, p7 nucleocapsid protein; RT, p66/p51 reverse 
transcriptase; SU, gp120 surface envelope protein; TM, gp41 transmembrane 
envelope protein.   
From: Robinson, Harriet L., New hope for an aids vaccine. Nat Rev Immunol 2 (4), 
239 (2002). 
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1.5.2.3.  HIV life cycle  
Like all retroviruses, HIV replicates through a complex life cycle.  A short summary 
of the steps of the cycle is as follows (Knipe et al., 2007, Scherer et al., 2007) (see 
figure 1.12): 
1. Adsorption of cell-free virion to the cell and their interactions with both CD4 
receptor and either CXCR4 or CCR5 co-receptor.   
2. Fusion of virus and cellular membranes  
3. Uncoating of viral genomic RNA dimer  
4. Reverse transcription by virion, reverse transcriptase (RT), occurs within 
subviral particles in the cytoplasm to form cDNA 
5. Formation of pre-integration complex (PIC)  
6. Nuclear import of PIC  
7. Integration of proviral DNA into host chromosomal DNA – mediated by viral 
integrase (IN) 
8. Transcription of early multiply spliced mRNAs by DNA dependent RNA 
polymerase II (pol II).  
9. Translation of early regulatory proteins, Tat and Rev by viral DNA dependent 
RNA polymerase II (pol II).  
10. Nuclear import of Tat and Rev. Tat increases transcription of viral mRNAs.  
11. Rev mediates export of singly spliced and unspliced viral mRNAs.  
12. Translation of viral structural proteins. 
13. Assembly at the plasma membrane of viral genomic RNA, proteins (Envelope, 
gag and gag-pol), and cellular factors including tRNA (Lys3), the obligate 
primer for reverse transcription.  
14. Viral budding to release immature particles from the cell.  
15. Viral maturation – due to proteolysis by virion encoded protease (PR) which 
produces virions containing a condensed core. 
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Figure 1.12:  Life cycle of a HIV 
 
 
Numbers correspond to stages of the HIV replication cycle listed in section 1.5.2.3. 
Small arrowheads = viral entry to integration  
Curved arrows = early replication  
Double-headed arrows = late replication 
 
From: Scherer, L., Rossi, J. J., and Weinberg, M. S., Progress and prospects: RNA-
based therapies for treatment of HIV infection. Gene Ther 14 (14), 1057 (2007). 
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1.5.3.  Natural History of HIV infection 
HIV infection has three clinical stages – acute viraemia, a clinically latent phase of 
variable duration and a symptomatic phase which includes, but is not restricted to, the 
development of AIDS defining illnesses (See figure 1.14).  In the next section each 
phase will be described with relation to the following areas: i) duration of phase; ii) 
clinical features; iii) impact on plasma viral load and iv) adaptive immune response (T 
cells (CD4+ and CD8+) and B cells). 
In the absence of treatment, the period from acute infection to clinical AIDS is very 
variable from as short as a few months (especially in infants) (Markowitz et al., 2005) 
to more than 25 years (Knipe et al., 2007).  Effective anti-HIV treatment, known as 
highly active antiretroviral therapy (HAART), dramatically prolongs this time course.  
Indeed some patients, called long term non-progressors, can be infected and remain 
symptom free with normal CD4+ T cell counts and no evidence of immune deficiency 
even in the absence of anti-HIV medication (Knipe et al., 2007).  The causes of these 
differences are currently incompletely known – it is likely to be multifactorial with 
contributions from both the virus and the host affecting the outcome of the disease 
and the rate of progression. 
 
Figure 1.13:  Diagram showing the natural history of HIV-1 infection 
 
Adapted from:  
Mogensen, T. H., Melchjorsen, J., Larsen, C. S., and Paludan, S. R., Innate immune 
recognition and activation during HIV infection. Retrovirology 7, 54. 
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1.5.3.1.  The acute phase  
Transmission begins by HIV infecting: resting or activated CD4+ T cells; dendritic 
cells (DCs); resident macrophages or mucosal cells lining the rectum, penis, cervix or 
vagina (Haase, 2005).  HIV uses these cells to establish an initial foothold as it can 
replicate within these differentiated cells (Levy, 2007).   Within two days, DCs and 
CD4+ T cells transport the virus to local lymph nodes where naïve T cells become 
infected after they have been activated. 
 
1.5.3.1.1.  Duration  
The duration of the acute phase is variable from approximately 2-4 months.  The end 
of the acute phase is marked by the establishment of the viral set point and the return 
of peripheral CD4+ T cell numbers to near normal levels.     
 
1.5.3.1.2.  Clinical features 
Primary infection has a varied presentation from asymptomatic seroconversion to 
severe illness requiring hospitalisation (Gurunathan, 2009).  Within two to six weeks 
of exposure, 50-70% of individuals experience an infectious mononucleosis type 
illness known as acute retroviral syndrome (ARS) (Kahn and Walker, 1998).  This 
comprises fever, disseminated lymphadenopathy, often with pharyngitis, headache, 
artheralgia, myalgias, anorexia and rash (Kahn and Walker, 1998).  As this clinical 
picture is similar to many febrile illnesses, it often is not diagnosed.    
 
1.5.3.1.3.  Plasma viral load 
Once the infection is established, viral replication and dissemination proceeds at a 
rapid rate.  There are high titres of plasma viraemia (viral loads reaches a peak of 105 
-107 virions/ml blood (Daar et al., 1991, Zhu et al., 1993)), cell-associated virus and 
antigenemia.  The peak in viral load usually occurs 14-28 days post exposure (this can 
range from 5-70 days).  Following this peak, the level of viraemia begins to decrease 
as the HIV-specific adaptive immune response (CTLs and neutralising antibodies) 
attacks virally infected cells and free virus.  Whether the decrease in viral load is due 
to a control by the innate and adaptive immune system or due to a reduction in the 
number of target cells available for viral replication is disputed (Phillips, 1996, Knipe 
et al., 2007).  After approximately 4-6 months following infection, a quasi-steady 
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state or viral set point is reached.  This represents the beginning of the phase of 
clinical latency.   
 
1.5.3.1.4.  Adaptive immune response 
1.5.3.1.4.1.  CD4+ T cells 
CD4+ T cells are the main target of HIV infection due to the presence of receptors that 
HIV uses for entry into the cell. CD4 is required for cell entry (Dalgleish et al., 1984), 
however, alone it is not sufficient. In order for the virus to enter the cell a co-receptor 
is also required (Moore et al., 2004).  The main co-receptors have been identified as 
chemokine receptors, CCR5 and CXCR4 (Alkhatib et al., 1996, Feng et al., 1996).  
CCR5 is nearly always the receptor for the founder virus early in infection (Zhu et al., 
1993, Alkhatib et al., 1996, Feng et al., 1996, Moore et al., 2004).   
CD4+ T cells are not just targets.  They are also required to co-ordinate and to provide 
CD4+ T cell help for the generation of the cellular adaptive immune response 
(cytotoxic T lymphocytes (CTLs)) and humoral adaptive immune response (B cells 
which can produce antibodies).  The maximum function of anti-HIV CTLs depends 
on the presence of HIV specific CD4+ T cells (Day and Walker, 2003).  The 
magnitude of IFN-% response to virus is always much smaller from anti-HIV CD4+ T 
cell population compared to the anti-HIV CD8+ T cell population (Ramduth et al., 
2005).  The breadth of the anti-HIV CD4+ T cell response is also much smaller and is 
predominantly directed against the HIV gag peptide (Ramduth et al., 2005).  In early 
infection there is a strong induction of anti-HIV CD4+ T cells and these provide help 
to generate a strong CTL response, which can proliferate in vitro in response to 
cognate antigen (Lichterfeld et al., 2004).  In chronic infection, this ability is lost and 
has been shown to be recovered by the addition of CD4+ T cells that were removed 
during acute infection (Lichterfeld et al., 2004).  This suggests that HIV infection 
impairs the anti-HIV CD4+ T cell response.  It is yet to be determined whether this is 
due to it preferentially targeting anti-HIV CD4+ T cells (Douek et al., 2002) or 
whether it is because the infection, or the immune response it elicits, causes 
impairment of T cell function.   
The impact of CD4+ T cell depletion in the acute phase needs to be assessed both in 
the peripheral blood and at mucosal site.   
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1.5.3.1.4.1.1.  CD4+ T cells in the peripheral blood  
In a healthy seronegative individual, CD4+ T cell count varies from 500 to 1200 
cells/µL (Lyles, 2000). During the acute phase there is a decrease in CD4+ T cells, 
which corresponds with an increase in plasma viral load.  As HIV-specific adaptive 
immune response escalates, there is an increase in CD4+ T cells in the periphery with 
levels rising to approximately 600-700cells/µL (Lyles, 2000). 
 
1.5.3.1.4.1.2.  CD4+ T cells at mucosal sites 
As the founder virus usually has R5 tropism, CCR5+ CD4+ activated memory T cells 
are targeted early in infection (Anton et al., 2000).  The vast majority of these cells 
are located in mucosal lymphoid tissue of the intestinal, respiratory and reproductive 
tracts.  By comparison there are relatively few of these cells in the peripheral blood 
and lymph nodes (Brenchley et al., 2004b).  Indeed, the GI tract mucosa contains the 
majority of the body’s lymphocytes compared to the peripheral blood, which only 
contains between 2-5% (Mehandru et al., 2004).  At the mucosal sites, particularly the 
GI tract, CD4+ depletion occurs within days after infection regardless of the route of 
infection (Mehandru et al., 2004). It has been speculated that the amount of depletion 
of CD4+ T cells at mucosal site in the acute phase of HIV infection is important in 
determining disease progression (Brenchley et al., 2006, Hel et al., 2006). It is 
difficult to measure the degree of T cell depletion in humans infected with HIV.  Yet, 
in SIV infected rhesus macaques, it has been shown that up to 60% of CD4+ memory 
T cells throughout the organism, including in the blood, lymph nodes and GALT, are 
infected by SIV and that the majority of these cells disappear within 4 days 
(Mattapallil et al., 2005).  Quantitatively, the majority of T cells are lost from the  
mucosal tissue due to the high numbers of T cells which express the chemokine 
receptor CCR5 in mucosal tissue (Mattapallil et al., 2005, Mogensen et al., 2010).  
 
1.5.3.1.4.2.  CD8+ T cell response 
In many viral infections a strong multi-specific CD8+ T cell response is associated 
with viral control while a weak mono-specific response is associated with disease 
progression.  During the acute phase, there is an increase in the number of anti-HIV 
CD8+ T cells constituting the cytotoxic T lymphocyte (CTL) response and a reduction 
in the number of CD4+ T cells due to killing, so there is an inversion in the ratio of 
CD4+ to CD8+ T cells (Koup et al., 1994).  The emergence of a HIV specific CTL 
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response coincides with a reduction in viral load, suggesting these cells are key to the 
anti-HIV arm of the adaptive immune response (Borrow et al., 1994, Koup et al., 
1994).  When CD8+ T cells are depleted prior to infection in animal models of AIDS, 
there is no control in the viraemia and viral load remains high (Schmitz et al., 1999).  
However, the emergence of the CTL response is too late to prevent the establishment 
of infection (Reynolds et al., 2005, Levy, 2007).  
 
1.5.3.1.5.  Humoral immune response 
Seroconversion is defined by the presence of anti-HIV antibodies and usually occurs 
after acute retroviral syndrome (Kahn and Walker, 1998). The window for 
seroconversion has been estimated to be within two months of infection for the 
majority of patients (Busch and Satten, 1997).  Most antibodies generated are against 
virion debris (Poignard et al., 1999), however, neutralising antibodies are also 
produced. Neutralising antibodies prevent the fusion of the viral and cell membranes 
by binding directly to the envelope glycoprotein of free virus or by binding to 
epitopes which are exposed following CD4-gp120 engagement (Burton et al., 2004).  
Neutralising antibodies fail to control the virus because it has a high mutation rate 
leading to antigenic variation in the epitopes recognised and the selection of escape 
mutants (Richman et al., 2003).  The development of a broadly neutralising cross-
reactive antibody is being pursued in HIV vaccine development but has not, as yet, 
been accomplished.  
 
1.5.3.2.  The chronic phase 
Three to six months after primary HIV infection, the CD4+ T cell number returns to 
near normal levels (Levy, 2007).  The HIV-specific adaptive immune response holds 
the viraemia at a manageable level.  Equilibrium is established between viral 
replication and the host immune response. HIV is contained but not eliminated from 
the body causing the viraemia to subside, symptoms to resolve and the infected 
individual enters a period of chronic infection but clinical latency.   
 
1.5.3.2.1.  Duration 
The period of clinical latency varies between individuals: it can range from a few 
months to more than 16 years (in long term non-progressors) (Markowitz et al., 2005, 
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Levy, 2009).  However, it has been shown to last for 10 years in 50% of untreated 
patients (Buchbinder et al., 1994).  
 
1.5.3.2.2.  Clinical features 
The chronic phase is characterised by the absence of symptoms associated with HIV 
infection.  
 
1.5.3.2.3.  Plasma viral load  
The virus set point established at the beginning of clinical latency is highly variable 
from <50 to > 500,000 HIV RNA copies /mL plasma with viral loads in infants in the 
millions (Gurunathan, 2009).  It tends to remain relatively stable during the course of 
the chronic phase –albeit increasing very slowly (Lyles, 2000). One study found that 
it increased at a rate of 0.15% per week (Schacker et al., 1998).  The magnitude of the 
viral set point has been shown to correlate with the rate of CD4+ T cell decline and the 
length of time of progression to AIDS (Mellors et al., 1997, Lyles, 2000, Sterling et 
al., 2001).  
1.5.3.2.4.  Adaptive immune response 
1.5.3.2.4.1.  T cell response 
During the chronic phase there is a gradual loss of CD4+ T cells at an estimated rate 
of 50-100 cells/µL per year (Gurunathan, 2009).  The rate of CD4+ T cell depletion is 
very variable.  The loss of CD4+ T cells results from several mechanisms: i) Viral 
destruction of activated effector memory cells in the mucosal tissue; ii) Increased 
memory T cell turnover; iii) Reduced thymic output due to HIV pathology; iv) Limits 
on the ability for peripheral T cell renewal (Douek et al., 2003).  Due to the key role 
CD4+ T cells play in the immune response there is a loss of immune homeostasis.  
This is manifested in the failure to control pathogens and commensal organisms at the 
mucosal barrier.  This leads to immune activation, which further disrupts the 
organisation and structure in the immune system.  Immune activation eventually leads 
to immune exhaustion, characterised by increased activation induced cell death, and 
reduced regenerative capacity (Haase, 2005, Brenchley et al., 2006, Appay and Sauce, 
2008).   
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The anti-HIV CD8+ T cell immune response continues to attempt to suppress HIV 
replication (Rowland-Jones et al., 1997) however, due to this selection pressure, there 
is increased heterogeneity in the virus population (McDonald et al., 1997).  The 
responses of CD8+ T cells can be evaluated in terms of their breadth and magnitude.  
The character of the anti-HIV CD8+ T cell immune response varies amongst patients.  
Anti-HIV CD8+ T cell responses can be detected to all nine HIV viral peptides.  On 
average, more than a dozen viral peptides are simultaneously targeted (Addo et al., 
2003) and the anti-HIV CD8+ T cells constitutes more than 15% of all circulating 
CD8+ T cells (Betts et al., 2001, Knipe et al., 2007).   However, neither the breadth 
nor the magnitude of the total HIV-1-specific CD8+ T cell responses correlate with 
plasma viral load (Betts et al., 2001, Addo et al., 2003).  A common finding is that a 
strong CTL response to HIV-1 gag protein is associated with a reduced viral load 
(Ramduth et al., 2005, Zuniga et al., 2006).  Which factors affect the potency of the 
CTL response is a key question especially in the design of T cell based vaccines.    
 
Due to the progressive loss of CD4+ T cells, immune function and viral evolution, 
eventually there is a loss of equilibrium between the virus and the immune response 
and this results in the progression to AIDS (Gurunathan, 2009).   
 
1.5.3.2.4.2.  Humoral immune response 
Neutralising antibodies are not thought to play a major role in the chronic phase.  The 
high mutation rate of the HIV means there is an ongoing cycle of new antibodies to 
neutralise escape variants that then mutate again to escape recognition (Knipe et al., 
2007).  The antibodies generated are generally strain specific and not cross-reactive 
and therefore do not function against the escape variant (Knipe et al., 2007).  The role 
of antibodies in the chronic phase is highlighted in animal experiments in which B 
cells were depleted, reducing neutralizing antibody titres  - this did not affect the 
decline of viral load in the acute phase but was associated with increased viral load in 
the post acute phase (Schmitz et al., 2003).  Similar increases in plasma viral load 
occurred when a patient was treated with rituximab for low-grade 
lymphoplasmacytoid lymphoma causing depletion of CD20+ B cells and a decline in 
neutralising antibody titres (Huang et al., 2010).  This suggests that B cell function 
contributes to long-term control of plasma viral load (Huang et al., 2010).   
 
 79 
1.5.3.3.  The AIDS phase 
The onset of AIDS is defined by the Center for Disease Control (CDC) as a CD4+ T 
cell count below 200 cells/µL or the presence of a CDC category C disease.  The 
mean survival time from the diagnosis of AIDS, in the absence of HAART, has been 
estimated to be 3-51 months depending on the AIDS defining illness. (Gail et al., 
1997)  
 
1.5.3.3.1.  Clinical features 
At the end of clinical latency the patient enters a symptomatic period.  Eventually, the 
disruption to the host’s immune system causes the patient to succumb to opportunistic 
infections and certain neoplasia  (Pantaleo et al., 1993).   
 
1.5.3.3.2.  Plasma viral load 
Increase in viral load occurs 2-5 years before the onset of AIDS (Lyles, 2000, 
Gurunathan, 2009) and the rate of increase in viral load per year increases as patients 
approach AIDS (Gurunathan, 2009).  One study estimated the plasma viral load at the 
time of progression to AIDS at 5.2-5.3 log10 copies/µL (Lyles, 2000). 
 
1.5.3.3.3.  Adaptive immune response 
AIDS is characterised by: a decrease in anti-HIV antibody titres and the number of 
anti-HIV CTLs (Levy, 2009); an increasing viral load and destruction of the follicular 
dendritic cell (FDC) network, which releases virus trapped in immune complexes 
(Pantaleo et al., 1993).  The combined loss of CD4+ T cells, follicular dendritic cells 
and lymph node microenvironment causes alterations in cytokine profiles and 
consequently a reduced ability to mount effective adaptive immune responses.  
 
1.5.4.  Antiretroviral therapy  
Since 1996, HIV-1 infection has been treated by a combination of treatments known 
as highly active antiretroviral therapy (HAART).  HAART provides substantial 
benefit to HIV infected individuals by reducing opportunistic infections and 
hospitalisations and by improving quality and duration of life.  HAART usually 
comprises a combination of three drugs, typically either a protease inhibitor or a non-
nucleoside analogue reverse transcriptase inhibitor with two nucleoside analogue 
reverse-transcriptase inhibitors.  HAART fully suppresses viral replication (as 
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measured by the inability to detect viral RNA in plasma with a detection limit of 50 
HIV RNA copies/ml plasma) in >80% of patients. 
Integration of the provirus into the genome of long-lived, quiescent cells that are not 
transcriptionally active and hence do not produce viral proteins or enzymes, is the 
principal reason why neither the immune system nor HAART can eliminate HIV 
infection (Finzi et al., 1999, Knipe et al., 2007).   Therefore, in order to maintain an 
undetectable viral load, patients have to continue HAART for the duration of their 
lives.  Due to the necessity for long-term use, HAART has several drawbacks: 
1. Resistance - antiretroviral therapy selects for viruses with mutations that 
reduce drug sensitivity resulting in treatment failure and necessitating changes 
in treatment regimen in order to maintain efficacy. 
2. Cost - life long HAART is costly to the patient or health care provider.  
3. Side effects - side effects and toxicities of HAART are occasionally life 
threatening. These include disorders of the cardiovascular system, pancreas, 
kidney and liver (Nolan et al., 2005).  Non-life threatening disturbances 
resulting in chronic morbidity are common. 
 
1.5.5.  Predictive markers of HIV disease progression 
 
1.5.5.1.  CD4+ T cell count  
CD4+ T cell count is regarded as a surrogate immunological parameter of the ability 
of the adaptive immune system to fight infection.  CD4+ T helper cells are crucial as 
they secrete cytokines that coordinate the cellular and humoral arms of the adaptive 
immune responses against exogenous antigens (Mosmann and Coffman, 1989).  CD4+ 
T cell help via production of IL-2 and IFN% is particularly important for the 
generation of an efficient anti-HIV CTL response (Levy, 2009).  In addition, some 
CD4+ T cells have been shown to have cytotoxic activity in their own right (Norris et 
al., 2004).  However, CD4+ T cells are also the primary target of HIV infection.  HIV 
preferentially targets activated memory CD4+ T cells (Brenchley et al., 2004a, 
Stebbing et al., 2004) but it has even been shown to integrate into resting naïve CD4+ 
T cells (Siliciano and Siliciano, 2000, Agosto et al., 2007).  The depletion of CD4+ T 
cells severely limits the capacity to mount an HIV-specific immune response, leading 
to disease progression (Chinen and Shearer, 2002, Langford, 2007).  
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In 1988, it was recommended that prophylactic treatment against the AIDS defining 
illness, Pneumocystis jiroveci pneumonia, be commenced at a CD4+ T cell count of 
200 cells/µL (Fischl et al., 1988, Phair et al., 1990).  As the AIDS epidemic grew, 
evidence was amassed that showed that a low CD4+ T cell count (50-100 cells/µL) 
gave an increased risk of Mycobacterium avium intracellulare bacteremia 
(Horsburgh, 1991), toxoplasmosis (Porter and Sande, 1992) and cytomegalovirus 
infection (Masur et al., 1989).  Consequently, CD4+ T cell count was the first 
recognised short-term prognostic indicator for disease progression (Anastos, 1999) 
and for the risk of developing opportunistic infections and HIV related diseases 
(Gurunathan, 2009).  In 1993, the US Centers for Disease Control and Prevention 
expanded its definition of AIDS to include all HIV positive persons with a CD4+ T 
cell count <200cells/μL (Centers for Disease Control, 1992).  
Several large studies have been conducted to investigate the predictive value of CD4+ 
T cell in assessing the risk of the development of AIDS, namely the Multicenter AIDS 
Cohort Study (MACS) and the Concerted Action on Seroconversion to AIDS and 
Death in Europe (CASCADE) cohort study (Collaboration, 2004).  The data from the 
CASCADE cohort was used to study the short-term risk of developing AIDS (Mellors 
et al., 1997, Collaboration, 2004).  They showed that lower CD4+ T cell counts are 
associated with a greater 6-month risk of AIDS, with the greatest risk increase 
occurring as CD4+ T cell counts fall below 200 cells/µL (Collaboration, 2004).  For 
these reasons, the use of CD4+ T cell count in order to determine when to commence 
antiretroviral therapy and as a means of monitoring antiretroviral therapy efficacy is 
well established.   
However, diagnosis of AIDS using the laboratory criteria (CD4+ T cell count < 200 
cell/µL) gives, on average, a date of AIDS diagnosis from time of infection two years 
earlier than CDC clinical criteria (development of an opportunistic infection) alone 
(Gurunathan, 2009).  Furthermore, early in the course of infection, when CD4+ T cell 
count is normal or subnormal, the predictive power of CD4+ T cell count is low. 
(Gurunathan, 2009).  As a result, it is important not to use CD4+ T cell count as the 
only parameter of HIV disease progression.  Instead it should be used in combination 
with plasma viral load and the level of immune activation to guide clinical decision 
making.  
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1.5.5.2.  Plasma viral load  
The plasma viral load is calculated by measuring the level of HIV RNA circulating in 
plasma using quantitative reverse transcriptase polymerase chain reaction (RT-PCR), 
branched DNA, and nucleic acid sequence-based assay (NASBA) techniques.  
The viral load reflects the rate of virus replication and is an independent predictor of 
the risk of disease progression and the rate of CD4+ T cell decline (Saksela et al., 
1994, Mellors et al., 1996).  For these reasons, it is extensively used clinically to 
monitor HIV disease progression.   
Higher viral loads are associated with more rapid decline of CD4+ T cells and so 
assist in the prediction of the rate of CD4 count decline and disease progression 
(Langford, 2007).  This is evident in the CASCADE cohort: the risk of progression to 
AIDS in the next six months increases four-fold between patients with a HIV-RNA of 
3000 copies/mL and those with *300 000 copies/mL (Collaboration, 2004, Langford, 
2007). 
The monitoring of viral load is used to assess the efficacy of anti-HIV therapy. This is 
because plasma levels of HIV-1 RNA markedly decrease after the initiation of 
antiretroviral therapy and are a good indicator of clinical outcome (O'Brien et al., 
1996).  It has been shown that baseline viral load before initiating therapy is a good 
predictor of future virological failure – defined as: 
a. the failure to achieve an undetectable HIV-RNA (<50 copies/mL) after 6 
months on therapy (van Leth et al., 2005). 
or  
b. the failure to achieve an undetectable HIV-RNA (<50 copies/mL) on two 
consecutive samples after a patient has previously had an undetectable HIV-
RNA viral load.  
However, it has been suggested that once the CD4+ T cell count is very low (<50–100 
cells/µL), the risk of disease progression is so high that plasma viral loads add little 
prognostic information (Lepri et al., 1998, Arduino et al., 2001, Langford, 2007). 
 
1.5.5.3.  Immune activation as a marker of HIV disease severity  
Immune activation involves active molecular and cellular processes including cell 
activation, proliferation, cell death and secretion of soluble molecules (Appay and 
Sauce, 2008).  When faced with challenge from a pathogen, activation of the immune 
system is an appropriate response in order to control infection.  HIV causes immune 
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activation as shown by: i) increases in marker of activation and/or apoptosis on CD8+ 
and CD4+ T cells (Giorgi and Detels, 1989, Finkel et al., 1995, Gougeon et al., 1996), 
B cells, NK cells and monocytes (Appay and Sauce, 2008); ii) high levels of pro-
inflammatory cytokines including TNF-#, IL-6, IL-1' (Molina et al., 1989, Weiss et 
al., 1989, Emilie et al., 1990, Lafeuillade et al., 1991); iii) secretion of chemokines 
such as MIP-1#, MIP-', and RANTES (Canque et al., 1996, Cotter et al., 2001) and 
increased levels of the soluble products of immune activation including '2-
microglobulin, neopterin, IL-2 receptor and soluble CD8 (Fahey et al., 1990, Prince et 
al., 1990, Osmond et al., 1991, Appay and Sauce, 2008).   
However, the immune activation in HIV infection fails to assist in controlling the 
virus and instead is found to be a predictor of disease progression.   This was first 
reported by Giorgi et al. after studying the level of immune activation within patients 
enrolled in the Multicentre AIDS Cohort Study (MACS) (Giorgi et al., 1993).  They 
showed that the frequency of CD8+CD38+ T cells was greater in the men who 
developed AIDS and, after adjustment for CD4+ T cell count, it remained a significant 
predictor of the development of AIDS (Giorgi et al., 1993).  In comparison, although 
the level of CD8+ HLA-DR+ T cells is elevated in HIV infection, it was found that it 
increases at seroconversion and then remains high but stable throughout infection 
(Giorgi and Detels, 1989) and as such is not a good predictor of progression to AIDS 
(Giorgi et al., 1993).  It was also shown that CD8+CD38+HLA-DR+ T cells are 
elevated in HIV+ patients and that they are expressed on anti-HIV CTLs (Ho et al., 
1993).  This work was extended in 1996 when it was shown that the mean 
fluorescence intensity of CD38 on CD8+ T cells had a similar prognostic value to the 
percentage of CD8+CD38+ T cells (Liu et al., 1996).  The level of expression of CD38 
on CD8+ T cells was also found to be highly correlated with both viral load and CD4+ 
T cell count (Liu et al., 1998) and found to be more predictive of the development of 
AIDS or progression to death than plasma viral load (Liu et al., 1998).  
 
1.5.5.3.1.  Does immune activation vary over the course of HIV infection? 
The level of immune activation prior to seroconversion has been associated with an 
increased risk of AIDS (Hazenberg et al., 2003).  This study also found that following 
seroconversion, CD38 and HLA-DR were increased on both CD4+ and CD8+ T cells 
and that there was a significant inverse correlation between the CD4+ T cell count and 
the frequency of CD4+HLA-DR+ T cells (Hazenberg et al., 2003).  In addition, at 5 
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years after seroconversion, the expression of HLA-DR on CD4+ T cells and CD38 on 
CD8+ T cells was predictive of the development of AIDS (Hazenberg et al., 2003).    
Deeks et al.  investigated the impact of immune activation in early infection. They 
found that: i) as the viral load increased, the CD38 MFI on both CD4+ and CD8+ T 
cells increased; ii) after this initial increase CD38 MFI stabilised, suggesting the 
establishment of a immune activation set point; iii) in untreated patients, CD38 MFI 
on CD8+ T cells at this set point is a strong independent predictor of CD4+ T cell 
decline; and iv) ART dramatically reduces the level of CD38 MFI on CD8+ T cells 
(Deeks et al., 2004).  This reduction in immune activation after treatment has reduced 
viral load suggests that the viral set point and the immune activation set point have an 
impact on each other (Deeks et al., 2004).  They suggest that immune activation may 
be used to help inform when treatment should be initiated (Deeks et al., 2004).  
In advanced HIV-1 infection, the level of immune activation is particularly elevated 
and the expression of CD38 on CD8+ T cells is associated with shorter survival 
(Giorgi et al., 1999). This was found to be a better predictor of poor prognosis than 
viral load (Giorgi et al., 1999). 
 
1.5.5.3.2.  What is the cause of immune activation?  
Several causal mechanisms of immune activation have been proposed and they can be 
divided into two groups: those mechanisms directly caused by viral replication; or 
those indirectly resulting from HIV due to the pathology caused by the infection but 
not the virions themselves. It is likely that immune activation is down to a 
combination of these mechanisms.  
Immune activation that is directly caused by the virus includes: 
1. Antigenic stimulation by the virus (Betts et al., 2001). 
2. HIV gene products (gp120 and Nef) may stimulate the immune system 
(Rieckmann et al., 1991, Simmons et al., 2001). 
Mechanisms of immune activation that results indirectly from HIV infection include:  
1. Reactivation and suboptimal immune control of persistent viruses (CMV and 
EBV) due to the immune deficiency and the pro-inflammatory environment 
caused by HIV infection (Doisne et al., 2004). 
2. Dysfunctional mucosal barrier of the gut as a result of massive depletion of the 
gut’s CD4+ T cells early in HIV infection (Brenchley et al., 2004b, Mehandru 
et al., 2004).  This allows the translocation of pathogens and microbial 
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products across the gut wall which activate the innate immune system 
resulting in the release of proinflammatory cytokines (TNF-#, IL-6, IL-1') 
which cause T cell activation (Appay and Sauce, 2008) and further impairs the 
gut’s barrier function (Stockmann et al., 2000). 
 
1.5.5.3.3.  How does immune activation cause immune dysfunction?  
This can be addressed at two levels: i) how does immune activation cause immune 
exhaustion or senescence?  ii) what causes the depletion of CD4+ T cells? 
Appay et al. propose a model of HIV pathogenesis due to: i) CD4+ T cell depletion; 
ii) chronic immune activation and iii) HIV accelerated immune senescence.  This is 
shown in figure 1.14.    
 
1.5.5.3.3.1.  How HIV induced immune activation may cause immune 
senescence?  
HIV-1 infection can accelerate immune senescence at two levels:  first, by causing the 
exhaustion of anti-HIV T cell responses (Appay and Sauce, 2008);  second, by 
affecting the immune system’s ability to replace exhausted cells - a result of reduced 
thymic output, dysregulated haematopoiesis and fibrosis of lymphoid organs (Moses 
et al., 1998, Schacker et al., 2002, Appay and Sauce, 2008).  This causes a progressive 
enrichment of poorly functional, differentiated, oligoclonal, senescent antigen–
experienced cells (Appay and Rowland-Jones, 2002).  
 
1.5.5.3.3.2.  What causes depletion of CD4+ T cells? 
The direct cytopathic effect of HIV contributes to the gradual depletion of CD4+ T 
cells (Gandhi et al., 1998).  However, the percentage of CD4+ T cells productively 
infected is very low, estimated to be between 0.01-1% (Brenchley et al., 2004a). 
Therefore, the number of productively infected CD4+ T cells is not sufficient to 
account for the level of CD4+ T cell depletion seen in HIV infection (Chun et al., 
1997, Clark et al., 1999).  It has also been shown that the majority of cells that die in 
vivo are not productively infected with HIV (Finkel et al., 1995).  It is hypothesised 
that, the immune activation seen in HIV infection, accelerates the cycle of T cell 
proliferation, expansion and death and that this increased T cell turnover eventually 
results in the impairment of the immune system’s regenerative capacity, known as 
immune exhaustion (Hazenberg et al., 2000, Deeks et al., 2004).  In virus infected 
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cells, immune activation increases NF+B levels which increase provirus transcription 
and consequently enhance productive infection and increase the rate of virion 
generation which can then infect new cells (Kawakami et al., 1988).  
It has been shown that there is increased proliferation of T cells in HIV infection and 
that these cells then die through activation induced cell death (Gougeon et al., 1996, 
Kovacs et al., 2001).  Immune activation accelerates the recruitment of naïve T cells 
to the pool of rapidly proliferating and dying T cells and, as the replacement of lost 
naïve cells is limited (Hazenberg et al., 2000), this leads to a contraction of the naïve 
lymphocyte repertoire and ensuing immune deficiency (Hazenberg et al., 2003).   
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Figure 1.14: Model of HIV pathogenesis due to immune activation 
 
Causes of immune activation are shown in yellow and the consequences in red 
 
From: Appay, V. and Sauce, D., Immune activation and inflammation in HIV-1 
infection: causes and consequences. J Pathol 214 (2), 231 (2008). 
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1.5.6.  T cell dysfunction in HIV infection 
In HIV seropositive patients functional activities of T cells are impaired. The 
principal abnormality is the progressive quantitative and qualitative impairment of 
CD4+ T helper cells.  A reduction in CD4+ T cell number starts early in infection and 
is caused by: 
• Cytopathicity of HIV-1 (Boasso et al., 2009a) 
• Viral proteins: 
o  gp120 has been shown to: 
! be cytotoxic (Levy, 2007) 
! increase apoptosis (Banda et al., 1992) 
o Tat has been shown to: 
! induce apoptosis in uninfected cells (Li et al., 1995) 
• Immune activation induced apoptosis (Finkel et al., 1995) 
• Altered homing (compartmentalisation)– HIV induced upregulation of CD62L 
causing CD4+ T cell to home to the lymph node and reducing their frequency 
in peripheral circulation (Wong et al., 1997). 
• Reduced cell proliferation: 
o due to upregulation of the inhibitory molecules cytotoxic T 
lymphocyte antigen (CTLA-4) (Kaufmann et al., 2007) and 
programmed death-1 (PD-1) (D'Souza et al., 2007)  
o HIV Tat has been shown to decrease CD4+ T cell proliferative 
responses to antigens (Viscidi et al., 1989) 
o HIV gp120 has been shown to decrease proliferation by inhibiting IL-2 
production and inducing IL-10 production by monocytes  
• Limited de novo cell regeneration from the thymus (Dion et al., 2004) 
• Altered cytokine secretion (Levy, 2007) 
 
Although depletion of CD4+ T cells explains much of the immunosuppression, the 
precise reasons for the onset of immunopathology during HIV infections are not yet 
fully understood (Appay and Sauce, 2008).  
 
Functional activities of T cells can be measured, in part, by the proliferative response 
to specific stimuli.  In HIV infection, T cell proliferative responses are reduced prior 
to reduction in T cell number (Clerici et al., 1989).  The loss of this proliferative 
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response occurs in stages.  First, CD4+ T cells have a diminished ability to respond to 
recall antigens, then to alloantigens and finally to mitogens (lectins).  Patients with a 
reduction in all three responses have a poor prognosis compared to those who have all 
or some immunological functions still intact (Clerici et al., 1989, Shearer and Clerici, 
1991, Levy, 2007).    
 
In addition to the dysregulation of the CD4+ T cell response, there are also 
abnormalities in the CD8+ CTL response.  Despite the increase in frequency of CD8+ 
T cells in HIV infection, the overall anti-HIV response may not be more efficient as 
the effector function is reduced (Levy, 2009).  HIV induced hyper-activation of the 
immune system can cause a reduction in the level of perforin and other cytotoxic 
proteins (Lieberman, 2004) or immune senescence (Levy, 2009).  In addition, 
upregulation of PD-1 on HIV specific CD8+ T cells has been shown to occur and after 
ligation with its ligands (PD-L1/2) blocks CTL function (Day et al., 2006, Levy, 
2009).  Also, the presence of a CTL response can be detrimental as well as beneficial 
especially if they kill autologous uninfected CD4+ T cells and APCs (Zinkernagel and 
Hengartner, 1994).  
 
1.5.6.1.  T cell CD3" expression in HIV infection   
CD3! is the main signal transduction molecule of the T cell receptor (TCR) complex. 
After ligation of the TCR complex, CD3! ITAM motifs are phosphorylated leading to 
the activation of various intracellular signalling cascades that are required for T cell 
activation (Baniyash, 2004).  In HIV infection, dysfunctional TCRs and decreased 
expression of CD3! have been reported (Stefanova et al., 1996, Geertsma et al., 
1999).  This has been suggested as a reason for poor HIV-specific CTL cytotoxicity 
and T cell functional responses (Trimble and Lieberman, 1998, Geertsma et al., 
1999).  Both CD4+ and CD8+ T cells from HIV+ patients have reduced CD3! 
expression (Geertsma et al., 1999).  However, the reduction in CD3! expression is not 
limited to HIV specific T cells as it has been shown that a large fraction of HIV+ 
patients’ CD8+ T cells have downregulated CD3! expression (Trimble and 
Lieberman, 1998, Trimble et al., 2000b). CD3! expression in HIV+ patients is 
associated with disease severity as measured by CD4+ T cell count and plasma viral 
load (Geertsma et al., 1999).  In addition, it was found that CD3! expression increases 
following antiretroviral therapy (Geertsma et al., 1999) and that long term non-
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progressors do not have a reduction in CD3! expression (Stefanova et al., 1996). It 
has been proposed that reduced CD3! expression is not only due to a direct effect of 
the virus as: i) in vitro infection of healthy T cells with HIV does not causes a 
reduction in CD3! expression (Stefanova et al., 1996) and ii) in vitro culture in the 
presence of IL-2 can restore CD8+ T cell HIV-specific cytotoxicity and CD3! 
expression (Trimble and Lieberman, 1998).  This suggests the chronic inflammation 
caused by HIV infection might be responsible for the decrease in CD3! expression 
and T cell dysfunction.  
 
1.5.7.  Counter-regulatory mechanisms induced by HIV infection  
Similar to Newton’s third law of motion – “every action has an equal and opposite 
reaction” – a recurrent theme in immunology is that inflammation frequently elicits a 
counter-regulatory (anti-inflammatory) response (Mellor and Munn, 2004b).  HIV 
causes systemic immune activation, with a reduction in the number of CD4+ T cells. 
Consequently, it also induces mechanisms of immunoregulation that would usually 
exist to dampen down an excessive immune response.   Such mechanisms include the 
upregulation of IDO (Boasso et al., 2007), inhibitory co-signalling pathways (CTLA-
4 and PD-1) (D'Souza et al., 2007, Kaufmann et al., 2007) and regulatory T cells 
(Andersson et al., 2005).  
   
1.5.7.1. Indoleamine-2,3-dioxygenase activity in HIV infection 
Increased IDO activity has been proposed as a cause of immune dysregulation in 
HIV+ patients (Boasso et al., 2007, Levy, 2007).  HIV/SIV infection causes a 
decrease in plasma tryptophan (Werner et al., 1988, Schroecksnadel et al., 2007) and 
increased expression of IDO (Murray, 2003, Boasso et al., 2007) which is reduced in 
the presence of HAART (Boasso et al., 2009b).  IDO expression is increased in 
lymphoid tissue in HIV/SIV infection (Andersson et al., 2005, Boasso et al., 2007).  
In vitro it has been shown that HIV-induced IDO differentially inhibits CD4+ and 
CD8+ T cell responses by arresting the CD4+ T lymphocyte cell cycle at the G1-S 
transition and by reducing CD28 expression on CD8+ T cells (Boasso et al., 2008).   It 
has been show that infectious and reverse transcriptase deficient HIV particles can 
induce IDO in macrophages (Grant, 2000, Grant et al., 2000) and plasmacytoid DCs 
(Boasso et al., 2007, Boasso et al., 2009b).  Interestingly, HIV seems to be more 
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potent than CTLA-4 in inducing IDO in vitro (Boasso et al., 2007).  This offers an 
insight as to how HIV might upregulate IDO.  
 
Increased tryptophan metabolism in the presence of HIV infection is one example of 
how a metabolic pathway might contribute to immunological dysfunction seen in 
HIV. To determine whether HIV utilises another of these homeostatic mechanisms, 
namely arginase induced L-arginine depletion, to the detriment of the cell mediated 
anti-HIV response and to enhance its own survival is the aim of this thesis. 
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1.6.  Hypotheses and Objectives  
 
1.6.1.  Hypotheses  
HIV-associated down-modulation of the CD3! chain in T cells has previously been 
shown to correlate with HIV disease severity (Geertsma et al., 1999, Trimble et al., 
2000b).  Reduced CD3! expression is also considered to be one of the best markers of 
T cell hyporesponsiveness caused by L-arginine deprivation in vitro.  Based on these 
findings it was hypothesised that arginase activity increases with disease severity in 
HIV seropositive patients and impairs T cell responses, thereby contributing to 
immune dysfunction and disease progression.  Thus, depletion of L-arginine might be 
one of the factors that determine when a patient will develop opportunistic infections 
or symptoms relating to immune deficiency.  Investigating L-arginine metabolism 
may provide novel therapeutic targets to prevent further immune dysfunction in HIV 
infection.  Arginase activity levels may constitute a new way to monitor immune 
dysfunction and the course of disease in HIV positive patients.  
 
1.6.2.  Objectives 
The objective of this thesis is to characterise arginase-mediated L-arginine 
metabolism in HIV infected patients and to investigate its contribution to the 
functional impairment of T cells and disease progression. 
To test our hypothesis, the following questions will be investigated: 
1. Are arginase activity and L-arginine levels markers of HIV disease severity? 
2. Is arginase activity modified during the course of infection? How does 
HAART affect arginase activity? 
3. Which cells express arginase and how are these altered by HIV infection? 
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Chapter II: Materials and methods 
 
2.1.  Study cohorts  
During the study, patients were recruited from St Mary’s Hospital (London).  The 
study protocol was approved by the National Research Ethics Service (COREC 
references 05/Q0410/93 and 09/H0801/77). The only exclusion criterion was that the 
patients must be at least 18 years old.  Eleven healthy, age-matched volunteers were 
recruited as controls.  All subjects gave written, informed consent before 
participation.  
Three separate cohorts of patients had to be recruited as: 
1. The study evolved to ask different questions; 
2. The ethics approval changed from COREC reference 05/Q0410/93 to COREC 
reference 09/H0801/77;  
3. Flow cytometry was only performed on freshly isolated cells; 
4. Paper reviewers asked for extra experimental data. 
  These cohorts were:  
1. Cohort 1 (n=44, mixed – 22 patients on HAART, 22 HAART naïve) –  
used for:  
a. Measuring the level of PBMC and plasma arginase activity and plasma 
L-arginine determination in order to assess  association of arginase 
activity with HIV disease severity as measured by CD4+ T cell count 
and plasma viral load.   
2. Cohort 2 (n=25, HAART naïve) - used for: 
a. Determination of PBMC arginase activity 
b. Phenotyping arginase1+ cells in PBMC fraction – Phenotype 1 panel 
(see section 2.3.1.5.) 
c. Determination of percentage of CD38+ and HLA-DR+ CD4+ and CD8+ 
T cells in PBMC fraction 
d. Determination of CD3! expression on CD4+ and CD8+  T cells in 
PBMC fraction  
3. Cohort 3 (n=21, HAART naïve) – used for: 
a. Phenotypic analysis of LDGs and NDGs from HIV+ patients – 
phenotype panel 2 and ARG1 panel (see section 2.3.1.5.) 
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Details of each of the individual cohorts can be found in: 
Cohort 1  Appendix Table 9.1 and 9.2 
Cohort 2   Appendix Table 9.3 
Cohort 3   Appendix Table 9.4 
  
2.2.  Laboratory evaluation 
Data from quantitative HIV-I plasma viral RNA and lymphocyte phenotypic assays 
were obtained as close to the date of venipuncture as possible.  Plasma HIV-I viral 
RNA level was quantified by real-time PCR (Bayer Quantiplex assay (bDNA) PCR 
test; lower detection level of 50 copies/mL).  The standard T cell markers, including 
CD4+ T cell count, were determined by flow cytometry under standard conditions in 
the chemical pathology laboratory at St Mary’s Hospital. 
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2.3.  Antibodies, Cell culture media and solutions 
 
2.3.1.  Antibodies 
All antibodies were titrated and tested against isotype controls (all isotype controls 
were <1%).  The final volume used for staining is shown in the table below.  
 
2.3.1.1.  Extracellular antibodies 
Antigen  Flurophore Clone Isotype Produced by  
Product 
code  
Volume 
used 
(µL) 
Quantity 
(µg) 
Panels 
used in: 
CD4 PE 13B8.2 mouse IgG1 
Beckman 
Coulter A07751 10 NP BrdU 
CD8 PB RPA-T8 mouse IgG1 
BD 
Biosciences  558207 2 0.4 BrdU 
CD4 FITC OKT4 mouse IgG2b eBioscience 11-0048 5 0.25 
CD3! / 
activation 
markers 
CD8a APC OKT8 mouse IgG2a eBioscience 17-0086 5 0.06 
CD3! / 
activation 
markers 
CD15 PE H198 mouse IgM 
BD 
Pharmingen 555402 20 NP 
Phenotype 
1 and 2 / 
Arg 
CD14 FITC M5E2 mouse IgG2a 
BD 
Pharmingen 555397 14 NP 
Phenotype 
1 
CD1a APC HI149 mouse IgG1 
BD 
Pharmingen 559775 20 NP 
Phenotype 
1 
CD38 PE HIT2 mouse IgG1 eBioscience 12-0389 5 0.25 
Activation 
markers 
HLA-
DR PE-Cy7 Imm-357 
mouse 
IgG1 
Beckman 
Coulter A40579 10 NP 
Activation 
markers 
CD11b PerCP-eFluor710 ICRF44 
mouse 
IgG1 eBioscience 46-0118 3 0.075 
Phenotype 
2 
CD13 APC-Cy7 WM15 mouse IgG1 Biolegend 301710 7 NP 
Phenotype 
2 and Arg 
CD16 eFluor 450 eBioCB16 mouse IgG1 eBioscience 48-0168 3 0.15 
Phenotype 
2 and Arg 
CD33 PE-Cy7 WM-53 mouse IgG1 eBioscience 25-0338 3 0.15 
Phenotype 
2 
CD63 FITC CLBGran/ 12 
mouse 
IgG1 
Beckman 
Coulter IM1165U 14 NP Arg 
CD66b FITC 80H3 mouse IgG1 
Beckman 
Coulter IM05310 3 NP 
Phenotype 
2 
 
NP = Not provided by manufacturer 
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2.3.1.2.  Intracellular antibodies 
 
NP = Not provided by manufacturer 
 
2.3.1.2.1.  Conjugation of Arginase 1 using Zenon® labelling kit 
In the panel’s phenotype 1 and ARG the intracellular antibody arginase 1 was used.  It 
is an unconjugated antibody therefore it was labelled using Zenon® labelling kit.  It 
was labelled with Zenon® Pacific Blue™ Mouse IgG1  labelling kit (Invitrogen, 
USA) for the phenotype 1 panel and with Zenon® Alexa Fluor® 647 Mouse IgG1  
labelling kit (Invitrogen, USA) for the ARG panel.  Labelling was performed as 
follows (volumes given per test):  
1. 2.75µL arginase1 antibody mixed with 1.375µL kit component A (stain), left 
in the dark for 5 minutes  
2. 1.375µL of kit component B (block) added and left in the dark for 5 minutes. 
3. 5.5µL added to each test following permabilisation and FcR blocking, tube 
vortexed and left in the dark for 30 minutes.  
 
2.3.1.3.  Antibody panels tested in chapter 3 
CD3!: 
o CD4  FITC 
o CD8  APC 
o CD3!  PE 
BrdU: 
o CD4  PE 
o CD8  PB 
o BrdU  FITC 
Antigen  Flurophore Clone Isotype Produced by  
Product 
code  
Volume 
used 
(µL) 
Quantity 
(µg) 
Panels 
used in: 
BrdU/ 
Dnase FITC B44 
mouse 
IgG1 
BD 
Pharmingen BD340649 20 NP BrdU 
CD3! PE 6BIO.2 mouse IgG1 
Santa Cruz 
Biotech. sc-1239PE 10 NP CD3! 
ARG1 Zenon
® labeled see 
below  
mouse 
IgG1 
Hycult 
biotech. HM2162 2.75 0.275 
Phenotype 
1 and 
ARG 
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2.3.1.4.  Antibody panels tested in chapter 4  
CD3!: 
o CD4  FITC 
o CD8  APC 
o CD3!  PE 
Activation markers:  
o CD4  FITC 
o CD8  APC 
o CD38  PE 
o HLA-DR PE-Cy7 
 
2.3.1.5.  Antibody panels tested in chapter 5 
Phenotype 1: 
o CD1a  APC 
o CD14   FITC 
o CD15   PE 
o ARG1  PB  
Phenotype 2: 
o CD11b  PerCP-eFluro710 
o CD13  APC-Cy7 
o CD15  PE 
o CD16  eFluro450 
o CD33  PE-Cy7 
o CD66b  FITC 
ARG 1: 
o CD13  APC-Cy7 
o CD15  PE 
o CD16  eFluro450 
o CD63  FITC 
o ARG1  APC (Alexa Fluor® 647) 
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2.3.2.  Cell culture media 
2.3.2.1.  Complement-inactivated Foetal Bovine Serum (FBS) 
FBS (Gibco, UK) was complement-inactivated by incubation at 56°C for 45 minutes 
and was frozen in 50mL aliquots at -20°C until further use. 
 
2.3.2.2.  Complete RPMI (1148.2 µM L-arginine, 0µM L-Glutamine) 
Custom made RPMI 1640 without L-Glutamine (PromoCell GmbH, Heildelberg, 
Germany) was supplemented with 50 IU/mL penicillin/50µg/ml streptomycin (Gibco, 
UK), 0.05mM "-mercaptoethanol (Sigma, UK) and 5% complement-inactivated FBS. 
 
2.3.2.3.  Complete L-arginine-free RPMI (0µM L-arginine, 0µM L-glutamine) 
Custom made RPMI 1640 without L-Glutamine and L-arginine (PromoCell GmbH, 
Heildelberg, Germany) was supplemented with 50 IU/mL penicillin/50µg/ml 
streptomycin (Gibco, UK), 0.05mM "-mercaptoethanol (Sigma, UK) and 5% 
complement-inactivated FBS. 
 
2.3.3.  Solutions 
2.3.3.1.  Acid mix 
Phosphoric acid (#85%, Fluka, UK), sulphuric acid (98%, Fluka, UK) and distilled 
H2O (dH2O)  was prepared to a v/v/v ratio of 1/3/7 and was kept at 4°C until required. 
 
2.3.3.2.  Albumin standard 
Albumin standard (2mg/mL stock solution, Thermo Scientific, UK) was serially 
diluted using PBS and kept at -20°C until required. 
 
2.3.3.3.  Bicinchoninic acid (BCA) protein assay 
The BCA protein assay (Pierce/Thermo Scientific, UK) was performed following the 
manufacturer’s protocol.  49 parts of reagent A are added to every one part of reagent 
B (v/v) and 200µL of solution is added to 10µL sample. 
 
2.3.3.4.  5-Bromo-2-deoxyuridine (BrdU)  
BrdU (Sigma, UK) was prepared to a stock concentration of 10mg/100µL in DMSO 
(Fluka, UK) and kept frozen until required.  Prior to use, 1µL BrdU stock was diluted 
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in 110µL DMSO and 0.6 µL of the diluted BrdU added to each well (200µL cells in 
culture) to give a final concentration of 2.7µg/mL of BrdU. 
 
2.3.3.5.  Dextran sulphate (3% solution)   
3g Dextran sulphate (AppliChem (VWR)) was dissolved in 100mL PBS (without 
Calcium and Magnesium), filtered sterile and kept at 4°C until required.   
    
2.3.3.6.  EasySep Cell Separation Medium 
PBS (without calcium and magnesium) stock solution (Gibco, UK) was prepared with 
dH2O and supplemented with 2% complement-inactivated FBS (v/v, Gibco, UK) and 
1mM EDTA (Sigma, UK). It was then filtered sterile and kept at 4°C until required. 
 
2.3.3.7.  Erythrocyte-Lysis-buffer   
A 155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.4 solution was made up by 
dissolving 8.3g NH4Cl (Sigma, UK), 1g KHCO3 (Sigma, UK) and adding 0.2 mL of a 
0.5M EDTA (Sigma, UK) stock solution to 1L dH2O. This was then filtered sterile 
and kept at 4°C. 
 
2.3.3.8.  Fluorescence Activated Cell Sorting (FACS) medium 
PBS was supplemented with 3% complement-inactivated FBS (Gibco, UK) and 0.1% 
sodium azide (v/v, Sigma, UK). This was kept at 4°C until required. 
 
2.3.3.9.  4% Formaldehyde 
37% Formaldehyde (Sigma, UK) was prepared to a concentration of 4% in PBS. This 
was kept at 4°C until required. 
 
2.3.3.10.  Gel buffer for western blot 
Made by mixing: 90mL dH2O, 10mL transfer buffer (see section 2.3.3.25.) and 100µL 
antioxidant (Invitrogen, UK).  This was made fresh for each western blot. 
 
2.3.3.11.  6% !-isonitrosopropiophenone (ISPF) 
!-isonitrosopropiophenone (ISPF, Sigma, UK) was prepared to a 6% solution (w/v) in 
ethanol (99.7-100%, BDH, UK).  This was kept in the dark at 4°C until required. 
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2.3.3.12.  0.5M L-arginine for arginase enzymatic assay 
L-arginine (Carl Roth GmBH, Germany) was prepared to a 0.5M concentration  
in dH2O and adjusted to pH 9.7 using a 5M solution of sodium hydroxide (BDH, 
UK).  10 mL aliquots were frozen at -20°C until required. 
 
2.3.3.13.  Lysis buffer 
Lysis buffer was prepared by mixing 0.1% triton (Sigma, UK), 50mM tris-HCl (see 
section 2.3.3.23.) and 100mM manganese chloride (Sigma, UK) at a 10/10/1 ratio. ).  
This was kept at 4°C until required. 
 
2.3.3.14.  100mM magnesium chloride 
Manganese chloride (Sigma, UK) was prepared to a concentration of 100mM in 
dH2O. 
 
2.3.3.15.  5% Milk containing 0.001% Tween-20 
Non-fat dried milk (Marvel, UK) was prepared to a 5% (w/v) solution in PBS and 
supplemented with 0.001% Tween-20 (v/v, Sigma, UK) and used immediately. 
 
2.3.3.16.  Membrane buffer for western blot 
Made by mixing: 70mL dH2O, 20mL 100% methanol (VWR, France), 10mL transfer 
buffer (see section 2.3.3.25) and 100µL antioxidant (Invitrogen, UK).  
 
2.3.3.17. 2-(N-morpholino)ethanesulfonic acid (MES) running buffer 
20X 2-(N-morpholino)ethanesulfonic acid (MES) sodium dodecyl sulfate (SDS) 
running buffer (Invitrogen, UK) was made to a 1X solution with dH2O and used 
immediately. 
 
2.3.3.18.  MES running buffer containing antioxidant 
200 mL MES running buffer was supplemented with 500µL antioxidant (Invitrogen, 
UK) and used immediately. 
 
2.3.3.19.  Phosphate buffered saline (PBS) 
A 0.01M phosphate buffer (0.0027M potassium chloride and 0.137M sodium 
chloride) was prepared by dissolving one tablet (Sigma, UK) in 200mL dH2O. 
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2.3.3.20.  PBS (without Calcium, without Magnesium) 
PBS (without calcium and magnesium) 10x stock solution (Gibco, UK) was diluted 
with dH2O. 
 
2.3.3.21.  0.5% Saponin 
Saponin (Sigma, UK) was prepared to a concentration of 0.5% (w/v) in FACS 
medium and kept at room temperature (RT°C). 
 
2.3.3.22.  0.15M sodium chloride 
Sodium chloride (Sigma, UK) was prepared to a 0.15M concentration in dH2O, 
filtered sterile and kept at 4°C until required. 
 
2.3.3.23.  50mM Tris(hydroxymethyl)-aminomethane (Tris)-hydrochloric acid 
(HCl) 
Tris (Merck, Germany) was prepared to a concentration of 50mM and adjusted to 
pH7.5 using 1M HCl (BDH, UK) and kept at RT°C. 
 
2.3.3.24.  0.1% Triton 
Triton X-100 (Sigma, UK) was prepared to a concentration of 0.1% (v/v) in dH2O and 
kept at RT°C. 
 
2.3.3.25.  Transfer buffer 
20X Transfer buffer (Invitrogen, UK) was made to a 1X solution with dH2O and used 
immediately. 
 
2.3.3.26.  Urea standard stock solution (10X) 
A 10X stock solution of urea (Fluka, Switzerland) was prepared to a concentration of 
600µg/mL in dH2O and kept frozen at -20°C in 1mL aliquots.  Prior to use, the 10X 
urea stock solution was diluted to a 1X urea solution with dH2O.  Serial dilutions of 
urea were made using dH2O. 
 
2.3.3.27.  Western blot wash buffer 
PBS was supplemented with 0.001% Tween-20 (v/v, Sigma, UK) and kept at RT°C. 
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2.4.  Preparatory methods 
 
2.4.1. Cell counting 
Cell numbers were counted using a FastRead Counting Slide (Immune Systems 
Limited, UK).  Viable cells were distinguished by trypan blue exclusion (Sigma, UK). 
 
2.4.2.  Sample preparation 
Twenty mL of anti-coagulated venous blood was collected in EDTA tubes from 
patients and controls.  Blood was processed immediately after venipuncture. 
 
2.4.2.1.  Preparation of plasma 
Plasma was isolated by centrifuging 10 mL of blood at 1900 revolutions per minute 
(rpm) for 10 minutes. Two ml was then frozen at -20°C until further use. 
 
2.4.2.2.  Preparation of PBMC  
PBMCs were isolated by density gradient centrifugation. Eighteen mL of blood was 
diluted in 22 mL of PBS.  Twenty mL of diluted blood was layered slowly over 20 
mL of Histopaque$-1077 (Sigma) in a 50mL tube.  The tubes were centrifuged at 1900 
rpm at 22°C with no break for 20 minutes. PBMCs were harvested from the 
interphase using a Pasteur pipette (see figure 2.1). PBMCs were washed in 45mL PBS 
and centrifuged at 1900 rpm at 22°C with break applied for 10 minutes. 
 
The next stage of processing depended on what the PBMCs were going to be used for:  
• For arginase activity determination: the cells were resuspended in 40µL lysis 
buffer per mL blood (i.e. 800µL for 20mL blood) and frozen at -20°C until 
further use. 
• For flow cytometry or purification: the cells were kept in PBS until required. 
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Figure 2.1:  Diagram showing the location of the PBMC fraction (containing low 
density granulocytes) and the erythrocyte fraction (containing normal density 
granulocytes) following density gradient centrifugation 
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2.4.2.3.  Isolation of neutrophils 
After density gradient centrifugation, neutrophils (Normal density granulocytes = 
NDG) can be isolated from the erythrocyte fraction (see figure 2.1).  This is done by:  
1. Aspirating the plasma and ficoll layers left after density gradient 
centrifugation  
2. Resuspend the pellet, in 10mL of PBS (without Ca2+ and Mg2+) and mix with 
10mL 3% Dextran solution. Leave the tube at room temperature for 20 
minutes for sedimentationation of erythrocytes.  
3. Harvest the upper phase (NDG-rich supernatant) and centrifuge it at 1200 rpm 
for 8 minutes.  
4. Aspirate the supernatant and keep the pellet (containing NDGs and 
contaminating erythrocytes).   
5. Resuspend pellet in 20mL cold erythrocyte lysis buffer and incubate for 15 
minutes on ice. Centrifuge the tube at 1200 rpm for 8 minutes.   
6. Wash the pellet (just containing NDGs) in 10ml PBS and centrifuge at 1200 
rpm for 8 minutes.  
After washing, cell purity and viability were checked by flow cytometry and 
microscopy. The method reproducibly yields PMNs with a purity and viability of 
more than 95%. 
 
2.4.2.4.  Purification of lymphocytes by removal of CD14+ monocytes 
To access the impact of L-arginine deprivation on T cell functions,  PBMCs were 
stimulated with #CD3/#CD28 beads.  However, before this experiment can be 
performed, CD14+ monocytes must be removed from PBMCs as they will 
phagocytose the #CD3/#CD28 beads.   
CD14+ monocytes were isolated from PBMCs by magnetic bead separation in a 5mL 
round bottomed test tube (BD Labware, USA) following the manufacturer’s protocol 
(EasySep, Stem Cell Technologies, France): PBMCs were adjusted to 1x108/mL in 
EasySep Cell Separation Medium and incubated with 100µL/mL EasySep CD14 
Selection Cocktail for 15 minutes at room temperature (RT°C).  Then, 50µL/mL 
EasySep Magnetic Nanoparticles were added and incubated for 10 minutes at RT°C.  
PBMC suspensions were then brought up to a total volume of 2.5mL using EasySep 
Cell Separation Medium for magnetic separation.  PBMC suspensions were subjected 
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to five minutes of magnetic incubation, the supernatant fraction containing the 
lymphocytes is then poured off into a 5mL round bottomed test tube (BD Labware, 
USA) and kept and the positively selected CD14+ monocytes discarded.  The tube 
containing the supernatant fraction was placed back in to the magnet for a further 5 
minutes.  This process was repeated to give a total of three 5 minutes separations.  
The lymphocytes minus CD14+ monocytes were then washed in PBS, counted and the 
removal of CD14+ monocytes checked by flow cytometric analysis using a FACS 
Canto II (BD, USA).  The lymphocytes harvested contained < 1% monocytes.  Single 
cell suspensions were then resuspended at a concentration of 4x105/mL in complete 
RPMI or complete L-arginine-free RPMI. 
 
2.4.3.  Polyclonal stimulation of lymphocytes with !CD3/!CD28 beads 
Lymphocytes were polyclonally stimulated in a 96 well round bottom polystyrene 
microplate (Corning, USA) using #CD3/#CD28 beads (Dynal, Invitrogen, Norway). 
Lymphocytes were either resuspended in complete RPMI with L-arginine (containing 
1148.2 µM of L-arginine) or in L-arginine free complete RPMI at a concentration of 
4x105/mL. 200µL cell (8x104 cells) were added to each well and stimulated with 2µL 
#CD3/#CD28 beads (8x104 beads). Plates were incubated at 37°C/5% CO2 for 24, 48 
and 72 hours.  Cells were harvested and placed in DynaMag™ -2 (Dynal, Invitrogen, 
Norway) for one minute to remove #CD3/#CD28 beads.  The cells were then ready 
for antibody staining prior to being analysed by flow cytometry.   
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2.5.  Analytical methods 
 
2.5.1.  Detection of extracellular and intracellular marker expression by flow 
cytometry 
PBMCs were harvested, counted and resuspended in FACs medium at a concentration 
of 1 x 107 cell/mL. From this PBMC suspension, 100µL was added to a 5mL round 
bottom test tube (BD Labware, USA) and incubated with 20µL human FcR blocking 
reagent (Miltenyi Biotec, Germany) for five minutes at RT°C prior to incubation with 
extracellular antibodies being tested (see section 2.3.1.1. for details of individual 
antibodies and antibody panels) for 20 minutes on ice in the dark.  The cells were 
washed in FACS medium (washed = addition of excess FACs medium followed by a 
5 minute centrifugation at 1800 rpm for 5 minutes and then the supernatant is 
discarded), resuspended in 500µL of ice cold PBS, fixed with 500µL of 4% 
formaldehyde and incubated on ice for 20 minutes in the dark.  Cells were washed and 
permabilised with 1mL 0.5% saponin and incubated at RT°C for 20 minutes in the 
dark. Cells were incubated with 20µL human FcR blocking reagent (Miltenyi Biotec, 
Germany) for five minutes at RT°C in the dark prior to addition of intracellular 
antibodies being tested (see section 2.3.1.2. for details of individual antibodies and 
antibody panels) added to cells and incubated at RT°C for 30 minutes in the dark.  
The cells were washed and resuspended in FACS medium and analysed by flow 
cytometry using a FACS Canto II (BD, UK).  FACs data was analysed using FlowJo 
version 8.7 (Tree Star, Ashland, OR) and Summit version 4.0 software. 
 
2.5.2.  Cell proliferation by BrdU incorporation and detection by flow cytometry 
BrdU is a thymidine analogue and is incorporated into the DNA of proliferating cells.  
The detection of BrdU using a monoclonal antibody enables the identification of 
replicating cells (Carayon and Bord, 1992).  Combined with cell surface staining, this 
method allows for the identification of proliferating cells.  0.6µL of diluted BrdU 
stock solution was added to each well (to give a final concentration of 2.7µg/mL) for 
the final 18 hours of culture.  Cells were harvested, washed and resuspended in 100µL 
FACS medium, incubated with 20µL human FcR blocking reagent (Miltenyi Biotec, 
Germany) for five minutes at RT°C prior to incubation with 10µL anti-human CD4PE 
and 2µL anti-human CD8PB for 20 minutes on ice in the dark.  The cells were washed 
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in FACS medium and resuspended in 500µL of ice cold 0.15M sodium chloride and 6 
x 200µL of ice cold 95% ethanol while gently vortexing and incubated on ice for 20 
minutes in the dark.  The cells were then centrifuged at 1900 rpm for 5 minutes, the 
supernatant discarded and the pellet resuspended in 1 mL of 0.1% paraformaldehyde 
containing 0.1% Tween-20 incubated at RT°C for 20 minutes in the dark to 
permabilise the cells. The cells were then centrifuged at 1900 rpm for 5 minutes, the 
supernatant discarded and the pellet resuspended in 100µL FACS medium and 
incubated with 20µL/test !BrdUFITC mAb or a mouse IgG1 as an isotype control at 
RT°C for 20 minutes in the dark.  The cells were washed and resuspended in FACS 
medium and the detection of BrdU was determined by flow cytometric analysis using 
a FACS Canto II (BD, UK).  FACs data was analysed using FlowJo version 8.7 (Tree 
Star, Ashland, OR) and Summit version 4.0 software. 
 
2.5.3.  Determination of arginase enzymatic activity 
Arginase activity was measured in PBMC lysates and plasma by measuring the 
conversion of L-arginine to urea. PBMCs for arginase activity determination were 
harvested in lysis buffer, which lyses the cells releasing intracellular arginase and 
contains manganese chloride, which is the co-factor required for maximum arginase 
activity (Iyer et al., 1998, Grillo and Colombatto, 2004).  50µL of PBMCs are used 
per test.  As plasma has not been diluted in lysis buffer 25µL of plasma is mixed with 
25µL lysis buffer. Arginase is activated by heating the sample at 56°C for 7 minutes. 
L-arginine hydrolysis was conducted by incubating the activated lysates with 50µL 
0.5M L-arginine (pH 9.7) at 37oC for 120 minutes.  The reaction was stopped with 
400µL acid mix (H2SO4 (96%)/H3PO4(85%)/H2O (1:3:7, v/v/v)).  Twenty µL #-
isonitrosopropiophenone (ISPF, dissolved in 100% ethanol, Sigma) was added to each 
sample.  Urea production by L-arginine hydrolysis in samples was measured against a 
urea standard (as described in 2.3.3.26.) treated with 20µl ISPF and incubated with 
samples at 100°C for 45 minutes, followed by 30 minutes at 4oC.  
To subtract the background plasma urea levels, each plasma experiment was 
duplicated with the exception of adding 75µL of PBS in place of 25µL lysis buffer 
and 50µL 0.5M L-arginine.  
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The optical density (OD) of the reaction was measured using an ELISA plate reader 
(Anthos Labtec Instruments, UK) at 550nm and the results were analysed using the 
Deltasoft3 software.  One unit of enzyme activity was defined as the amount of 
enzyme that catalyses the formation of 1µM urea per min as compared to the urea 
standard. 
2.5.4.  Protein determination 
The concentration of protein in each sample was determined using the BCA protein 
assay.  Serial dilutions of sample protein were added at 10µL per well with the 
addition of 200µL BCA assay reagent.  Following incubation at 37°C/5% CO2 for 30 
minutes, the OD of the reaction was measured using an ELISA plate reader (Anthos 
Labtec Instruments, UK) at 570nm and the results were analysed using the Deltasoft3 
software and protein level were calculated against the albumin standard.   
2.5.5.  Calculation of arginase activity 
From each sample: 
Volume of blood: 20mL blood, that were processed and PBMCs harvested and 
resuspended in 800µL of lysis buffer; from this, 50µL was used in the arginase assay.  
mU/mg protein 
mU/sample   = (µg urea x mU) / (µM urea x time) 
mU/mg protein  = ((mU/sample x mU) / (µL sample)) / (mg protein/mL) 
mU arginase/mL blood 
mU/ 20 mL blood  = ((ug urea x mU) / (uM urea x time)) x 16 (= 800µL / 50µL) 
mU/mL   = (mU/ 20 mL blood) / 20  
NOTE: 
mg urea -  Optical density measured in the arginase enzymatic assay 
mg protein/mL  - Optical density measured by BCA protein assay 
µM urea  = 60 
mU   = 1000 
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2.5.6.  L-arginine determination 
L-arginine concentrations were determined in the plasma.  Free amino acids were 
separated by ion-exchange chromatography and quantified by postcolumn ninhydrin 
derivatisation using an amino acid analyser (AminoTac JLC-500/V).  An internal 
standard, S-(2-aminoethyl)-L-cysteine hydrochloride and amino acid standard 
solutions (basics; acidics and neutrals) were supplied by Sigma.  This work was done 
in collaboration with Dr Margaret R Hancock at the Department of Clinical 
Biochemistry, Imperial College Healthcare NHS Trust, Charing Cross Hospital. 
 
2.5.7.  Western blot analysis 
Equal amounts of protein (80µg/65µL brought to volume using distilled water) was 
denatured by the addition of 10µL reducing buffer (Invitrogen, UK) and 25µL sample 
buffer (Invitrogen, UK) to a total volume of 100µL and incubated at 100°C for 10 
minutes.  Protein was separated on a 4-12% sodium dodecyl sulphate (SDS) 
polyacrylamide gradient gel (Invitrogen, UK) by electrophoresis (Bio-Rad, UK) at 
150 volts in 800mL MES running buffer and 200mL MES running buffer containing 
antioxidant.  The SDS gel was treated with gel buffer. The polyvinylidine difluoride 
(PVDF) membrane (Invitrogen, UK) was activated by being treated for 5 minutes in 
methanol (100%, VWR, UK) and was then transferred into membrane buffer for 5 
minutes prior to semi-dry transfer (Bio-Rad, UK) of the protein from the gel to the 
PVDF membrane at 333milli-Amperes (mA) for 1 hour.  PVDF membranes were then 
washed in PBS for 10 minutes at RT°C on a shaker.  For the immunodetection of 
CD3!, PVDF membranes were first blocked for 6 hours with 5% milk containing 
0.001% Tween-20 at 4°C on a shaker.  Liquid was discarded from the PVDF 
membrane, 40µL(8 µg) mouse anti-human CD3!-HRP monoclonal antibody (Santa 
Cruz Biotechnology, Germany) was diluted in 20mL 5% milk containing 0.001% 
Tween-20 and incubated with the PVDF membrane for 18 hours at RT°C on a shaker.  
PVDF membranes were then washed four times for five minutes with western blot 
wash buffer at RT°C on a shaker.  Western blotting luminol reagent (a 
chemiluminescent detection system, Santa Cruz, Germany) was used to detect PVDF 
membrane-bound antibodies and visualised using Amersham HyperfilmTM ECL (High 
performance chemiluminescence film, GE Healthcare, UK).  Amersham 
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HyperfilmTM ECL development took place using a JP-33 automatic x-ray film 
processor (JPI America, USA). 
2.5.8.  Statistical analyses 
Data were evaluated for statistical differences using GraphPad PRISM version 5.0: 
1. For grouped data: a two-tailed Mann-Whitney test (non-parametric t-test) 
2. For correlation: a Spearman’s rank test (non-parametric assessment of 
correlation) 
3. For differences between LDGs and NDGs: a Wilcoxon signed rank test (a 
non-parametric, two-tailed, paired t-test) 
 
 
 111 
Chapter III: Results – Impact of L-arginine deprivation on human T cells in vitro 
 
3.1.  Introduction 
The role of arginase mediated L-arginine metabolism has never been studied in HIV 
infection.  Fundamental to studying the impact of arginase metabolism in HIV 
infection is to understand the impact of the absence of L-arginine on T cells.  
Therefore, an in vitro system was setup for measuring the impact of the absence of L-
arginine on T cells taken from healthy controls and polyclonally stimulated with 
paramagnetic beads coupled with anti-CD3 and anti-CD28 beads for 24, 48, and 72 
hours.   
Three functional parameters were measured to assess the impact of the absence of L-
arginine on T cells: i) proliferation, as demonstrated by BrdU incorporation and the 
presence of blast cells (shown by increased forward and side scatter on a flow 
cytometry dot plot); ii) the level of expression of CD3! and iii) the level of expression 
of CD4 and CD8 cell surface markers.   
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3.2. Experimental Results 
 
3.2.1. Effect of L-arginine on T cell proliferation and blast formation 
3.2.1.1.  Proliferation  
The aim of these experiments was to assess the impact of the absence of L-arginine on 
proliferation of human T cells.  In order to do this, lymphocytes were isolated from 
PBMCs from healthy human subjects by density gradient separation and cultured for 
either 24, 48 or 72 hours in RPMI-1640 (RPMI + L-arg) which contains 1148µM L-
arginine or in RPMI-1640 without L-arginine (RPMI – L-arg).  T cells were 
polyclonally stimulated with anti-CD3/CD28 beads (Dynal) at a ratio of 1:1. 
First, proliferation was analysed by measuring BrdU incorporation in CD4+ and CD8+ 
at 24, 48 or 72 hours.  Figure 3.1 shows the hierarchical gating strategy applied to the 
analysis of the flow cytometry data acquired.  The gates were applied in the following 
order: i) a singlet gate was set; ii) a region was drawn around the living cells to 
exclude dead cells and debris; iii) a gate was set around the CD4+ and CD8+ T cells so 
that BrdU expression could be determined in these two populations.   
Figure 3.2 shows the percentage of cells proliferating at 24, 48 and 72 hours.  At 24 
hours, there is no difference in proliferation between CD4+ and CD8+ T cells cultured 
in RPMI with or without L-arginine (figure 3.2).   However, by 48 hours there is 22.3 
times more proliferation in CD4+ T cells cultured in RPMI with L-arginine than in 
RPMI without L-arginine and 15.1 times more proliferation in CD8+ T cells cultured 
in RPMI with L-arginine than in RPMI without L-arginine (Table 3.1).  By 72 hours, 
the magnitude of the difference in percentage of cells that incorporate BrdU is 
reduced for both CD4+ and CD8+ T cells.  However there is still significantly more 
proliferation in cells cultured in the presence of L-arginine (figure 3.2).   These results 
are summarised in Table 3.1.  
 
These results show that both CD4+ and CD8+ T cells show a markedly impaired 
capacity to proliferate in the absence of L-arginine at 48 and 72 hours post 
stimulation.   
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Figure 3.1:  Gating strategy for measuring proliferation by BrdU incorporation 
in CD4+ and CD8+ T cells 
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Figure 3.2:  Effect of L-arginine on CD4+ and CD8+ T cell proliferation 
  
 
 
Blood was taken from healthy human controls and PBMCs were isolated by Ficoll 
gradient. 8 x 104  lymphocytes were seeded in 200µl of complete RPMI (1148µM L-
arginine) or complete RPMI without L-arginine (0µM L-arginine) and stimulated with 
2µl anti-CD3/CD28 beads (Dynal) for 24, 48, and 96 hours.  0.54µg BrdU was added 
to the culture 18 hours prior to harvest and the percentage (%) of (A) CD4+BrdU+ and 
(B) CD8+BrdU+ cells was assessed by flow cytometry. Results are averages ± SD for 
duplicates. One representative experiment out of three independent experiments is 
shown.  
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Table 3.1:  BrdU incorporation in CD4+ and CD8+ T cells as a % of live cells 
 
 
Time in 
hours 
24 48 72 
L-arginine in 
medium 
+ - + - + - 
% CD4+ 
BrdU+ 
0.73 ± 
0.41 
0.77 ± 
0.05 
25.45 ± 
1.63 
1.14 ± 
0.04 
37.45 ± 
2.76 
4.18 ± 
0.08 
% CD8+ 
BrdU+ 
0.26 ± 
0.05 
0.23 ± 
0.11 
11.2 ± 
0.14 
0.74 ± 
0.18 
14.8 ± 0 
3.18 ± 
0.11 
 
 
Blood was taken from healthy human controls and PBMCs were isolated by Ficoll 
gradient. 4 x 108  lymphocytes were seeded in 200µl of complete RPMI (1148µM L-
arginine) or complete RPMI without L-arginine (0µM L-arginine) and stimulated with 
2µl anti-CD3/CD28 beads (Dynal) for 24, 48, and 72 hours.  0.54µg BrdU was added 
to the culture 18 hours prior to harvest and the percentage (%) of CD4+BrdU+ and 
CD8+BrdU+ cells was assessed by flow cytometry. Results are averages ± SD for 
duplicates. One representative experiment out of three independent experiments is 
shown. 
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3.2.1.2.  Proliferation by blast formation  
When cells are stimulated with anti-CD3/CD28 beads they transform into blast cells 
which proliferate.  Blast cells have a larger size and granularity.  This can be assessed 
by flow cytometry by measuring forward and side scatter.  The aim of the following 
experiments was to analyse the impact of the absence of L-arginine on blast 
formation.  
At 48 hours, when the difference in BrdU incorporation is most marked, the forward 
and side scatter of BrdU+ cells was measured. A representative dot plot for 
lymphocyte cells cultured in RPMI with and without L-arginine can be seen in figure 
3.3 and shows that the majority (>75%) of proliferating cells are found in a distinct 
region with a larger forward and side scatter (FSC and SSC respectively).  This 
population of dividing cells represents blasts.  In the presence of L-arginine, this 
represents 40.65 ± 0.35 % of live cells compared to 5.97 ± 3.14 % of live cells in 
RPMI –L-arginine. 
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Figure 3.3:  Effect of L-arginine on T cell blast formation  
 
 
 
 
Blood was taken from healthy human controls and PBMCs were isolated by Ficoll 
gradient.  8 x 104  cells were seeded in 200µl of complete RPMI (1148µM L-arginine) 
or complete RPMI without L-arginine (0µM L-arginine) and stimulated with 2µl anti-
CD3/CD28 beads (Dynal) for 48 hours.  0.54µg BrdU was added to the culture 18 
hours prior to harvest.  Ellipse indicates region of blasting cells with the region as a 
percentage of all live cells shown. One representative experiment out of three 
independent experiments is shown. 
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3.2.2.  Impact of L-arginine availability on T cell CD3" expression 
These experiments are designed to determine the effect of the absence of L-arginine 
on the expression of CD3! in human CD4+ and CD8+ T cells.  CD3! is part of the T 
cell receptor complex.  The expression of CD3! has been shown to be exquisitely 
sensitive to L-arginine availability (Bansal and Ochoa, 2003) and low levels of CD3! 
expression are considered one of the best markers of in vitro T cell dysfunction 
caused by L-arginine starvation.   
Lymphocytes were isolated from PBMCs from healthy human subjects.  After 
isolation by density gradient centrifugation, an aliquot of cells was taken to measure 
purity and baseline CD3! expression.  The remaining T cells were cultured for either 
24, 48 or 72 hours in RPMI + L-arg or in RPMI – L-arg.  T cells were polyclonally 
stimulated with anti-CD3/CD28 beads (Dynal) and CD3! expression was measured 
by flow cytometry. 
Figure 3.4 shows the hierarchical gating strategy applied to the analysis of the flow 
cytometry data acquired.  The gates were applied in the following order: i) a singlet 
gate was set; ii) a region was drawn around the living cells to exclude dead cells and 
debris; iii) a gate was set around the CD4+ and CD8+ T cells so that CD3! expression 
could be determined in these two populations. 
Culture of T cells in the absence of L-arginine led to a decrease in both CD4+ and 
CD8+ T cell’s CD3! expression by 24 hours (figure 3.5).  This decrease in CD3! 
mean fluorescence intensity (MFI) from baseline readings was maintained at 48 and 
72 hours.  By comparison, in RPMI with L-arginine both CD4+ and CD8+ T cells 
show an initial decrease in CD3! MFI at 24 hours compared to the baseline level 
taken ex-vivo.  However, the expression of CD3! increases throughout the experiment 
with CD4+ CD3! MFI approaching the baseline level by 72 hours and CD8+ CD3! 
MFI exceeding the baseline level by 72 hours.  These results are summarised in Table 
3.2.  
 
These results show that in both CD4+ and CD8+ T cells the expression of CD3! is 
higher in the presence of L-arginine.  In addition, in the absence of L-arginine 
polyclonally stimulated human T cells are unable to re-express the level of CD3! seen 
at baseline.  
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Figure 3.4:  Gating strategy for measuring CD3" expression in CD4+ and CD8+ T 
cells 
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Figure 3.5:  Effect of L-arginine on CD4+ and CD8+ T cell CD3ζ expression  
 
 
 
Blood was taken from a healthy human control and PBMCs were isolated by Ficoll 
gradient.  8 x 104  cells were seeded in 200µl of complete RPMI (1148µM L-arginine) 
or complete RPMI without L-arginine (0µM L-arginine) and stimulated with 2µl anti-
CD3/CD28 beads (Dynal) for  24, 48, and 72 hours.  The expression of CD3! was 
analysed in (A) CD4+ T cells and (B) CD8+ T cells by flow cytometry. Results are 
averages ± SD for duplicates. One representative experiment out of three independent 
experiments is shown.  
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Table 3.2:  Summary of CD3" expression in CD4+ and CD8+ T cells at 0, 24, 48 
and 72 hours.  
 
CD4+ T cells 
Time in 
hours  
0 24 48 72 
L-arg in 
culture  
n/a + - + - + - 
CD3" MFI 
± SD  
4160.5 ± 95.46 
1487.5 
± 
12.02 
1363.5 
± 
20.51 
2959.0 
± 
16.97 
1450.5 
± 
19.09 
3538.5 
±  
6.36 
1261.0 
± 
19.80 
 
CD8+ T cells 
Time in 
hours 
0 24 48 72 
L-arg in 
culture 
n/a + - + - + - 
CD3" MFI 
± SD  
3578.5 ± 9.19 
1103.0 
± 
12.73 
1031.5 
± 
10.61 
2826.5 
± 
26.16 
1382.5 
± 
27.58 
3733.0 
±  
2.83 
1334.5 
±  
4.95 
 
 
Blood was taken from healthy human controls and PBMCs were isolated by Ficoll 
gradient.  8 x 104  cells were seeded in 200µl of complete RPMI (1148µM L-arginine) 
or complete RPMI without L-arginine (0µM L-arginine) and stimulated with 2µl anti-
CD3/CD28 beads (Dynal) for  24, 48, and 72 hours.  The expression of CD3! was 
analysed in CD4+ T cells and CD8+ T cells by flow cytometry. Results are averages ± 
SD for duplicates. One representative experiment out of three independent 
experiments is shown.  
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3.2.3.  Impact of L-arginine availability on T cell CD4 and CD8 expression 
In addition to investigating the impact of L-arginine on the expression of CD3!, 
experiments were also designed to study how the absence of L-arginine affects the 
expression of the T cell lineage cell surface molecules CD4 and CD8.  
At the time of lymphocyte isolation an aliquot of cells was taken to check purity and 
to measure baseline CD4 and CD8 expression. The remaining lymphocytes were put 
in culture and stimulated with CD3/CD28 beads for 24, 48 or 72 hours before CD4 
and CD8 expression was measured by flow cytometry.  
Stimulation of CD4+ T cells in the absence of L-arginine led to a decrease in the 
expression of CD4 after only 24 hours in culture (Figure 3.6A and Table 3.3).  The 
expression of CD4 continues to fall in the absence of L-arginine reaching its lowest 
levels after 72 hours in culture. By comparison, CD4+ T cells cultured in the presence 
of L-arginine show an initial decrease at 24 hours from baseline CD4 expression 
followed by a rise in CD4 expression between 24 and 48 hours.  This CD4 expression 
is then maintained at 72 hours post stimulation in vitro.  This shows that at all time 
points the expression of CD4 is higher in CD4+ T cells cultured in the presence of L-
arginine compared to CD4+ T cultured in the absence of L-arginine.  
A different trend is observed in CD8+ T cells cultured in the presence and absence of 
L-arginine (Figure 3.6B and Table 3.3).  After 24 hours the expression of CD8 
remains stable at approximately baseline levels in cells cultured in the presence and 
the absence of L-arginine.  By 48 hours the impact of L-arginine becomes apparent.  
The expression increases above baseline levels in cells cultured in the presence of L-
arginine.  Conversely, in the absence of L-arginine, the level falls below baseline 
expression.  Between 48 and 72 hours the expression of CD8 decreases in both the 
presence and absence of L-arginine, however, importantly the level of CD8 is still 
higher in cells cultured in the presence of L-arginine.  
 
These results show that the expression of both CD4 and CD8 is greater at all time 
points in cells cultured in the presence of L-arginine compared to cells cultured in the 
absence of L-arginine.  
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Figure 3.6:  Effect of L-arginine on CD4 and CD8 expression following polyclonal 
stimulation  
 
 
Blood was taken from healthy human controls and PBMCs were isolated by Ficoll 
gradient.  8 x 104  cells were seeded in 200µl of complete RPMI (1148µM L-arginine) 
or complete RPMI without L-arginine (0µM L-arginine) and stimulated with 2µl anti-
CD3/CD28 beads (Dynal) for  24, 48, and 72 hours.  Flow cytometry was used to 
measure the MFI of (A) CD4 and (B) CD8. Results are averages ± SD for duplicates. 
One representative experiment out of three independent experiments is shown.  
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Table 3.3:  Kinetic CD4 and CD8 expression in the presence and absence of L-
arginine at 0, 24, 48 and 72 hours 
 
CD4+ T cells 
Time in 
hours  
0 24 48 72 
L-arg in 
culture  
n/a + - + - + - 
CD4 MFI 
± SD  
5393.5 ± 13.44 
4325.5 
± 7.78 
3778 ± 
15.56 
6589.5 
± 
137.89 
3400.5 
± 
82.73 
6589.5 
± 
70.00 
2090 ± 
11.31 
CD8+ T cells 
Time in 
hours 
0 24 48 72 
L-arg in 
culture 
n/a + - + - + - 
CD8 MFI 
± SD 
5306.5 ± 67.18 
5392 ± 
62.23 
5342.5 
± 
86.97 
6254 ± 
568.51 
4049 ± 
104.65 
4873.5 
± 
13.44 
3211 ± 
90.51 
 
Blood was taken from healthy human controls and PBMCs were isolated by Ficoll 
gradient. 8 x 104 cells were seeded in 200µl of complete RPMI (1148µM L-arginine) 
or complete RPMI without L-arginine (0µM L-arginine) and stimulated with 2µl anti-
CD3/CD28 beads (Dynal) for 24, 48, and 72 hours.  Flow cytometry was used to 
measure the expression of CD4 and CD8. Results are averages ± SD for duplicates. 
One representative experiment out of three independent experiments is shown.  
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3.3.  Discussion 
Effector functions of activated human T cells obtained from healthy controls in the 
absence of the amino acid L-arginine have been assessed and compared to human T 
cells cultured in the presence of L-arginine over the course of 72 hours.  This has been 
done to establish the experimental protocol in terms of methodology and to identify 
the optimum time for the determination of the impact of L-arginine deprivation on 
human T cells.  For these reasons it was important to complete these experiments 
before investigating the effect of L-arginine depletion on T cells from patients with 
HIV infection.   
 
Both CD4+ and CD8+ T cells were examined by looking at three key parameters: i) T 
cell proliferation – assessed by measuring the percentage of T cells incorporating the 
thymidine analogue BrdU and by measuring the percentage of cells with an increased 
size and granularity indicative of blast cells; ii) Expression levels of CD3! (an integral 
part of the T cell receptor) and iii) Expression levels of the CD4 and CD8 cell surface 
molecules. 
 
In the absence of L-arginine, both CD4+ and CD8+ T cells showed decreased 
proliferation at 48 and 72 hours.  The evidence for this was a decrease in the 
percentage of CD4+ and CD8+ T cell that incorporated BrdU (figure 3.2 and table 3.1) 
and a lower percentage of blasting cells (figure 3.3) in the absence of L-arginine.  The 
small amount of proliferation observed in the absence of L-arginine (figure 3.2 and 
table 3.1) is likely to be due to the L-arginine present in the FCS added to the culture 
medium or due to the arginine stored within the cells when they went into culture.  A 
study by Munder et al. shows that when L-arginine was removed by dialyzing, the 
FCS suppression of T cell proliferation was complete (Munder et al., 2006).   
 
After 24 hours the incorporation of BrdU and the increase in size and granularity in 
both the presence and absence of L-arginine was comparable and very low.  This 
absence or very low levels of proliferation, even in the presence of L-arginine, 
suggests that the transduction of the signal for the T cells to proliferate in response to 
the CD3/CD28 stimulus takes time to result in the increased expression of genes that 
drive the cell cycle.  Therefore, it is too early to see the effect of the absence of L-
arginine in the first 24 hours.  Alternatively, it could be that during the first 24 hours 
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the cells are adjusting to the shock of being removed from their usual physiological 
environment in the body and therefore it takes a period of time for the cells to adjust 
to this new environment before proliferation occurs.  This is supported by looking at 
the size and granularity of the cells after 24 hours.  In both the presence and absence 
of L-arginine the cells show a distinct population with a low size (forward scatter) and 
granularity (side scatter) indicative of cells that are not blasting.  This is supported by 
the work of Zea et al. who showed that the absence of L-arginine did not alter calcium 
flux or protein phosphorylation in the first 24 hours of culture (Zea et al., 2004).  
Furthermore, these results are in agreement with the results of Zea et al. which 
showed for the first time that human T lymphocytes stimulated in the absence of L-
arginine had a reduced proliferation as measured by thymidine incorporation (Zea et 
al., 2004) and the results of Munder et al. which showed that the absence of L-
arginine caused reduced T cell proliferation at varying concentrations of anti-CD3 
antibody as by measured [3H]thymidine incorporation and cell division measured by 
CFSE labeling (Munder et al., 2006).  Munder et al. showed that proliferation is most 
reduced in the absence of L-arginine when T cells are stimulated by anti-CD3 and 
anti-CD28-coupled microbeads as these provide maximal stimulation to T cells 
(Munder et al., 2006).   
The results shown here support the literature that T cells polyclonally stimulated in 
the absence of L-arginine have decreased proliferation (Taheri et al., 2001, Rodriguez 
et al., 2002, Rodriguez et al., 2003, Zea et al., 2004, Munder et al., 2006, Choi et al., 
2009).   The results on the use of BrdU incorporation reproduces the findings shown 
by others when measuring proliferation by [3H]thymidine incorporation (Zea et al., 
2004) or CFSE labelling (Munder et al., 2006).  In addition, the results indicate that 
the best time to measure the impact of L-arginine on T cell function is at 48 hours 
when the magnitude of the difference between cells stimulated in the presence and 
absence of L-arginine is greatest (figure 3.5 and table 3.2).  
 
The next parameter investigated was CD3! expression.  CD3! is the main signal 
transduction molecule of the T cell receptor (TCR) complex. Upon presentation to a T 
cell of an antigen in the context of MHC complex by an antigen presenting cell (APC) 
(signal 1) and CD28 co-receptor ligation (signal 2) CD3! ITAM motifs are 
phosphorylated leading to activation of various intracellular signaling cascades, the 
formation of an immunological synapse and activation of the T cell (Baniyash, 2004).  
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This is important as once activated T cells proliferate and produce cytokines that co-
ordinate various cells of the innate and adaptive immune system leading to a 
controlled immune response (Baniyash, 2004).   
After 24 hours, both in the presence and absence of L-arginine, the expression of 
CD3! in both CD4+ and CD8+ T cells is lower compared to its expression post PBMC 
separation (figure 3.5 and table 3.2).  This is in agreement with previous studies 
which show that after ligation of the TCR by antigen, or anti-CD3 antibody, there is a 
cycle of internalisation, T cell receptor degradation, synthesis of new T cell receptor 
components, assembly and eventually re-expression at the cell surface (Valitutti et al., 
1997, Bronstein-Sitton et al., 1999, Baniyash, 2004).  Indeed the study by Zea et al. 
showed that in unstimulated T cells there is no decrease in CD3! expression in the 
presence or the absence of L-arginine and that, in both the presence and the absence 
of L-arginine, activated T cells show a decrease in CD3! expression at 24 hours (Zea 
et al., 2004).  The data shows that the expression of CD3! increases in CD4+ and 
CD8+ T cells cultured in the presence of L-arginine, however, it remains below 
baseline after 24 hours in the cells cultured in the absence of L-arginine (see table 3.2 
and figure 3.5).  This is in agreement with the work of Zea et al. which found an 
initial decrease in CD3! expression followed by a recovery after 24 hours only in the 
presence of L-arginine (Zea et al., 2004).  Interestingly, the absence of other amino 
acids (L-glutamine, L-glycine, L-leucine and L-lysine) did not have an effect on re-
expression of CD3! (Zea et al., 2004).  
Zea et al studied potential causes for decreased CD3! expression in the absence of L-
arginine and found that it was not due to T cell apoptosis, decreased stability of CD3! 
or increased CD3! degradation (Zea et al., 2004).  
As already stated, sustained T cell receptor signalling is required for complete T cell 
activation and subsequent cell proliferation and cytokine production (Baniyash, 
2004).  CD3! availability is the rate-limiting step in TCR complex formation and 
surface expression.  Therefore, it could be hypothesised that in the absence of L-
arginine there is a decreased CD3! synthesis that consequently results in T cell 
hyporesponsiveness.  However, Munder et al. showed that the reduction of 
proliferation in the absence of L-arginine is not exclusively dependent on the T cell 
receptor complex by reproducing the lack of T cell proliferation even when T cells 
were stimulated with PMA and ionomycin which leads to direct activation of protein 
kinase C and Ca2+ signaling without CD3! phosphorylation (Munder et al., 2006).  
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Therefore, the downregulation of CD3! alone does not fully explain the lack of T cell 
proliferation in the absence of L-arginine.  Reduction in CD3! does not prove that it is 
the direct cause of the alteration in T cell function.  It has been shown that in the 
absence of L-arginine T cells are arrested in the G0-G1 phase of the cell cycle 
(Rodriguez et al., 2007).  The transition between phases G0 and G1is regulated by 
cyclin D3 and cyclin-dependent kinase 4(cdk4) both of which are unable to be 
upregulated in the absence of L-arginine leading to cell cycle arrest (Rodriguez et al., 
2007). 
 
The mechanisms behind arginase induced T cell hyporesponsiveness have recently 
been elucidated.  The depletion of L-arginine is sensed by T cells due to the 
accumulation of empty tRNAs.  This activates GCN2 kinase, which phosphorylates 
the serine residue at position 51 of the #-subunit of eukaryotic initiation factor 2# 
(EIF2#).  This results in eIF2# having an increased binding affinity to eIF2' 
preventing eIF2' exchanging GTP for GDP.  Consequently, the eIF2 complex 
prevents methionine aminoacyl tRNA accessing the ribosome inhibiting translation 
initiation (Lee et al., 2003b, Bronte and Zanovello, 2005). 
 
The expression of both CD4 and CD8 was decreased in the absence of L-arginine 
(figure 3.6 and table 3.3).  This is in disagreement with the work of Zea et al. where 
they state that L-arginine did not alter the expression of CD4 and CD8 (Zea et al., 
2004).  However, they do not show their results so it is difficult to know for how long 
they cultured the cells before measuring CD4 and CD8 expression.  Indeed, on the 
basis of our results, if they had only measured CD4 and CD8 expression at 24 hours 
they would not have observed much difference between cells activated in the presence 
and absence of L-arginine (see figure 3.6 and table 3.3).  However, a large difference 
in expression is observed after 48 hours and this fits with a generalised decrease in 
protein translation in the absence of L-arginine (Rodriguez et al., 2007, Rodriguez et 
al., 2010).    
 
T cell hyporesponsiveness caused by the absence of L-arginine has been demonstrated 
in this chapter by reduced proliferation, decreased blast cell formation, reduced CD4 
and CD8 expression and reduced CD3! expression.  In addition, the absence of L-
arginine has other impacts on human T cells.  Munder et al. showed that upregulation 
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of the activation markers CD25 and HLA-DR and the production of the cytokine 
IFN% was dependent on L-arginine (Munder et al., 2006).  Zea et al. demonstrated that 
in the absence of L-arginine not only IFN% but also the production of IL-5 and IL-10 
were reduced however IL-2 was not affected (Zea et al., 2004).  Therefore, in addition 
to the parameters I have investigated, the absence of L-arginine also affects T cell 
activation marker expression and cytokine production.  
T cells are not the only cells of the immune system affected by the absence of L-
arginine. L-arginine deprivation also affects human natural killer (NK) cells (Oberlies 
et al., 2009).  L-arginine depletion markedly reduces proliferation and IL-12/IL-18-
induced secretion of IFN-% in primary NK cells and IL-2 activated NK cells (Oberlies 
et al., 2009).  This suppression of IFN-% production was found to be due to a 
posttranscriptional effect as IFN-% mRNA levels were found to be comparable in the 
presence and absence of L-arginine (Oberlies et al., 2009).  They also showed that 
these functions were not affected by tryptophan depletion and therefore were specific 
to the lack of L-arginine and not just a generalised feature of an amino acid integrated 
stress response (Oberlies et al., 2009).  However, not all NK cell functions were 
affected by the absence of L-arginine.  NK cell viability, CD69 expression, granule 
exocytosis (shown by presence of CD107 on cell surface) and cytotoxicity were not 
altered in the absence of L-arginine (Oberlies et al., 2009).  The demonstration that L-
arginine depletion not only affects T cells but also NK cells is important because this 
means that arginase induced L-arginine depletion affects both the adaptive and innate 
arms of the immune response.  
 
To conclude these results support the fundamental principle that L-arginine depletion 
causes T cell dysfunction in humans.  In the absence of L-arginine activated CD4+ 
and CD8+ human T cell show reduced proliferation, CD4, CD8 and CD3! expression.  
The difference caused by the absence of this single amino acid is marked and is of 
greatest magnitude after 48 hours.  This supports the findings of others who found 
that L-arginine deprivation affects the ability of T cells to up-regulate activation 
markers and to produce the cytokines IFN%, IL-5 and IL-10 (Zea et al., 2004).  Taken 
together this shows that human T cells are rendered functionally hyporesponsive in 
the absence of L-arginine.  It has been known for many years that T cell dysfunction 
is part of the pathogenesis of HIV infection, therefore, in the rest of the thesis the role 
of arginase mediated L-arginine metabolism will be investigated in HIV infection. 
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Chapter IV: Results - Association between arginase activity and HIV disease 
severity  
 
4.1.  Introduction 
HIV-associated down-modulation of the CD3! chain in T cells has previously been 
shown to correlate with HIV disease severity (Geertsma et al., 1999, Trimble et al., 
2000a).  As detailed in chapter 3, reduced CD3! expression is a hallmark of T cell 
hyporesponsiveness caused by L-arginine deprivation.  Based on these findings it is 
hypothesised that arginase activity increases with disease severity in HIV seropositive 
patients and impairs T cell responses, thereby contributing to immune dysfunction and 
disease progression. 
To test this, the level of arginase activity in the plasma and PBMCs of HIV+ patients 
and age-matched uninfected controls have been compared.  This data was then 
combined with the clinical data collected from the patients at the time of 
venipuncture. 
Study enrolment was initiated at the time of routine venipuncture in the clinic.  CD4+ 
T cell count and plasma viral load are frequently measured, as they are important 
clinically for: disease staging; assessment of disease progression; to guide optimum 
timing of treatment initiation and to monitor the response to therapy (Gazzard, 2008).  
CD4+ T cell count and plasma viral load were recorded as there is ample population 
based data which shows that they are good markers for assessing HIV disease severity 
(see section 1.5.5.3.).  In addition, a cohort of patients were recruited where the level 
of PBMC arginase activity was measured and the percentage of CD4+ or CD8+ T cells 
expressing CD38+ or HLA-DR+ was analysed by flow cytometry as means to assess 
the level of immune activation.  Therefore, the combination of the experimental 
results with routine clinical data should answer the question – “Is PBMC arginase 
activity associated with HIV disease progression?”.  
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4.2.  Setting up experiments for chapter 4  
 
4.2.1.  Stability of arginase activity after freeze-thawing 
During the course of this study participants’ PBMC samples were analysed by; 
enzymatic assay; determination of protein concentration; western blot and all assays 
were repeated to increase reliability of the data.  This requires repeated freeze thawing 
of the samples.  As a result, the stability of PBMC arginase activity following 
repeated thawing and freezing was determined. 
After being frozen and thawed on two consecutive days, the level of arginase activity 
in PBMCs from HIV+ patients was measured. As shown in figure 4.1, the arginase 
level in each sample is reproducible after the freeze/thaw process.  Similar results 
were obtained with all the samples thus showing arginase activity is stable. 
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Figure 4.1:  Effect of freeze-thawing on arginase activity 
 
 
 
 
 
Arginase activity after freezing and thawing was determined by enzymatic assay on 
two different days in the PBMCs from HIV positive patients (n=7) 
   
  
 
 
Day 1 
 
 
Day 2
 
Day 2 
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4.3.  Results 
 
4.3.1.  Plasma arginase activity  
Arginase is classically considered to be an intracellular enzyme that only appears in 
the plasma after cell damage or death.  However, due to its expression by neutrophils, 
it may also be released by degranulation (Munder et al., 2005). 
If arginase activity increases with disease severity in HIV infection it may be a 
potential novel marker of immune dysfunction.  The easiest way of measuring 
arginase activity is in the patients’ plasma as this requires minimal processing.  Also, 
the plasma is bathing all of the cells in the intravascular compartment and therefore 
the arginase activity levels in the plasma would reflect what the T cells experience in 
the bloodstream. 
 
4.3.1.1.  Arginase activity in the plasma of HIV positive patients 
First, plasma arginase activity was tested to see if there was a difference between 
HIV+ patients and age matched uninfected controls.  As shown in Figure 4.2, there 
were similar levels of arginase activity in plasma isolated from HIV+ patients and 
uninfected controls (30.90 ± 1.9 mU/mL vs. 26.50 ± 4.1 mU/mL protein, P=0.12, 
median ± SEM). 
 
To summarise, no difference was found in the plasma arginase activity between 
uninfected controls and HIV+ patients.  
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Figure 4.2:  Plasma arginase activity in HIV seropositive patients and age 
matched uninfected controls 
 
 
 
 
Plasma from controls (n=11) and HIV+ patients (n=35) were isolated by 
centrifugation of peripheral blood and the activity of arginase was measured by 
enzymatic assay.  
 
ns = p * 0.05 
Box = interquartile range and median; whiskers = range  
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4.3.1.2.  Associations between plasma arginase activity and CD4+ T cell count 
To investigate the effect of disease progression on plasma arginase activity, the cohort 
of HIV+ patients was subdivided into two groups based on their CD4+ T cell count.  
The end of clinical latency marks a key point in HIV disease progression. From this 
point there is a dramatic decrease in the level of circulating CD4+ T cells.  A cut-off 
CD4+ count of 350 cells/µL was chosen as this is the value below which significant 
differences in clinical outcome start to appear (Phillips and Pezzotti, 2004) and the 
initiation of antiretroviral therapy in the UK is recommended (Gazzard, 2008). 
There was no significant difference in plasma arginase activity from HIV+ patients 
with CD4+ T cell count " 350 cells/µL (CD4low) or CD4+ T cell count  >350 cells/µL 
(CD4high) compared to age-matched uninfected controls (CD4low 29.4 ± 2.1 mU/mL 
vs. 26.5 ± 4.1 mU/mL, P=0.37; CD4high 33.1 ± 3.1 mU/mL vs. 26.5 ± 4.1 mU/mL, 
P=0.05, median ± SEM, Figure 4.3).  In addition, no significant difference in plasma 
arginase activities was found between HIV+ CD4low patients compared with HIV+ 
CD4high patients (29.4 ± 2.1 mU/mL vs. 33.1 ± 3.1 mU/mL, P=0.07, median ± SEM, 
Figure 4.3).  
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Figure 4.3:  Plasma arginase activity in HIV seropositive patients with a CD4+ cell 
count >350 cells/µL compared to HIV seropositive patients with a CD4+ cell 
count #350 cells/µL and uninfected controls  
 
 
 
 
HIV positive patients were divided according to their CD4+ T cell count into CD4high 
>350 cells/µL (n=15) and CD4low "350 cells/µL (n=20) and the activity of arginase 
in the plasma was measured by enzymatic assay. Plasma from uninfected volunteers 
(n=11) was used as controls. 
 
& = median, ns = p * 0.05 
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4.3.2.  PBMC arginase activity 
HIV-associated down-modulation of the CD3! chain in T cells has been shown to 
correlate with HIV disease severity (Geertsma et al., 1999, Trimble et al., 2000a). 
Reduced CD3! expression is also a hallmark of T cell hyporesponsiveness caused by 
L-arginine deprivation (see section 3.2.2.).  The level of arginase activity in the 
PBMC fraction of patients with HIV infection was measured to test the hypothesis 
that arginase activity is increased in HIV-seropositive patients and impairs T cell 
functions.    
 
4.3.2.1.  Arginase activity in PBMCs from HIV+ patients  
First, the levels of arginase activity in the PBMCs of HIV+ patients and age-matched 
uninfected controls were tested.  As shown in Figure 4.4, there were similar levels of 
arginase activity in PBMCs isolated from HIV+ patients and uninfected controls (14.2 
± 3.1 mU/mg protein vs. 12.1 ± 1.5 mU/mg protein, P=0.17, median ± SEM, Figure 
4.4).  Expressing arginase activity in mU/mg protein uses the level of protein as a 
comparative measure.  However, the aim of the study was to assess the levels of 
arginase activity in the blood of HIV+ patients; accordingly, arginase activity has also 
been calculated as mU per ml of blood.  There were no statistically significant 
differences between HIV+ patients and uninfected controls when arginase activity 
measured in mU/ml was compared (HIV+ patients 2.030 ± 1.20 mU/ml vs. uninfected 
controls 1.855 ± 0.49 mU/ml, P=0.50, median ± SEM, data not illustrated see 
appendix tables 9.5 and 9.6 for raw data). 
 
Despite the lack of significance between the two groups, it appears that within the 
HIV+ cohort there is a group of patients whose PBMC arginase activity is greater 
than that in uninfected controls. 
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Figure 4.4:  PBMC arginase activity in HIV seropositive patients and age 
matched uninfected controls 
 
 
 
 
 
 
PBMCs from controls (n=11) and HIV+ patients (n=44) were isolated by Ficoll 
gradient and the activity of arginase was measured by enzymatic assay. 
 
ns = p * 0.05 
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4.3.2.1.1. PBMC arginase activity and CD4+ T cell count 
To investigate the effect of disease progression on arginase activity, the cohort of 
HIV+ patients was subdivided into two groups based on their CD4+ T cell count.  
Arginase activities measured in PBMCs isolated from HIV+ patients with CD4+ T cell 
counts  >350 cells/µL (CD4high) and controls were similar (10.7 ± 1.5 mU/mg 
protein vs. 12.1 ± 1.5 mU/mg protein, P=0.61, median ± SEM, Figure 4.5); however 
arginase activities were significantly higher in HIV+ patients with CD4+ T cell count 
"350 cells/µL (CD4low) as compared to controls (21.9 ± 5.2 mU/mg protein vs. 12.1 
± 1.5 mU/mg protein, P=0.0041, median ± SEM, Figure 4.5).  Moreover, there were 
significantly higher arginase activities in PBMCs from HIV+ CD4low patients 
compared with HIV+ CD4high patients (21.9 ± 5.2 mU/mg protein vs. 10.7 ± 1.5 
mU/mg protein, P=0.0003, median ± SEM, Figure 4.5).    
To exclude that the increased arginase activity observed in the PBMCs of HIV+ 
patients with low CD4+ T cell counts (Figure 4.5) could be due to a switch in the ratio 
of T cells vs. arginase-expressing cells, arginase activity as mU per mL of blood was 
also calculated. There were also significantly higher arginase activities in PBMCs 
from HIV+ CD4low patients compared with HIV+ CD4high patients (2.2 ± 0.3 
mU/mL blood vs. 1.4 ± 0.1 mU/mL blood, P=0.0003, median ± SEM, data not 
illustrated see appendix tables 9.5 and 9.6 for raw data). 
   
These results show that PBMCs from patients with low CD4+ T cell counts express 
higher levels of arginase activity than those with high CD4+ T cell counts. 
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Figure 4.5:  PBMC arginase activity in HIV seropositive patients with CD4+ cell 
counts >350 cells/µL compared to HIV seropositive patients with CD4+ cell 
counts #350 cells/µL and uninfected controls 
 
 
 
HIV positive patients were divided according to their CD4+ T cell counts into 
CD4high >350 cells/µL (n=21) and CD4low "350 cells/µL (n=23). The activity of 
arginase in the PBMCs was measured by enzymatic assay and compared to the 
arginase activity in PBMCs from uninfected controls (n=11) 
 
& = median, ns = p * 0.05,  ** P<0.01, *** P = 0.001 
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4.3.2.1.1.1.  Association between PBMC arginase activity and CD4+ T cell counts 
To analyse whether there is an association between PBMC arginase activity and CD4+ 
T cell counts, the level of PBMC arginase activity was plotted against CD4+ T cell 
counts in HIV+ patients.  As shown in Figure 4.6, there was a highly significant 
inverse association between arginase activities and CD4+ T cell counts in the PBMCs 
from HIV+ patients (Spearman’s rank, r=-0.60, P<0.0001).  Arginase activity was 
also inversely associated with CD4+ T cell counts when arginase activity was 
expressed in mU/mL (Spearman’s rank, r=-0.59, P<0.0001, data not illustrated, see 
appendix tables 9.5 and 9.6 for raw data). 
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Figure 4.6:  Association between arginase activity in the PBMCs and CD4+ T cell 
counts of HIV+ patients 
 
 
 
 
 
Arginase activity in the PBMCs is plotted against CD4+ T cell counts of HIV+ 
patients (n=44) 
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4.3.2.1.1.1.1.  Impact of highly active anti-retroviral therapy (HAART) on the 
association between PBMC arginase activity and CD4+ T cells counts 
Treatment of HIV+ patients with HAART can profoundly suppress viral replication 
(O'Brien et al., 1996) causing an increase in CD4+ T cell count and a restoration of the 
immune dysfunction caused by the virus (Levy, 2007). 
To assess the impact of HAART on arginase activity the cohort was further stratified 
into two groups - patients on HAART (treated) and patients not on HAART 
(untreated).  Interestingly, a highly significant inverse association was found between 
CD4+ T cell counts and arginase activities in PBMCs isolated from the untreated 
group (Figure 4.7A, r=-0.80, P<0.0001), but not in the treated group (Figure 4.7B, r=-
0.25, P=0.25).  Similar results were obtained when the CD4+ T cell counts were 
plotted against arginase activity as expressed as mU/mL of blood (untreated group: 
r=-0.68, P=0.0006; treated: r=-0.23, P=0.30, data not illustrated, see appendix tables 
9.5 and 9.6 for raw data). 
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Figure 4.7:  Impact of highly active anti-retroviral therapy on the association 
between arginase activity in the PBMCs and CD4+ T cell counts of HIV+ patients  
 
 
 
 
 
Arginase activity in the PBMCs is plotted against CD4+ T cell counts. (A) HIV+ 
patients not on HAART (untreated, n=22) and (B) HIV+ patients on HAART (treated, 
n=22). 
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4.3.2.1.2.  Association between PBMC arginase activity and CD8+ T cell counts 
It has been shown that a large fraction of circulating CD8+ T cells from HIV+ patients 
have down-modulated CD3! (Trimble et al., 2000a).  As reduced CD3! expression on 
the surface of cells is a hallmark of T cell hyporesponsiveness caused by arginase 
mediated L-arginine depletion, it was investigated whether there was a similar 
association between CD8+ T cell counts and arginase activity.  Figure 4.8A shows 
there was a significant inverse association between CD8+ T cell counts and arginase 
activity in the HIV+ cohort (r=-0.51, P=0.0004; mU/mL of blood: r=-0.37, P=0.01 
data not illustrated, see appendix tables 9.5 and 9.6 for raw data).  
 
4.3.2.1.2.1.  Impact of HAART on the association between PBMC arginase 
activity and CD8+ T cell counts  
Similar to the results obtained with CD4+ T cells, there was a statistically significant 
inverse association between CD8+ T cell counts and arginase activity in the untreated 
group (mU/mg protein: r=-0.73, P=0.0001, Figure 4.7B; mU/mL of blood: r=-0.51, 
P=0.02, data not illustrated, see appendix tables 9.5 and 9.6 for raw data), but not in 
the treated group (mU/mg protein: r=0.09, P=0.70, Figure 4.7C; mU/mL of blood: r=-
0.03, P=0.89, data not illustrated, see appendix tables 9.5 and 9.6 for raw data). 
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Figure 4.8:  Association between arginase activity in the PBMCs and CD8+ T cell 
counts of HIV+ patients  
 
 
 
 
Arginase activity in the PBMCs is plotted against CD8+ T cell counts for: (A) HIV+ 
patients (n=44); (B) HIV+ patients not on HAART (untreated, n=22) and (C) HIV+ 
patients on HAART (treated, n=22).  
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4.3.2.1.3.  Association between PBMC arginase activity and plasma viral load  
Measurement of the levels of circulating virus provides a direct indication of the 
efficiency of the antiviral response of the patient’s immune system (O'Brien et al., 
1996).  The measurement of plasma HIV-1 RNA is more sensitive than the 
quantitation of either the HIV-1 p24 core antigen in plasma or the infectious virus in 
the blood (O'Brien et al., 1996).  Plasma levels of HIV-1 RNA markedly decrease 
after the initiation of antiretroviral therapy and are a good indicator of clinical 
outcome (O'Brien et al., 1996). 
In light of this, it was investgated whether plasma viral load is associated with 
arginase activity in PBMCs from HIV+ patients.  The results reveal a significant 
association between viral load and arginase activity in PBMCs isolated from HIV+ 
patients (Figure 4.9A, r= 0.38, P=0.01). 
 
4.3.2.1.3.1.  Impact of HAART on the association between PBMC arginase 
activity and plasma viral load 
The cohort of HIV+ patients was subdivided into treated and untreated patients. As 
expected, no association was observed in the treated group, as nearly all patients on 
HAART have an undetectable viral load (Figure 4.7C, r=0.26, P=0.25).  However, the 
association between viral load and arginase activity was significant in untreated 
patients (Figure 4.7B, r=0.53, P=0.01).  Similar results were obtained when the viral 
loads were plotted against arginase activity as expressed as mU/mL of blood 
(untreated group: r=0.47, P=0.03; treated: r=0.25, P=0.27, data not illustrated, see 
appendix tables 9.5 and 9.6 for raw data). 
 
These results show that high viral load correlates with high arginase activity in 
untreated HIV+ patients.   
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Figure 4.9:  Association between arginase activity in the PBMCs and plasma viral 
load of HIV+ patients  
 
 
 
Arginase activity in the PBMCs is plotted against viral load. (A) HIV+ patients 
(n=44), (B) HIV+ patients not on HAART (untreated, n=22) and (C) HIV+ patients 
on HAART (treated, n=22). 
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4.3.2.1.4.  Association between PBMC arginase activity and markers of immune 
activation 
HIV infection causes immune activation which contributes to the pathogenesis of 
disease (see section 1.5.5.3.) and is found to be a predictor of disease progression.  In 
HIV infection, the frequency of CD8+CD38+ and CD8+ HLA-DR+ T cells is elevated 
(Giorgi et al., 1993).  Following seroconversion CD38 and HLA-DR is increased on 
both CD4+ and CD8+ T cells and there is a significant inverse correlation between the 
CD4+ T cell counts and the frequency of CD4+HLA-DR+ T cells (Hazenberg et al., 
2003).  In addition, at 5 years after seroconversion, the expression of HLA-DR on 
CD4+ T cells and CD38 on CD8+ T cells was predictive for the development of AIDS 
(Hazenberg et al., 2003).  Liu et al. found that the level of expression of CD38 on 
CD8+ T cells was more predictive of the development of AIDS or the progression to 
death than plasma viral load (Liu et al., 1998).   
For these reasons, it was investigated whether the frequency of CD38 and HLA-DR 
positive CD4+ and CD8+ T cells was associated with PBMC arginase activity.  As no 
statistically significant association between PBMC arginase activity and CD4+ T cell 
count or plasma viral load was found in patients receiving HAART, the following 
experiments were performed only on HAART naïve HIV+ patients.  
4.3.2.1.4.1.  HLA-DR 
To assess the percentages of HLA-DR-expressing CD4+ and CD8+ T cells, a further 
25 treatment naïve HIV+ patients were recruited and the frequency of HLA-DR was 
measured by flow cytometry.  A statistically significant correlation was observed 
between the frequency of HLA-DR+CD4+ T cells and PBMC arginase activity 
(r=0.70, P=0.0001, Figure 4.10A), but not between HLA-DR+CD8+ T cell and PBMC 
arginase activity(r=0.10, P=0.65, Figure 4.10B). 
4.3.2.1.4.2.  CD38 
As shown in Figures 4.11A and 4.11B, a statistically significant correlation was 
observed between the frequency of CD38+CD8+ T cells and PBMC arginase 
activity(r=0.43, P=0.03), but not CD38+CD4+ T cell and PBMC arginase activity 
(r=0.27, P=0.19). 
 
To summarise it was found that, in HIV+ treatment naïve patients, PBMC arginase 
activity was associated with the frequency of CD38+CD8+ and HLA-DR+CD4+ T 
cells.  
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Figure 4.10:  Association between arginase activity in the PBMCs and percentage 
HLA-DR+ CD4+ and CD8+ T cells in HIV+ patients  
 
 
 
 
The percentage of HLA-DR+ cells was determined by flow cytometry within CD4+ 
and CD8+ T cell populations. The percentage of HLA-DR+ cells in (A) CD4+ (n=25) 
and (B) CD8+ T cells (n=25) was plotted against PBMC arginase activity.   
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Figure 4.11:  Association between arginase activity in the PBMCs and percentage 
CD38+ CD4+ and CD8+ T cells in HIV+ patients  
 
 
 
The percentage of CD38+ cells was determined by flow cytometry within CD4+ and 
CD8+ T cell populations. The percentage of CD38+ cells in (A) CD4+ (n=25) and (B) 
CD8+ T cells  (n=25) was plotted against PBMC arginase activity.   
 
 152 
4.3.2.2.  L-arginine levels in the plasma of HIV+ patients  
In chapter 3, it was shown that the presence of L-arginine in the extracellular milieu 
surrounding the T cells is crucial for T cell function.  In the absence of L-arginine, T 
cell proliferation and CD3! expression were reduced.  The impact of fluctuating L-
arginine levels can be tested experimentally by varying the L-arginine level in the 
culture medium.  However, in vivo, cells in peripheral circulation are bathed in 
plasma.  Arginase is constitutively expressed in human neutrophils and is released 
following degranulation or cell death (Munder et al., 2005, Muller et al., 2009).  Upon 
release into the plasma, arginase can metabolise free L-arginine into L-ornithine and 
urea.  Therefore, it is important to measure the concentration of L-arginine in the 
plasma of HIV+ patients, as this equates to the extracellular level of L-arginine that T 
cells are exposed to in circulation.  
Here, it was hypothesised that the increased arginase activity measured in the PBMC 
fraction of HIV+ patients with low CD4+ T cell counts (Figure 4.5) will be 
accompanied by decreased plasma L-arginine concentrations.   
First, the L-arginine concentrations in the plasma of HIV+ CD4high and HIV+ 
CD4low patients were compared.  As shown in Figure 4.12A, L-arginine levels in the 
plasma of CD4low HIV+ patients were lower than in CD4high HIV+ patients, but this 
difference was not statistically significant  (65.0 ± 6.7 µmol/L vs. 87.0 ± 4.7 µmol/L, 
P=0.17, median ± SEM).  No differences were observed when the cohort of HIV+ 
patients was subdivided into treated and untreated (Figure 4.12B, 71.0 ± 5.8 µmol/L 
vs. 79.5 ± 5.2 µmol/L, P=0.68, median ± SEM).   
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Figure 4.12:  L-arginine levels in the plasma of HIV+ patients divided by CD4+ T 
cell count and treatment status   
 
 
(A)  HIV+ patients were divided according to their CD4+ T cell count into 
CD4high >350 cells/µL (n=13) and CD4low "350 cells/µL (n=17).  
(B)  HIV+ patients were divided according to their treatment status into: patients 
on ART (treated, n=15) and patients not on ART (untreated, n=20). 
& = median, ns = p * 0.05  
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4.3.2.2.1.  Association between PBMC arginase activity and plasma L-arginine 
levels   
Next, the association between L-arginine levels and arginase activity was assessed.  
As shown in Figure 4.13, no significant association was observed between L-arginine 
levels and arginase activity (Figure 4.13A, r=-0.14, P=0.43) when the cohort of 
patients was subdivided into treated patients (Figure 4.13B, r=0.17, P=0.54) and 
untreated patients (Figure 4.13C, r=-0.19, P=0.42).  
However, the HIV+ patients were recruited from two sources: outpatients and 
inpatients.  All the inpatients were hospitalised with AIDS defining illnesses.  
Although all inpatients were recruited prior to commencing HAART, they were 
receiving other therapeutic and/or nutritional interventions. Interestingly, when the 
inpatients (Figure 4.13D, r=-0.14, P=0.78) were removed from the cohort of untreated 
patients, a correlation between arginase activity and L-arginine levels was observed 
(Figure 4.13E, r=-0.59, P=0.03) - as arginase activity in the PBMCs fraction 
increases, the level of L-arginine in the plasma decreases.  
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Figure 4.13:  Association between PBMC arginase activity and L-arginine levels 
in the plasma of HIV+ patients  
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Arginase activity in the PBMCs is plotted against sera L-arginine level.  (A) HIV+ 
patients (n=35); (B) HIV+ patients not on ART (untreated, n=20) and (C) HIV+ 
patients on ART (treated, n=15); (D) HIV+ inpatients not on ART (untreated, n=7) 
and (E) HIV+ outpatients not on ART (untreated, n=13). 
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4.3.2.3.  CD3" chain expression in PBMCs from untreated HIV+ patients  
Arginase-induced L-arginine depletion has been associated with profound T cell 
dysfunction and the expression levels of CD3! in T cells is widely used as a marker of 
T cell hyporesponsiveness (Bronte and Zanovello, 2005, Kropf et al., 2007, Ochoa et 
al., 2007, Popovic et al., 2007).  Since it has been shown that higher arginase activity 
is expressed in PBMCs of CD4low HIV+ patients (Figure 4.5), the level of CD3! 
expression was assessed to see if it coincided with enhanced PBMC arginase activity.  
 
4.3.2.3.1.  CD3" protein expression by Western blot  
To test this, CD3! protein expression in PBMCs from treated and untreated HIV+ 
patients was assessed by Western blot. Samples were chosen from patients with 
similar CD3 T cell counts so that any differences could not be attributed to a 
reduction in T cell number.  Results in Figure 4.14 show that the expression levels of 
CD3! were lower in untreated patients (lanes 5-8) than in treated patients (lanes 1-4).  
Furthermore, higher arginase expression in PBMCs from HIV+ patients was 
associated with decreased levels of CD3! expression (Figure 4.14).  
 
4.3.2.3.2.  CD3" expression in CD4+ and CD8+ T cell by flow cytometry 
To characterise the association of CD3! and arginase activity, a further 18 treatment 
naïve patients were recruited and the MFI of CD3! in CD4+ and CD8+ T cells 
measured by flow cytometry.   
The results in Figures 4.15A and B suggest that, while the expression levels of CD3! 
in both CD4+ and CD8+ T cells decrease with increasing PBMC arginase activities, 
the correlation was not statistically significant (CD4 CD3! MFI vs. arginase: r= -0.41, 
P=0.09; CD8 CD3! MFI vs. arginase: r= -0.43, P=0.07).  In addition, no differences 
were found in CD3! expression on CD4+ or CD8+ T cells between CD4high HIV+ 
patients and CD4low HIV+ patients (CD3!MFI on CD4+ T cells: 134.4 ± 10.91 vs. 
121.1 ± 14.37, p=0.41; CD3!MFI on CD8+ T cells: 93.10 ± 6.97 vs. 85.75 ± 9.77, p= 
0.70, median ± SEM) 
 
To summarise, although qualitative analysis by flow cytometry is suggestive of an 
association between the level of CD3! expression and PBMC arginase activity, CD3! 
expression was reduced when PBMC arginase activity is elevated by western blot.  
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Figure 4.14:  PBMCs arginase activity and CD3" expression by western blot 
 
 
 
PBMCs were isolated by Ficoll gradient from the blood of treated HIV+ patients 
(lanes 1-4, CD3+ T cell count = 1250.0 ± 107.2 cells/µL) and untreated patient (lanes 
5-8, CD3+ T cell count = 1152.5 ± 228.9 cells/µL).  Arginase activity was measured 
by enzymatic assay and CD3! expression by Western Blot. One representative 
experiment out of four independent experiments is shown. 
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Figure 4.15:  Association between PBMC arginase activity and CD3" expression 
in CD4+ and CD8+ T cell from untreated HIV+ patients by flow cytometry  
 
 
 
 
 
 
 
PBMCs were isolated by density gradient centrifugation from the blood of untreated 
HIV+ patients.  The mean fluorescence intensity of CD3! was determined by flow 
cytometry within CD4+ cells and CD8+ T cell populations.  The CD3! MFI in (A) 
CD4+ T cells (n=18) and (B) CD8+ T cells (n=18) was plotted against arginase 
activity.   
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4.4.  Discussion 
In this chapter arginase activity was compared between HIV+ patients and uninfected 
controls in both the plasma and the PBMC fraction of the blood.  
 
Arginase activity is detected in the plasma due to the fact that it is released from cells 
by degranulation and after cell damage or death (Munder et al., 2005).  In the plasma 
there was no significant difference in arginase activity between uninfected controls 
and HIV+ patients (figure 4.2).  Moreover, there was no difference between plasma 
arginase activity from patients with a low CD4+ T cell count and uninfected controls 
or patients with a high CD4+ T cell count.  From this it can be concluded that plasma 
arginase activity is not associated with disease severity in HIV+ patients.  This is not 
unexpected as when we have measured arginase levels in the plasma of other human 
infectious diseases including tuberculosis and cutaneous leishmaniasis we have found 
no difference in the arginase activity between patients and uninfected controls (private 
communication T Cloke, I Müller and P Kropf).  This may be ascribed to the 
sensitivity of plasma arginase assay - it may not be sensitive enough to pick up 
changes in arginase activity in the plasma. Alternatively, it may be because the 
increase in arginase activity is transient and cleared from the plasma rapidly.   
However, more importantly, it is emerging that arginase mediated L-arginine 
depletion is a localised mechanism of immune regulation (Kropf et al., 2007, 
Modolell et al., 2009).  Consequently, it is possible, that by sampling in the plasma, 
the effect of increased arginase activity at the local site (for HIV infection in the 
lymphoid tissue) is diluted down by the circulating volume and is not detectable with 
the sensitivity of assay that is currently used.     
 
When comparing PBMC arginase activity between uninfected controls and all HIV+ 
patients (figure 4.4) there is no significant difference.  This lack of significance is 
expected as this is a cross-sectional cohort of HIV positive patients and, as such, 
includes patients both on and off HAART and at different points of disease 
progression.  Although it is of note, there is clearly a group of patients within the 
HIV+ cohort that have a higher PBMC arginase activity than uninfected controls.  
Indeed, when the cohort is subdivided into two groups based on their CD4+ T cell 
counts, it is clear that PBMCs from HIV+ CD4low patients express significantly more 
arginase activity than HIV+ CD4high patients (figure 4.5).  Moreover, there is a 
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significant association between the level of PBMC arginase activity and plasma viral 
load or CD4+ T cell count in untreated HIV+ patients.  Patients with a low CD4+ T 
cell count or a high viral load tend to have high levels of PBMC arginase activity.   
These results show that PBMC arginase activity in HIV+ patients is associated with 
two well-described markers of disease progression: high plasma viraemia and low 
CD4+ T cell counts.   
The association between PBMC arginase activity and HIV disease severity is further 
supported by the association of PBMC arginase activity with the percentage of 
CD8+CD38+ T cells and the percentage of CD4+HLA-DR+ T cells in untreated HIV 
positive patients.  These are both markers of immune activation.  HIV infection is 
known to cause chronic immune activation that results in bystander T cell death and 
eventually immune exhaustion with progression to AIDS (Appay and Sauce, 2008).  
Elevated CD8+CD38+ expression is well established as a marker of HIV disease 
severity.  This association strengthens the evidence that PBMC arginase activity is 
increased during the progression of HIV infection to AIDS.  It may seem paradoxical 
that arginase activity - which depletes L-arginine leading to T cell 
hyporesponsiveness - is associated with increased T cell activation.  However, it can 
be hypothesised that upregulation of arginase activity is the body’s attempt at 
homeostasis to bring down the level of inflammation and immune exhaustion in the 
face of chronic T cell activation. 
 
The data also shows that the levels of L-arginine are lower in the plasma of CD4low 
HIV+ patients than CD4high HIV+ patients and that higher arginase activity 
correlates with lower plasma L-arginine concentrations in the cohort of HIV+ 
untreated outpatients.  Although, it may appear that this cohort selection is a 
convenient result of post-hoc analysis.  When considering the entire untreated cohort, 
the lack of association between PBMC arginase activity and plasma L-arginine level 
could be attributed to the inpatients that had not commenced HAART but were 
receiving therapeutic and/or nutritional interventions.  If these interventions resulted 
in increased plasma L-arginine by decreasing arginase activity, this would skew any 
association found.  However, immunoregulation by arginase mediated L-arginine 
depletion is a localised phenomenon (Kropf et al., 2007, Modolell et al., 2009).  The 
local occurrence of this immunoregulatory mechanism is clearly evidenced by the 
physiological upregulation of arginase activity in the placenta in human pregnancy 
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(Kropf et al., 2007) and in the pathological upregulation at the local site of cutaneous 
lesions in experimental murine leishmaniasis (Kropf et al., 2005). 
In pregnancy the levels of arginase activity are highest in the placenta at the time of 
birth (Kropf et al., 2007).  In addition, in murine models of non-healing leishmaniasis, 
L-arginine depletion by arginase activity resulting in T cell hyporesponsiveness was 
most pronounced at the site of pathology, in the footpad lesions (Modolell et al., 
2009). By comparison, there was only minor downregulation of T cell responses in 
the regional lymph node (Modolell et al., 2009).  This supports the theory that 
arginase-induced T cell hyporesponsiveness is a localised mechanism of 
immunosuppression.  In the present study, the levels of arginase activity were 
measured in the PBMC fraction of the blood.  The anatomical reservoirs of HIV are 
defined by the tissue distribution of target cells, i.e. the gastrointestinal tract during 
acute HIV infection and into the chronic phase, other peripheral lymphoid organs 
(Stebbing et al., 2004).  There are many more HIV-infected cells in the lymph nodes 
than in the blood (Mehandru et al., 2004).  Consequently, it is possible that the 
enhanced levels of arginase activity observed in the PBMCs of untreated HIV+ 
patients in this study are merely a reflection of strongly increased arginase expression 
in local reservoirs of HIV infection such as the gastrointestinal track or the lymph 
nodes. It is also possible that the reduced L-arginine level at these local sites is not 
overtly evident at the level of total peripheral circulation.   
Therefore, it is possible that when looking at the association between plasma L-
arginine and PBMC arginase activity in all HAART naïve patients that firstly, other 
therapeutic or nutritional interventions are affecting total blood plasma L-arginine 
levels. Or, secondly, the most pronounced upregulation of arginase activity is at the 
anatomical reservoirs of HIV infection where there is a decreased level of L-arginine 
in the local micro-milieu leading to T cell hyporesponsiveness but this decrease in L-
arginine is less pronounced at the level of total peripheral circulation. These are not 
necessarily mutually exclusive. 
 
To assess the functional consequences of these low L-arginine levels, the level of 
CD3! expression in PBMCs was measured.  As shown in chapter 3, CD3! is 
commonly used as a marker of T cell hyporesponsiveness due to L-arginine depletion  
(Bansal and Ochoa, 2003, Bronte and Zanovello, 2005).  CD3! chain is shown to be 
downregulated in untreated HIV+ patients with high PBMC arginase activity by 
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western blot (see figure 4.14). Surprisingly though, there was not a statistically 
significant association between PBMC arginase activity and the level of CD3! 
expression in CD4+ or CD8+ T cells as measured by flow cytometry in this study.  The 
data suggests that the expression levels of CD3! decrease with increasing arginase 
activities (figure 4.15A and B); however, the correlation was not statistically 
significant.  This is in disagreement with the work by Geertsma et al. who showed a 
correlation between low CD3! chain expression and low CD4+ T cell count or high 
viral load (Geertsma et al., 1999).  Notably, in their study, the CD4+ T cell count 
profile of HIV+ patients recruited was markedly different from the cohort presented 
here, as they recruited considerably more patients with low CD4+ T cell counts: 33% 
of the HIV+ patients had a CD4+ T cell count below 10, 52% between 10 and 200 and 
15% between 200 and 600.  By contrast, in the cohort presented here: 0% of the HIV+ 
patients had a CD4+ T cell count below 10, 22% between 10 and 200, 50% between 
200 and 600, and 28% above 600.  In addition, when CD3! MFI was plotted against 
CD4+ T cell counts or viral load, there was no correlation (r=0.23, P=0.37; r=-0.36, 
P=0.13, respectively).   
These apparent contradictions between the results of Geertsma et al. and the data 
presented in this chapter are therefore likely to be due differences in proportion of 
AIDS patients with a CD4+ T cells count < 200 cells/µl.  These patients represent 
advanced disease progression where T cell dysfunction is most pronounced and so 
changes in CD3! expression would be most apparent.  Due to the advent of HAART 
with a favourable side effects profile, patients now start therapy earlier and as a result 
there were fewer advanced HAART naïve patients recruited in the cohort presented 
here.   Furthermore, as stated earlier, arginase-induced L-arginine depletion is a 
localised effect and consequently the downregulation of T cell function and CD3! 
expression is likely to be most pronounced in the anatomical reservoirs of HIV 
infection – the gastrointestinal tract and the lymphoid organs.  
 
To conclude, the data presented in this chapter shows that PBMC arginase activity is 
associated with disease severity in untreated HIV+ patients and that high PBMC 
arginase activity is associated with a reduced expression of CD3! as measured by 
western blot.  This supports the hypothesis that high arginase activity results in lower 
levels of L-arginine, thereby contributing to dysregulation of T cell responses in HIV 
infection.  
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Whether T cell function can be rescued once T cells have been activated in 
subphysiological levels of L-arginine is an important question.  It has been shown in 
the murine model of experimental leishmaniasis that Leishmania major-specific T 
cells stimulated ex vivo in the absence of L-arginine had reduced proliferation and 
IFN% cytokine production and that these functions could not be rescued by the 
addition of exogenous L-arginine (Munder et al., 2009).  In view of this, it is tempting 
to hypothesise that in the anatomical reservoirs of HIV there is high arginase activity 
resulting in low L-arginine bioavailability and T cells stimulated in this environment 
are functionally hyporesponsive.  Here, it was found that untreated patients with high 
PBMC arginase activity had reduced expression of CD3! by western blot.  CD3! is a 
hallmark of T cell hyporesponsiveness caused by L-arginine depletion.  It could then 
follow that these T cells were stimulated in a location where there was high arginase 
activity resulting in a reduction of free L-arginine and consequently a low CD3! 
expression and that these T cell’s function or CD3! expression cannot be rescued even 
if they return to the circulating pool of lymphocytes where L-arginine levels are 
normal.   
 
4.4.1.  PBMC arginase activity as a marker of disease severity   
Arginase activity has been found to be associated with disease severity in a number of 
different human pathologies.  For example in tuberculosis, active pulmonary disease 
is associated with higher PBMC arginase activity and lower plasma L-arginine levels 
compared to latent disease (Zea et al., 2006).  In addition, T cell CD3! expression is 
associated with PMBC arginase activity and CD3! expression increases following 
successful anti-TB therapy (Zea et al., 2006).  In prostate-, gallbladder- and 
colorectal- cancer it has been found that arginase activity is higher in more advanced 
tumours (Harris et al., 1983, Pretlow et al., 1985, Leu and Wang, 1992, Shukla et al., 
2009).  Arginase activity has also been found to be associated with other accepted 
measures of disease severity.  In the case of trauma, arginase activity is associated 
with serum lactate levels (Ochoa et al., 2001); in cystic fibrosis it is associated with 
force expiratory volume in one second (FEV1) as a marker of respiratory function 
(Grasemann et al., 2005) and in asthma it is associated with the inflammatory marker 
C-reactive protein (CRP) (Ogino et al., 2011).   Arginase activity is also associated 
with direct measures of morbidity.   For example, in trauma, arginase activity is 
associated with length of stay in intensive care (Ochoa et al., 2001) and in malaria, 
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dysregulated arginine metabolism assessed by the ratio of L-arginine: L-ornithine was 
associated with prospective mortality (Morris et al., 2005).   
In HIV infection, patients can progress to AIDS at variable rates.  There is a strong 
correlation between low plasma viral load, stable CD4+ T cell counts and long-term 
non-progressive HIV infection.  Conversely, rapid progression is associated with high 
viral load, rapid loss of CD4+ T cells and lack of immune response (Saksena et al., 
2007).  In particular, whilst there is ample population-based data correlating clinical 
outcomes with absolute CD4+ T cell counts, it is also apparent that individual 
outcomes vary widely at any given CD4+ T cell count.  Some HIV+ patients with low 
CD4+ T cell counts do not progress to AIDS (Keet et al., 1997) and AIDS patients can 
exhibit early CD4+ T cell dysfunctions prior to severe CD4+ T cell depletion (Shearer 
and Clerici, 1991).  Due to this phenomenon, policy dictating HAART initiation has 
to be very conservative.  Often patients start treatment when they are asymptomatic.  
The downside of this early initiation is: the cost of the medication to the healthcare 
provider; the increased probability of side effects and the development of drug 
resistance by the patient.  If there was a way to measure immune dysfunction in 
addition to CD4+ T cell count and viral load this might help better inform when 
HAART should be initiated and allow more effective treatment rationing.  This is 
particularly relevant where resources are limited such as the NHS and in resource 
poor countries.  In these countries the number of new infections continues to outstrip 
the advances in treatment coverage.   
Based on the results presented in this chapter, PBMC arginase activity might be one 
such marker as it is associated with CD4+ T cell count, plasma viral load and markers 
of immune activation in untreated HIV+ patients.  This data implies that either the 
high levels of virion or the resulting immune dysfunction could be responsible for the 
observed increase in PBMC arginase activity.  If this is true, PBMC arginase activity 
may be a reliable indicator of immune dysfunction.  
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Chapter V: Results - Identification and characterisation of arginase expressing 
cells in HIV infection 
 
In Chapter 4, it was shown that PBMC arginase activity is associated with disease 
severity in untreated HIV+ patients.  The aim of this chapter is to identify and 
characterise the cells that are responsible for increased arginase activity in the PBMC 
fraction.  This was done by:  
1. Identifying the arginase 1+ cells that co-purify in the PBMC fraction following 
density gradient centrifugation  
2. Measuring the level of expression of arginase 1 to see if it is associated with 
PBMC arginase activity  
3. Measuring the frequency of arginase1+ cells to see if it is associated with 
PBMC arginase activity   
4. Investigating whether the frequency of arginase1+ cells in the PBMC fraction 
is associated with HIV disease severity as measured by CD4+ T cell count and 
plasma viral load 
5. Studying the levels and expression patterns of six polymorphonuclear cell 
phenotypic markers (CD11b, CD13, CD15, CD16, CD33 and CD66b) on 
arginase 1+ cells in the PBMC and erythrocyte fractions 
6. Measuring the level of expression of arginase 1+ in arginase 1+ cells in the 
PBMC and erythrocyte fractions  
7. Measuring the expression of CD63, a marker of neutrophil degranulation  
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5.1.  Optimisation of protocols  
5.1.1.  Stability of arginase 1 producing cells in PBMC fraction  
Before embarking on identifying and characterising the arginase 1+ cells in the PBMC 
fraction of untreated HIV+ patients, investigations were carried out to ascertain if 
there were any factors that affected the frequency of arginase 1+ cells.  The frequency 
of arginase1+ cells using different anticoagulants used during blood collection 
(Ethylenediaminetetraacetic acid (EDTA) vs. Sodium Heparin (NH)) was evaluated.   
 
5.1.2.  Effect of anti-coagulant on frequency of arginase 1+ cells 
This was tested by collecting blood samples from the same subject in both EDTA and 
NH vacutainers. The samples were then processed in tandem so their treatment was as 
consistent as possible.  PBMCs were isolated by density gradient centrifugation from 
the blood.  The frequency of arginase 1+ cells in the PBMC fraction was determined 
by flow cytometry.  As shown in Table 5.1, blood stored in NH has markedly fewer 
arginase1+ cells in the PBMC fraction.  This was repeated on three separate occasions 
using different control subjects and on average there is 75.56 ± 17.26 % less arginase 
1+ cells in blood collected in NH compared to EDTA.    
Due to the dramatically lower yield of arginase 1+ cells in sodium heparin, EDTA 
vacutainers continued to be used for blood collection.   
 
 
 
 168 
Table 5.1:  Effect of anti-coagulant on frequency of arginase 1+ cells  
 
 
 % ARG1+ in PBMC fraction 
Test 1 2 3 
Average ± SD 
EDTA 2.77 1.41 3.27 2.48 ± 0.96 
NH 0.13 0.45 1.2 0.59 ± 0.55 
% change -95.31 -68.09 -63.30 -75.56 ± 17.26 
  
Blood was collected in EDTA and NH vacutainers from the same subject at the same 
time.  The blood was then processed in tandem and PBMCs were isolated by density 
gradient centrifugation.  The frequency of arginase 1+ cells in the PBMC fraction was 
determined by flow cytometry. Abbreviations: EDTA = Ethylenediaminetetraacetic 
acid; NH = Sodium Heparin  
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5.2.  Results  
5.2.1.  Identification of arginase producing cells in the PBMC  
In chapter III, it was shown that there is higher arginase activity in PBMCs from 
HIV+ patients with CD4+ T cell counts below 350 cells/mL (Figure 4.5).  In humans, 
the main arginase-expressing cell types are neutrophils (Munder et al., 2005), 
alternatively activated macrophages (Kropf et al., 2007) and myeloid derived 
suppressor cells (Ochoa et al., 2007).  The aim of the following experiments was to 
identify the phenotype of arginase-expressing cells in PBMCs of HIV+ patients.   
Flow cytometry was used to determine the phenotype of arginase 1 producing cells.  
A hierarchical gating strategy was applied to the analysis of the flow cytometry data 
acquired (figure 5.1).  The gates were applied in the following order: i) a singlet gate 
was set; ii) a region was drawn around the living cells to exclude dead cells and 
debris; iii) backgating was applied to the arginase 1+ cells and a tight region was set 
on the forward and side scatter.  Within the PBMC fraction  the expression of arginase 
was determined in the following populations: i) CD15+ cells (a marker of 
polymorphonuclear cells); ii) CD14+ cells (a marker of monocytic cells) and iii) 
CD1a+ cells (a marker of dendritic cells). 
As shown in Figure 5.2A, 93% (20.22% of 21.84%) of arginase-expressing cells are 
CD15+.  In addition, <1% of CD14+ cells and <0.1% CD1a+ express arginase (Figure 
5.2B and C). These results were confirmed on an additional 33 patients and in all 
cases > 90% of the arginase 1+ cells were found to be CD15+. 
The arginase 1+ cells express low levels of CD14 – CD14 MFI of arginase 1+ cells is 
9.05 compared to 7.56 on CD14- cells respectively (figure 5.2B).  This suggests that 
all CD15+ cells in the PBMC fraction express low levels of CD14 (Kropf et al., 2007) 
and are a distinct population from the CD14hi monocytes (figure 5.3).   
 
To summarise, the arginase expressing cells found in the PBMC fraction of HIV+ 
patients after density gradient centrifugation are CD15+ CD14low. 
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Figure 5.1:  Gating strategy to identify arginase 1+ cell in the PBMC fraction  
 
 
 
PBMCs were isolated by density gradient centrifugation from the blood of HIV+ 
patients.  The following gating strategy was applied before analysis of arginase 
expressing cells: i) a singlet gate was set; ii) a region was drawn around the living 
cells to exclude dead cells and debris; iii) backgating was applied to the arginase 1 
positive cells and a tight region was set on the forward and side scatter. 
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Figure 5.2:  Identification of arginase-expressing cells in PBMCs fraction of blood 
from patients with HIV infection  
 
 
PBMCs were isolated by density gradient centrifugation from the blood of HIV+ 
patients.  The phenotype of arginase-expressing cells was determined by flow 
cytometry.  
(A) Arginase 1 vs. CD15 dot plot 
(B) Arginase 1 vs. CD14 dot plot 
(C) Arginase 1 vs. CD1a dot plot  
 
Data shows the results of one representative experiment out of 33 independent 
experiments. 
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Figure 5.3:  Analysis of CD14+ and CD15+ cells 
 
 
 
 
PBMCs were isolated by density gradient centrifugation from the blood of HIV+ 
patients.  The expression of CD14 and CD15 was determined by flow cytometry. Data 
shows the results of one representative experiment out of 33 independent experiments. 
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5.2.2.  Nomenclature used to describe the two populations of CD15+ARG1+ cells 
that co-purify in the PBMC or erythrocyte fractions after density gradient 
centrifugation 
 
By virtue of the location of these two populations of granulocytic cells following 
density gradient centrifugation, a fundamental difference in these two populations is 
their density (see figure 5.4).  Therefore, throughout the rest of this chapter and the 
remaining sections of the thesis the two populations will be referred to as:  
o LDGs = Low-density granulocytes– are CD15+ARG1+ cells that co-purify in 
the PBMC fraction after density gradient centrifugation 
o NDGs = Normal-density granulocytes – are CD15+ARG1+ cells that co-purify 
in the erythrocyte fraction after density gradient centrifugation 
 
Figure 5.4:  Diagram showing the location of the PBMC fraction (containing low 
density granulocytes) and the erythrocyte fraction (containing normal density 
granulocytes) following density gradient centrifugation 
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5.2.3.  Association between arginase 1 MFI and arginase activity 
 
It was investigated whether LDG arginase 1 MFI is a good indicator of PBMC 
arginase activity.  This was studied as it could be hypothesised that, as the intensity of 
arginase 1 increases per cell (represented by the ARG1 MFI), this causes increased 
arginase activity.   
The MFI of arginase 1 was measured by flow cytometry and plotted against PBMC 
arginase activity.   As shown in Figure 5.5, there was no correlation between the 
levels of arginase activity measured by enzymatic assay and the MFI (r=0.17, 
P=0.41). 
 
To summarise, there is no association between LDG arginase 1 MFI and PBMC 
arginase activity.  
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Figure 5.5:  Association between PBMC arginase activity and LDG arginase 1 
expression in untreated HIV+ patients by flow cytometry  
 
 
 
 
 
PBMCs were isolated by density gradient centrifugation from the blood of HIV+ 
patients.  The arginase 1 MFI in CD15+ was determined by flow cytometry and 
plotted against PBMC arginase activity (n=25).   
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5.2.4 Association between the percentage of LDGs in the PBMC fraction and 
PBMC arginase activity  
The increase in PBMC arginase activity in HIV+ patients could be due to an increase 
in the frequency of LDGs.   As LDGs are CD15+, this was tested by determining the 
frequency of CD15+ cells in the PBMCs fraction by flow cytometry.  
Figure 5.6 is a representative experiment showing the location of LDGs on a forward 
and side scatter dot plot.  Patient 1’s LDGs represent 0.58% of PBMC fraction 
compared to patient 2 whose LDGs represent 13.91% of PBMC fraction (Patient 1 
CD4+ T cell count: 580 cells/mL; viral load: 2.39 log10copies/mL; Patient 2 CD4+ T 
cell count: 25 cells/mL; Viral load: 5.57 log10copies/mL, figure 5.6). 
To further investigate how the frequency of LDGs is associated with HIV disease 
severity, the frequency of CD15+ cells in the PBMCs fraction was plotted against the 
level of PBMC arginase activity.  Figure 5.7 shows there is a strong correlation 
between the levels of arginase activity and the frequency of CD15+ cells in PBMCs 
(r=0.75, P=<0.0001).  
 
To summarise, there is a strong association between the frequency LDGs and PBMC 
arginase activity.  
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Figure 5.6:  Representative flow cytometry data showing the size and granularity 
of LDGs from two untreated HIV+ patients one with a CD4+ T cell count #350 
cells/mL and one with CD4+ T cell count >350 cells/mL  
 
 
 
PBMCs were isolated by density gradient centrifugation from the blood of HIV+ 
patients.  The percentage of CD15+arginase 1+ cells in the PBMC fraction was 
determined by flow cytometry.  Cells highlighted in green are CD15+arginase 1+ cells. 
This is one representative experiment of 33 independent experiments.  
 178 
Figure 5.7:  Association between PBMC arginase activity and frequency of CD15+ 
cells in the PBMC fraction of untreated HIV+ patients as determined by flow 
cytometry  
 
 
 
PBMCs were isolated by density gradient centrifugation from the blood of HIV+ 
patients.  The percentage of CD15+arginase 1+ cells in the PBMC fraction was 
determined by flow cytometry and plotted against PBMC arginase activity (n=25). 
Inset shows magnification of data of patients whose percentage CD15+arginase 1+ in 
PBMC fraction was between 0-6%. 
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5.2.5.  Association between percentage of LDGs and HIV disease severity 
CD4+ T cell count and plasma viral load are the two most clinically relevant markers 
of HIV disease severity. In untreated HIV+ patients PBMC arginase activity was 
associated with CD4+ T cell count and plasma viral load (see chapter IV sections 
4.3.1.1. and 4.3.1.3.).  As a result, it was investigated whether the frequency of LDGs 
was also associated with HIV disease severity as measured by CD4+ T cell count and 
plasma viral load in untreated HIV+ patients. 
To investigate the effect of disease progression on arginase activity, the cohort of 
untreated HIV+ patients was subdivided into two groups based on their CD4+ T cell 
count.  A cut-off CD4+ count of 350 cell/µL was chosen as this is the value below 
which significant differences in clinical outcome start to appear (Phillips and Pezzotti, 
2004). 
The frequency of LDGs in untreated HIV+ patients with CD4+ T cell count "350 
cells/µL (CD4low) was significantly higher than for patients with CD4+ T cell count  
>350 cells/µL (CD4high) (5.65 ± 2.9 % vs. 0.76 ± 0.77%, P=0.0062, Figure 5.8A).  
Next, the frequency of CD15+ cells in the PBMCs fraction was plotted against the 
CD4+ T cell count.  Figure 5.8B shows there is a strong correlation between the CD4+ 
T cell count and the frequency of LDGs (r=-0.70, P=0.0004, Figure 5.8B). 
In addition, frequency of LDGs was plotted against the plasma viral load.  Figure 5.9 
shows there is a strong correlation between the plasma viral load and the frequency of 
LDGs (r=0.62, P=0.0058). 
 
These results show untreated patients with a low CD4+ T cell count have a higher 
frequency of LDGs and that the frequency LDGs is associated with both CD4+ T cell 
count and plasma viral load. 
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Figure 5.8:  Association between percentage of LDGs and CD4+ T cell count 
 
 
 
PBMCs were isolated by density gradient centrifugation from the blood of HIV+ 
patients.  The percentage of LDGs (CD15+arginase 1+ cells in the PBMC fraction) 
was determined by flow cytometry: 
 
(A)  Untreated HIV+ patients were divided according to their CD4+ T cell count 
into CD4high >350 cells/µL (n=9) and CD4low "350 cells/µL (n=12).  
 & = median, ** P<0.01 
(B)  The percentage of LDGs in the PBMC fraction was plotted against CD4+ T 
cell count of untreated HIV+ patients (n=21)  
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Figure 5.9:  Association between the percentage of LDGs in the PBMC fraction 
and plasma viral load 
 
 
 
 
PBMCs were isolated by density gradient centrifugation from the blood of untreated 
HIV+ patients.  The percentage of LDGs (CD15+arginase 1+ cells) in the PBMC 
fraction was determined by flow cytometry and plotted against plasma viral load for 
untreated HIV+ patients (n=18) 
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5.2.6.  Differences between LDGs and NDGs  
In untreated HIV+ patients both PBMC arginase activity and the percentage of LDGs 
are associated with disease severity and, as such, it is important to investigate how 
these cells are different from NDGs.  
This was done by determining the differences between LDGs and NDGs with regard 
to the following parameters: i) Size and granularity; ii) Expression of a panel of 
neutrophil phenotypic markers; iii) Expression of arginase and  iv) Degree of 
degranulation.  
 
5.2.6.1.  Difference in size and granularity between LDGs and NDGs 
Density gradient centrifugation separates cells on the basis of their density.  Density 
could be affected by varying the size and the granularity of the cells.  Therefore, size 
and granularity of LDGs and NDGs was studied by flow cytometry by measuring 
forward and side scatter respectively.  
As shown in figure 5.10A, LDGs have a larger size (as measured by forward scatter) 
than NDGs (111’000 ± 3,042 vs. 106’000 ± 3’119, P=0.0015, Figure 5.10A).  In 
addition, the granularity (as measured by side scatter) of the LDGs was greater than 
NDGs (110’000 ± 6’505 vs. 88’918 ± 5’242, P=0.0112, Figure 5.10B). 
 
In summary, LDGs are statistically significantly larger and more granular than NDGs. 
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Figure 5.10: Difference in size and granularity between LDGs and NDGs  
 
 
Leukocytes from untreated HIV+ patients (n=21) were separated into PBMCs and 
NDGs by density gradient centrifugation. NDGs were purified from the erythrocyte 
fraction using dextran sulphate sedimentation and hypotonic lysis to remove the 
erythrocytes. 
(A)  The forward scatter of the LDGs and NDGs was determined by flow 
cytometry 
 ** P<0.01 
(B)  The side scatter of the LDGs and NDGs was determined by flow cytometry  
 * P<0.05 
Box = interquartile range and median; whiskers = range  
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5.2.6.2.  Phenotypic differences between LDGs and NDGs  
In an attempt to further characterise the difference between LDGs and NDGs, the 
levels of expression of a panel of six markers were measured by flow cytometry.  The 
polymorphonuclear cell markers investigated were CD15, CD11b, CD13, CD16, 
CD33 and CD66b.   
Both LDGs and NDGs express all of these markers thus the aim of the following 
experiments was to determine whether there were differences in the level of 
expression between these two populations of granulocytes.  
In order to assess the differences between these two cell populations NDGs were 
purified from the erythrocyte fraction after density gradient centrifugation.  Flow 
cytometry was then used to gate on the LDGs (CD15+arginase1+ cells) in the PBMC 
fraction and the NDGs and the level of expression of the six phenotypic markers was 
compared.  
As can be seen in figure 5.11 and table 5.3 there are considerable phenotypic 
differences between LDGs and NDGs.  LDGs had statistically significant higher 
expression of CD15, CD33 and CD66b (Figure 5.11C, E and F) and a statistically 
significant lower expression of CD16 (Figure 5.11D).  No statistically significant 
differences were found in the expression of CD11b and CD13 (Figure 5.11A and B).  
Particularly notable was CD15 expression that was on average three times higher in 
LDGs compared to NDGs (Table 5.3B). 
 
To summarise, LDGs are phenotypically different from NDGs in that they express 
higher levels of CD15, CD33 and CD66b and lower levels of CD16. 
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Figure 5.11:  Difference in phenotypic markers between LDGs and NDGs  
 
 
 
Leukocytes from untreated HIV+ patients (n=21) were separated into PBMCs and 
NDGs.  The level of expression of (A) CD11b (n=10), (B) CD13 (n=21),(C) CD15 
(n=10), (D) CD16 (n=10), (E) CD33 (n=10) and (F) CD66b (n=21) was measured in 
LDGs and NDGs by flow cytometry.  
 
* P <0.05  *** P <0.001  
Box = interquartile range and median; whiskers = range  
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Table 5.3:  Summary of the difference in the expression of phenotypic markers 
between LDGs and NDGs  
A. 
 LDGs  NDGs 
Phenotypic 
Marker 
Median ± SEM  Median ± SEM  
Wilcoxon 
signed rank 
test P value  
CD11b 4157 ± 743.4  2389 ± 385.9 0.05 
CD13 2431 ± 367.6 3314 ± 321.4 0.33 
CD15 7874 ± 1498 2223 ± 792.4 0.0020 
CD16 6997 ± 1354 9680 ± 985.1 0.0020 
CD33 3681 ± 280.9 2465 ± 212.7  0.0020 
CD66b 8025 ± 1088 7697 ± 471.7 0.026 
 
B. 
Phenotypic 
Marker 
 Mean ± SEM percentage change in LDGs compared to NDGs  
CD11b 42 ± 12.70 %  
CD13 -11.04 ± 9.061 % 
CD15 300.5 ± 65.57 % 
CD16 20.17 ± 20.46 % 
CD33 49.03 ± 10.68 % 
CD66b 34.91 ± 13.84 % 
 
Leukocytes from untreated HIV+ patients were separated into PBMCs and NDGs.   
(A) The level of expression of CD11b (n=10), CD13 (n=21), CD15 (n=10), CD16 
(n=10), CD33 (n=10) and CD66b (n=21) was measured in LDGs and NDGs 
by flow cytometry.  
(B) The average percentage change in expression of CD11b, CD13, CD15, CD16, 
CD33 and CD66b between LDGs and NDGs was calculated (n=21). 
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5.2.6.3.  Differences in arginase 1 expression between LDGs and NDGs 
The causes of the reduction in density and the different purification properties 
between LDGs and NDGs need to be investigated.  One hypothesis is that LDGs are 
activated and therefore degranulate causing a reduction in cell density.   
If LDGs are activated neutrophils that have degranulated and released arginase 1 from 
within intracellular granules (Munder et al., 2005, Jacobsen et al., 2007) then their 
level of arginase 1 would be lower than that found in NDGs that have not 
degranulated.  This hypothesis was tested in the following experiment.  
Figure 5.12 shows that arginase 1 MFI is statistically significantly lower in LDGs 
compared to NDGs (1’321 ± 122.8 vs. 2’000 ± 1105, p=0.0059). On average, LDGs 
had 23.13 ± 6.19 % less arginase 1 expression than NDGs. 
  
This shows that LDGs express lower levels of arginase 1 than NDGs.  
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Figure 5.12:  Comparison of arginase 1 expression between LDGs and NDGs 
 
 
 
 
Leukocytes from untreated HIV+ patients (n=10) were separated into PBMCs and 
NDGs.  The level of expression of arginase 1 was measured in LDGs and NDGs by 
flow cytometry. 
 
** P <0.001  
Box = interquartile range and median; whiskers = range  
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5.2.6.4.  Differences in the level of degranulation between LDGs and NDGs  
The aim of the following experiments was to investigate the level of degranulation in 
LDGs and NDGs.  This can be done by comparing the cell surface expression of 
CD63 between LDGs and NDGs.  CD63 is a marker that is expressed in the 
membranes of azurophilic granules of neutrophils (Kuijpers et al., 1991).  It has been 
suggested that arginase 1 is contained within azurophilic granules of neutrophils 
(Munder et al., 2005).  When neutrophils are activated and degranulate there is 
exocytosis of the azurophilic granules resulting in the incorporation of CD63 into the 
extracellular facing cell surface membrane (Kuijpers et al., 1991, Martı,n-Martı,n et al., 
2000).  Consequently, the cell surface expression of CD63 gives an indirect indication 
of the level of neutrophil degranulation.  
As shown in Figure 5.13, CD63 cell surface expression is statistically significantly 
higher in LDGs compared to NDGs (1445 ± 224.8 vs. 740.4 ± 51.55, p=0.0059). On 
average, LDGs have double (105.6 ± 37.0% increase) the expression of CD63 on their 
cell surface. 
  
This shows that LDGs express statistically significantly higher levels of CD63 than 
NDGs. 
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Figure 5.13:  Comparison of CD63 expression between LDGs and NDGs  
 
 
 
Leukocytes from untreated HIV+ patients (n=10) were separated into PBMCs and 
NDGs.  The level of expression of CD63 was measured in LDGs (CD15+ Arginase 1+ 
cells in PBMC fraction) and NDGs (CD15+ Arginase 1+ cells in erythrocyte fraction)  
by flow cytometry.  
 
** P <0.01  
Box = interquartile range and median; whiskers = range  
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5.3.  Discussion  
The results presented in this chapter show, for the first time (manuscript in 
preparation), that there is a population of the arginase producing granulocytes that co-
purify in the PBMC fraction (LDGs) of untreated HIV+ patients and are associated 
with disease severity.  
 
Due to their separation with PBMCs after density gradient centrifugation these cells 
were called low density granulocytes (LDGs).  Initially, the frequency of arginase-
expressing cells was measured.  Then, in order to investigate how these cells were 
different from neutrophils that sediment with erythrocytes after density gradient 
centrifugation (normal density granulocytes = NDGs) I compared: the expression of 
granulocyte markers; activation markers; expression of arginase 1 and degree of 
degranulation between NDGs and LDGs.  
 
5.3.1.  Factors affecting LDG yield  
Before discussing these findings it is important to note that the LDGs described in this 
chapter are very difficult cells to study for the following reasons: 
1. The anticoagulant used for blood collection has a major impact on LDG yield 
with heparin yielding significantly fewer cells than EDTA. 
2. LDGs are not stable upon freezing so flow cytometry analysis has to be 
carried out on freshly processed cells 
Hence, studies in which blood: i) is collected in heparinised tubes; or ii) is processed 
and then frozen in liquid nitrogen before analysis, are likely to yield substantially less 
LDGs.  For these reasons, it is likely that LDGs are not routinely detected or, if they 
are, their frequency is underestimated. 
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5.3.2.  Presence of LDGs in the PBMC fraction following density gradient 
centrifugation   
LDGs in untreated HIV+ patients were found to be arginase1+, CD15hi, CD14low and 
CD1a-.  As CD15 is a marker of neutrophils, CD14 a marker of monocytes and CD1a 
a marker of antigen presenting cells, it is possible to conclude that the predominant 
arginase 1 expressing cells that contaminate the PBMC fraction after density gradient 
centrifugation are neutrophils.  These LDGs express low levels of CD14, similar to 
the arginase-expressing cells found in: the term placenta of pregnant women (Kropf et 
al., 2007); renal cell carcinoma (Zea et al., 2005) and SLE (Denny et al., 2010).  The 
expression of arginase was investigated in CD1a+ antigen presenting cells as it had 
been shown, by the groups of Munn and Mellor, that there is a population of 
tolerogenic dendritic cells in mice that express the enzyme IDO and deplete 
tryptophan, thereby causing immune regulation (Mellor and Munn, 2004a). These 
results are supported by the work of Munder et al. which showed that, in humans, 
arginase 1 is only constitutively expressed in granulocytes and not in macrophages or 
dendritic cells (Munder et al., 2005).  
 
5.3.3.  The phenotype of LDGs 
In untreated HIV+ patients LDGs and NDGs were found to be CD15+, CD11b+, 
CD13+, CD16+, CD33+, CD66b+ and arginase 1+.  However, there were significant 
differences between LDGs and NDGs.  LDGs had an increased FSC and SSC (size 
and granularity); an increased expression of CD15, CD33 and CD66b and a decreased 
expression of CD16 (Section 5.2.6. and figures 5.10 and 5.11).  
 
The presence of CD15+ granulocytes in the PBMC fraction has been demonstrated in 
a number of different pathologies including: cancer (Schmielau and Finn, 2001, 
Goddard et al., 2005, Zea et al., 2005, Liu et al., 2009a); pregnancy (Kropf et al., 
2007); trauma (Bryk et al., 2010) and SLE (Denny et al., 2010)  
 
5.3.3.1.  Phenotype of granulocytes that co-purify with PBMCs in cancer 
Schmielau et al. identified activated granulocytes in the PBMC fraction of patients 
with advanced pancreatic-, colon- and breast cancer. They showed that the 
granulocytes that co-purify in the PBMC fraction have a low buoyant density and 
express CD15 (Schmielau and Finn, 2001).  The group of Augusto Ochoa identified 
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that myeloid derived suppressor cells in the PBMC fraction of patients with renal cell 
carcinoma (RCC) were a subset of activated CD15+ granulocytes (Zea et al., 2005).  
They identified the arginase producing cells in the PBMC fraction as CD15+, CD11b+, 
CD14low and negative for CD80, CD83, CD86, CD11a and MHCII (Zea et al., 2005).  
Myeloid derived suppressor cells were recently identified to be CD66b+ neutrophils in 
patients with head and neck cancer, lung cancer and cancer of the bladder (Brandau et 
al., 2011).  Brandau et al. found that these cells co-purify with PBMCs and have a 
high side scatter and CD66b expression and were at an increased frequency in all of 
these neoplasms.  
The results from the studies described above suggest that in cancer patients, there is 
also a population of neutrophils that co-purify with PBMC. 
 
5.3.3.2.  Phenotype of granulocytes that co-purify with PBMCs in trauma 
patients 
Trauma patients were found to have an increase in the percentage of CD15+CD16+ 
activated granulocytes in the PBMC layer which was associated with an increase in 
PBMC arginase activity (Bryk et al., 2010).    It was confirmed that it was the 
activated granulocytes that were contributing to the PBMC arginase activity as: i) they 
were the only arginase expressing cells detected by flow cytometry and ii) depletion 
of CD16+ cell from the PBMC fraction resulted in baseline arginase activity (Bryk et 
al., 2010).  
 
5.3.3.3.  Phenotype of granulocytes that co-purify with PBMCs in pregnancy 
It was found there was an accumulation of CD15+, Arginase 1+, CD14low cells in the 
PBMC fraction of pregnant women at the time of birth (Kropf et al., 2007).  
 
5.3.3.4.  Phenotype of granulocytes that co-purify with PBMCs in SLE 
Denny et al. investigated the phenotype and functional properties of proinflammatory 
neutrophils in the PBMC fraction of patients with SLE and compared these to 
autologous NDGs and neutrophils from healthy controls (Denny et al., 2010).  They 
found that most control subjects had no contaminating proinflammatory neutrophils in 
the PBMC fraction.  In contrast, patients with SLE had on average 17% 
proinflammatory neutrophils in their PBMC fraction.  Proinflammatory neutrophils 
segregated directly adjacent to the monocyte population based on their size and 
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granularity by flow cytometry.  This is consistent with the result for patients with HIV 
infection.  The phenotype of proinflammatory neutrophils in SLE infection was found 
to be CD15+/CD14lo/MHC class II-/CD86-/CD10+/CD16hi.  Proinflammatory 
neutrophils also expressed PECAM/CD31, CD11c, G-CSFR (CD114) and GM-CSFR 
(CD116). Proinflammatory neutrophils did not express IL-3R #-chain (CD123) or M-
CSFR (CD115).  However, unlike LDGs in HIV infection, statistically significant 
differences in phenotypic markers between proinflammatory neutrophils and NDGs 
were not detected. 
 
Therefore, the LDGs described here in untreated HIV+ patients are similar to: 
1. myeloid derived suppressor cells (in RCC and solid cancers) 
2. activated granulocytes in: 
a.  advanced pancreatic, colon and breast cancer 
b.  patients with trauma 
c.  pregnant women 
3. proinflammatory neutrophils in patients with SLE. 
As these cells also co-purify in the PBMC fraction and express CD15.  However, 
there are differences between the LDGs identified here and the cells described in the 
variety of pathologies outlined above: i) the LDGs found in patients with HIV do not 
have a statistically significant upregulation of CD11b unlike patients with RCC (Zea 
et al., 2005) and ii) LDG from HIV+ patients have an increased side scatter rather 
than a decreased side scatter as described in patients with trauma (Bryk et al., 2010).  
It is likely that these granulocytes share certain properties which cause them to co-
purify in the PBMC fraction.  Yet, due to the difference in the inflammatory 
conditions associated with the different pathologies described above (the cytokine and 
chemokine profile and the level of pathogen associated molecular patterns (PAMPS) 
which can bind to pattern recognition receptors (PRRs)), it is to be expected that there 
are differences in the phenotypes of these granulocytes.     
 
5.3.4.  What causes the LDGs to co-purify in the PBMC fraction?  
LDGs that co-purify in the PBMC fraction following density gradient centrifugation 
have a density that is " 1.077g/mL. This compares to NDGs which sediment with 
erythrocytes following density gradient centrifugation.  An important question to ask 
is what causes LDGs to have a lower buoyant density than NDGs?  Here there are two 
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potential hypotheses that are related to: i) the size and granularity of the cells; ii) the 
degree of maturation of the cell and iii) the level of activation of the LDGs.   
The first hypothesis is that LDGs represent a population of immature granulocytes 
and therefore have a lower density.  The second hypothesis is that LDGs represent a 
subpopulation of activated neutrophils that have degranulated and this leads to a 
change in density and altered sedimentation properties. 
In order to test this, the size and granularity and the expression of markers of 
maturation and degranulation on LDGs and NDGs were measured by flow cytometry.  
 
5.3.4.1.  Size and granularity of LDGs compared to NDGs  
In untreated HIV+ patients it was found that the FSC MFI (cell size) and SSC MFI 
(cell granularity) were higher in LDGs compared to NDGs (section 5.2.6.1. figure 
5.10).   Size and granularity can be an indication of the level of maturation and 
activation of the cell.  
Neutrophils are formed in the bone marrow from colony-forming unit granulocyte 
macrophages (CFU-GM) which are progenitor cells (Elghetany, 2002).  Neutrophil 
development then follows defined morphological maturation stages: i) blasts; ii) 
promyeloblasts; iii) myeloblasts; iv) metamyelobalsts; v) band cells and vi) 
segmented neutrophils (Elghetany, 2002).  During the 10-14 days of granulopoiesis, 
there is a progressive increase in granularity and a decrease in the size of maturing 
cells (see figure 5.14) (Olofsson et al., 1980, Terstappen et al., 1990, Cowland and 
Borregaard, 1999, Bain, 2007, Bain et al., 2009).  Based on the density calculated by 
Olofsson et al. myeloblasts, promyelocytes and myelocytes all have a density which is 
<1.077 g/mL and consequently should co-purify in the PBMC fraction following 
density gradient centrifugation (Olofsson et al., 1980).  This is shown in the study of 
Brandau et al. who identified immature granulocytes from patients with cancer that 
co-purify in the PBMC fraction following density gradient centrifugation and they 
were found to have an increased side scatter compared to granulocytes that sediment 
with erythrocytes (Brandau et al., 2011).   
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Figure 5.14: Size, granularity and density changes during granulopoiesis 
 
 
 
 
 
 
 
 
 
Adapted from: Bain, Barbara J., Clark, David M., and Wilkins, Bridget S., The 
Normal Bone Marrow (Wiley-Blackwell, 2009).  
Neutrophil diameter from: Bain, BJ., Morphology of Blood Cells. (Wiley, 2007). 
Neutrophil density from: Olofsson, T., Gartner, I., and Olsson, I., Separation of 
human bone marrow cells in density gradients of polyvinylpyrrolidone coated silica 
gel (Percoll). Scand J Haematol 24 (3), 254 (1980). 
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Activation also induces changes in neutrophil size and granularity.   It has been 
suggested that activated neutrophils separate in the PBMC fraction is due to their 
increased buoyancy.  This was confirmed in trauma where activated granulocytes 
were found to be more swollen (larger FSC MFI) and degranulated (lower SSC MFI) 
than NDGs (Bryk et al., 2010).  This is only a theory, however, this kind of density 
shift has been shown to be due to a combination of cell swelling and degranulation 
during activation in eosinophils (Owen et al., 1989, Caulfield et al., 1990).  In patients 
with cutaneous T cell lymphoma (CTCL), whole blood analysis suggests, neutrophils 
have an increased forward scatter and similar side scatter compared to control 
neutrophils. Thus suggesting their increased buoyancy is predominantly due to cell 
swelling compared to degranulation (Goddard et al., 2005).   
In HIV+ patients, LDGs display an increased size (FSC MFI) compared to NDGs.  
This indicates that they could be activated or immature.  However, they also have an 
increased granularity, a finding that would suggest they have not degranulated.  They 
could still be activated cells as: i) like the granulocytes that co-purify with PBMCs in 
CTCL, the main factor that influences the reduction in density of the activated cells is 
how swollen the cell is and not the degree of granularity or ii) it could be that as the 
cells have been permabilised, in order to stain for intracellular arginase 1 expression, 
the side scatter reading has been affected.  In order to investigate this further cell 
surface markers of activation and maturation were measured.     
 
5.4.3.2.  Markers of maturation and degranulation 
During neutrophilic maturation there is a change in expression of surface antigens 
(Elghetany, 2002).  Some markers appear during maturation including CD16b, CD35, 
and CD10 (Elghetany, 2002). Other markers disappear with maturation such as 
CD49d and CD64 and some are maintained including CD32, CD59 and CD82 
(Elghetany, 2002).  A table showing the surface marker expression during different 
stages of neutrophilic development can be found in the appendix (Appendix Table 
9.8).  Of the panel of markers investigated in this study, CD16 is a marker found on 
mature granulocytes (Elghetany, 2002) and CD33 is a marker of immature 
neutrophils.  CD33 is found at high levels on CFU-GM, myeloblasts, promyelocytes 
and myelocytes and at low levels on neutrophils beyond the myelocytic stage 
(Elghetany, 2002).  
 198 
Activation of neutrophils induces mobilization of the four different intracellular 
compartments (Sengelov et al., 1995).  However, the degree of mobilisation, 
exocytosis and degranulation is dependent on the strength of the activating signal 
(Sengelov et al., 1995).  The order of granule release follows a strict hierarchy 
requiring increasing activation for degranulation: i) secretory granules; ii) gelatinous 
granules (tertiary granules); iii) specific granules (secondary granules) and iv) 
azurophilic granules (primary granules) (Sengelov et al., 1995).  The level of 
activation can be assessed as the different granules contain different markers in their 
plasma membranes (Borregaard and Cowland, 1997).  Upon granule exocytosis, 
granules bind with the cell membrane and release their contents leading to the 
appearance of markers of the different intracellular granules in the cell surface 
membrane.  From the panel of markers studied in this chapter: CD11b (complement 
receptor 3, Mac-1, integrin #M subunit) is found in the plasma membrane of secretory 
vesicles, gelatinase granules and specific granules; CD63 is only found in the plasma 
membrane of azurophilic granules and CD66b is found in the membrane of specific 
granules (Borregaard and Cowland, 1997).  Therefore, in order of activation from low 
to high, one would expect to see the increased expression of CD11b, CD66b and 
CD63 (Sengelov et al., 1995) on the cell surface membrane.  Particularly relevant for 
this study is the finding that arginase is found in azurophilic granules (Munder et al., 
2005) and so the cell surface expression of CD63 should correspond to arginase1 
exocytosis.  
In untreated HIV+ patients, LDGs had a reduced arginase 1 MFI and an increased 
CD63 MFI when compared to NDGs (sections 5.2.6.3 and 5.2.6.4. figures 5.12 and 
5.13).  Furthermore, LDGs had statistically significantly higher CD66b MFI and an 
increased CD11b expression (although this did not reach statistical significance) in 
comparison to NDGs. This suggests LDGs are activated neutrophils that have 
degranulated because they have: i) increased cell surface CD66b expression 
(indicative of specific granules exocytosis); ii) increased cell surface CD63 expression  
(indicative of azurophilic granule exocytosis) and iii) decreased intracellular arginase 
1 expression (indicative of azurophilic granule exocytosis).  Yet, there is also an 
increase in the expression of the granulocyte progenitor marker CD33 and a decrease 
in the expression of the CD16 found on LDGs compared to NDGs (section 5.2.6.2. 
figure 5.11D and E and Table 5.3).  Accordingly, LDGs may represent a 
heterogeneous population of neutrophils and not purely mature activated cells. 
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Granulocytes that purify in the PBMC fraction from other pathological conditions 
also show a spectrum from being purely mature activated cells through to a 
heterogeneous mix of mature and immature cells or purely immature granulocytes.  
 
Schmielau et al suggested the granulocytes that co-purify in the PBMC fraction, 
which were increased in patients with adenocarcinoma, were activated cells. This 
suggestion was made because this population could be reproduced by treating the 
whole blood of healthy donors with N-formyl-L-methionyl-L-leucyl-L-phenylalanine 
(fMLP) which activates the granulocytes causing them to co-purify in the PBMC 
fraction (Schmielau and Finn, 2001).  
In addition, MDSCs in patients with RCC were also shown to be a subpopulation of 
activated granulocytes (Rodriguez et al., 2009).  These MDSCs were shown to 
express high levels of CD66b, CD11b and VEGFR1 and low levels of CD62L and 
CD16 compared to NDGs (Rodriguez et al., 2009).  CD62L (L-selectin) is shed when 
neutrophils are activated thus making it another indicator of activation status.   
Although this supports the finding that LDGs in HIV infection are activated and have 
increased expression of CD66b it could be misleading because they compared 
MDSCs from patients with NDG from healthy controls.  This does not take into 
account the considerable variation found in a human population.  It would have been 
more convincing if they had shown the difference between MDSCs and NDGs from 
the same patient, as has been expressed in the results in this chapter. 
The morphology of the MDSCs in RCC showed them to be predominantly (( 90%) 
segmented mature granulocytes with a minority of band cells and other immature 
granulocytes (<10%) (Rodriguez et al., 2009).  Therefore, both the morphological and 
phenotypic findings suggest MDSCs in RCC are mature activated granulocytes.  This 
supports the findings in HIV infection that LDGs are mature activated granulocytes as 
opposed to immature cells.   
 
In cutaneous T cell lymphoma (CTCL), hypodense neutrophils were found to express 
increased levels of CD11b CD66b and decreased levels of CD62L (L-selectin) 
consistent with being activated granulocytes (Goddard et al., 2005).  Additional 
evidence of the activation status of hypodense neutrophils was their increased rate of 
granules mobilization after activation (increase in the cell surface expression of 
CD66b and CD11b and a decrease in the cell surface expression of CD62L) compared 
 200 
to NDGs (Goddard et al., 2005).  Therefore, CTCL is yet another pathology in which 
the granulocytes co-purifying in the PBMC fraction have a similar activation status 
and level of degranulation to LDGs found in HIV - in both pathologies LDGs have 
increased expression of CD66b, are mature, activated and have increased 
degranulation compared to NDGs.  
 
In contrast, MDSCs co-purifying in the PBMC fraction in patients with head and neck 
cancer, lung cancer and cancer of the bladder, had a varied morphology showing 
different stages of development including myelocytic, metamyelocytic and band-like 
nuclear morphology (Brandau et al., 2011).  This was confirmed by flow cytometry 
where Brandau et al. found a large number of different developmental stages of 
immature neutrophils.  This was supported by the findings that MDSCs had:  i) 
reduced spontaneous apoptosis; ii) reduced magnitude of primary (fMLP induced) and 
secondary (latex bead induced) oxidative bursts (production of ROI); and iii) reduced 
LPS induced IL-8 secretion compared to NDGs (Brandau et al., 2011).  These results 
are consistent with the MDSCs investigated in this study being immature granulocytes 
(Brandau et al., 2011).  
 
Using an oligigonucleotide microarray technique, over expression of interferon and 
granulopoiesis related genes were detected in paediatric patients with SLE (Bennett et 
al., 2003).  Indeed, the most upregulated genes were granulocyte-related genes 
(Bennett et al., 2003).  This gene expression was found to be due to granulocytes that 
co-purify in the PBMC fraction after density gradient centrifugation (Bennett et al., 
2003).  It was found that these granulocytes were a heterogeneous population with 
cells at all stages of granulocyte differentiation including pro-myelocytes, myelo and 
meta-myelocytes, early and late bands as well as segmented neutrophils (Bennett et 
al., 2003).  The most over expressed gene in SLE patients was defensin-3, which is 
predominantly found in cells at the intermediate phase of maturation (myelocyte-
metamyelocyte) and is absent in polymorphonuclear cells (Bennett et al., 2003).  The 
level of defensin-3 correlated with the number of granulocytes in the PBMC fraction 
found in SLE patients (Bennett et al., 2003).  However, it may be the mature LDGs 
that are contributing to disease pathogenesis as the transcription levels of the fMLP 
receptor (F2RPA), found in mature (band and segmented) polymorphonuclear cells, 
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was the gene that correlated best with SLE disease severity as measured by Systemic 
Lupus Erythematosus Disease Activity Index (SLEDAI) (Bennett et al., 2003).  
 
As stated earlier, Denny et al. investigated the phenotype and functional properties of 
proinflammatory neutrophils in SLE patients and compared these to autologous NDGs 
and neutrophils from healthy controls (Denny et al., 2010).  They found a mixed 
picture in terms of activation. Proinflammatory neutrophils had increased cell surface 
expression of CD11b and CD66 compared to NDGs (Denny et al., 2010).  However, 
proinflammatory neutrophils did not show any difference in L-selectin (CD62L) 
shedding either before or after stimulation when compared to NDGs or control 
neutrophils (Denny et al., 2010).   Morphology suggested proinflammatory 
neutrophils were a heterogeneous population with cells with band, lobular and 
myelocyte like nuclei (Denny et al., 2010). The proinflammatory neutrophil 
population always contained more immature cells than NDGs (PMN in 
proinflammatory neutrophils ( 60% NDGs >90%) (Denny et al., 2010).  To support 
this, proinflammatory neutrophils expressed low levels of the progenitor marker 
CD33 but did not express CD34 and Flt-3 (Denny et al., 2010). 
 
This shows that, in the pathologies in which granulocytes have been found to co-
purify in the PBMC fraction, there is a variation in the cell activation and maturation 
status from being predominantly mature activated granulocytes, as in RCC 
(Rodriguez et al., 2009) and CTCL (Goddard et al., 2005), to a heterogeneous 
population of mature and immature granulocytes found in cancers of the head and 
neck, lungs and bladder (Brandau et al., 2011) and in patients with SLE (Bennett et 
al., 2003, Denny et al., 2010).  This is consistent with the findings from HIV+ patients 
where LDGs express markers of activation (CD11b, CD66b, CD63 and reduced 
arginase) and yet, still have an increased expression of the progenitor marker CD33 
on LDGs compared to NDGs.   
 
5.4.4.  Association of LDGs with disease severity – a historical perspective 
The presence of contaminating cells in the PBMC layer is not a new finding.  Since 
Arne Böyum initially described the technique for lymphocyte isolation in 1968 
(Boyum, 1968), there have been a series of studies that have shown that there are cells 
that contaminate the mononuclear cell population at the interface between plasma and 
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Ficoll with a density of 1.077g/mL.  In 1976, Rothbarth et al. identified that in healthy 
subjects there was an average of 1.96% of the PBMC fraction that were granulocytes 
(Rothbarth et al., 1976).  In 1978, Currie et al. investigated mononuclear cell 
contamination following density gradient centrifugation in patients with active 
malignant disease (malignant melanoma and breast carcinoma) and healthy controls 
(Currie et al., 1978).  They found that patients with cancer had an increase in 
contamination from cells that stained positive for chloroacetate esterase (CAE+) – 
which stains for granulocytic cells and their precursors (Currie et al., 1978).  They 
found that higher levels of CAE+ cell contamination were found in patients with more 
advanced disease.  They refer to these cells as left-shifted granulocytes because they 
appeared to be predominantly immature granulocytes with a reduced density (Currie 
et al., 1978).  
This was extended in 1980, where work by Irene Check showed that there was a 
decrease in the percentage of lymphocytes in the PBMC fraction in patients with 
gynaecological (Check et al., 1980b), head and neck (Check et al., 1980a) and lung 
(Check et al., 1980a) cancers.  These studies did not identify the contaminating cells 
but hypothesised that the accumulation of these cells in advanced cancer are 
responsible for the reduction in lymphocyte response to mitogens and in mixed 
lymphocyte reactions which were found in patients with advanced disease.   They also 
found that the percentage of lymphocytes in the PBMC fraction was associated with 
the clinical stage of the disease and was a good prognostic marker for patient survival 
(Check et al., 1980b).  
In patients with chronic renal failure, the PBMC fraction is heavily contaminated with 
non-lymphoid cells following density gradient centrifugation (Gibbs et al., 1982).  
Gibbs et al. also showed that the presence of these contaminating cells reduced the 
lymphocyte response to mitogens and that plasma from ureamic patients also 
suppressed mitogen responses in the G1 phase and in replicative growth, suggesting 
that the contaminating non-lymphoid cells might be releasing suppressive factors 
(Gibbs et al., 1982).  As arginase mediated L-arginine depletion leads to G0-G1 cell 
cycle arrest (Rodriguez et al., 2007), it is tempting to speculate that the contaminating 
cells were activated granulocytes which had released arginase leading to decreases 
availabilty of free L-arginine and consequently causing T cell dysfunction. 
In 1986, it was shown that mature low density neutrophils are found in the PBMC 
fraction of patients with: SLE; rheumatoid arthritis (RA) and acute rheumatic fever 
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(ARF) (Hacbarth and Kajdacsy-Balla, 1986).  In all groups of patients there was an 
increase in the percentage of neutrophils and a decrease in the percentage of 
lymphocytes at the Ficoll interface compared to the control group (Hacbarth and 
Kajdacsy-Balla, 1986).  This was not due to neutrophil aggregation as this was 
investigated by phase-contrast microscopy and would increase the density of the 
neutrophils favouring their sedimentation with erythrocytes (Hacbarth and Kajdacsy-
Balla, 1986).  Like Check et al., they also show that a low ratio of lymphocyte to 
neutrophils is associated with disease severity.  
Granulocytes were also found to contaminate the PBMC fraction of patients that have 
suffered thermal injuries (Calvano et al., 1988).  
 
These early studies in cancer, rheumatic disease and burns patients show:  
1. An accumulation of granulocytes and non-lymphoid cells in the PBMC 
interface; 
2. An association between non-lymphocyte contamination and reduced 
lymphocyte functional responses;  
3. An association between non-lymphocyte contamination and disease severity.    
However, none of the studies from 1970-1990s tried to identify the precise phenotype 
of these contaminating granulocytes or why lymphocytes showed reduced functional 
responses with increasing non-lymphocyte contamination.  With the benefit of 
hindsight, there is a strong possibility that the cells contaminating the PBMC fraction 
were granulocytes.   This supports the findings shown in this chapter that, in untreated 
HIV+ patients, the percentage of LDGs is associated with disease severity as 
measured by CD4+ T cell count and plasma viral load (section 5.2.5. figure 5.8 and 
5.9).   
 
5.4.5.  Functional consequences of LDGs  
The functional role of LDGs in health and disease is a key question that needs to be 
addressed.  Granulocytes that co-purify in the PBMC fraction have been found to 
cause T cell suppression in RCC (Zea et al., 2005), and in solid cancers (HNC, lung 
cancer and cancer of the bladder and ureter) (Brandau et al., 2011).    
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5.4.5.1.  Arginase-mediated L-arginine depletion 
Based on the data presented in this chapter, it is concluded that LDGs accumulate 
with HIV disease severity and that they release arginase that reduces the level of L-
arginine resulting in T cell dysfunction. The results show there is a strong association 
between the frequency of LDGs in the PBMC fraction and PBMC arginase activity 
(section 5.2.4. figure 5.7).  This suggests that it is an accumulation of LDGs that 
express arginase that accounts for the increase in PBMC arginase activity with disease 
severity described in chapter IV.  In addition, LDGs in HIV+ patients have high cell 
surface levels of CD66b and CD63 suggesting that they have degranulated and the 
lower levels of arginase 1 suggest it has been released into extracellular space.  This, 
coupled to the findings in chapter III which showed human T cells have an absolute 
requirement on L-arginine in order to function, suggests that the LDGs identified in 
this chapter could be contributing to the T cell dysfunction seen in patients with HIV 
infection.    
It has been shown that MDSC arginase induced L-arginine depletion is one of the 
mechanisms operating to suppress T cell function in patients with RCC.  In RCC 
patients there is: a high PBMC arginase activity; low plasma L-arginine levels; low T 
cells CD3! expression and reduced production by T cells of IL-2 and IFN-% (Zea et 
al., 2005).   These results are consistent with arginase mediated L-arginine depletion 
causing T cell dysfunction.  Interestingly, a similar correlation was found in patients 
with RCC whereby the percentage of activated granulocytes in the PBMC fraction is 
associated with PBMC arginase activity (Zea et al., 2005).   They showed that these 
cells were responsible for the reduction in T cell proliferation, CD3! expression and 
IFN-% production as, when the CD11b cells were depleted, these functions were 
restored in an in vitro system.  In patients with RCC it was found that: i) plasma 
arginase activity was elevated; ii) plasma L-arginine levels were decreased; iii) 
MDSCs had lower arginase1 MFI and lower arginase enzymatic activity than NDGs 
(Rodriguez et al., 2009).  This suggests that MDSCs are mature activated 
granulocytes that have degranulated releasing arginase 1 into the extracellular fluid 
(in the case of peripheral blood the plasma) leading to reduced intracellular arginase 1 
and extracellular L-arginine consumption and, ultimately, T cell dysfunction.  This 
supports the hypothesis presented in this thesis that LDGs accumulate in HIV 
infection and cause T cell dysfunction through arginase mediated L-arginine 
metabolism. 
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5.4.5.2.  Other mechanisms of suppression 
It would be very inward looking to assume that all LDG suppression of T cells was 
due to arginase mediated L-arginine depletion.  Indeed, other mechanisms of LDG 
mediated T cell suppression have also been proposed, including, hydrogen peroxide 
(H2O2) dependent suppression by low density neutrophils in patients with metastatic 
adenocarcinomas of the pancreas, colon and breast (Schmielau and Finn, 2001).  They 
demonstrated that cell suppression might be H2O2 dependent as catalase (which 
degrades H2O2 to water) addition to the cell culture abrogated T cell suppression.  
This was further supported by the finding that the direct addition of H2O2 to cell 
culture mimicked the T cell suppression caused by granulocytes.   Although, there are 
weaknesses in this study: i) they do not look for arginase or IDO expression in the 
activated granulocytes; ii) the in vitro experiments do not use LDG from patients, 
rather granulocytes from healthy controls and iii) in these in vitro experiments, they 
activate the T cells and granulocytes with PMA/inomycin which they have not shown 
to cause density changes in the granulocytes.  Consequently, the results from their in 
vitro experiments could merely be reflecting neutrophil cell death in culture leading to 
the release of H2O2 rather than activation causing density changes and active 
degranulation of H2O2.  However, the presence of activated suppressive granulocytes 
in the PBMC fraction supports the findings in this chapter. 
 
5.4.5.3.  Impact of location on LDG function  
As discussed in chapter IV, immunoregulation by arginase mediated L-arginine 
depletion is a localised phenomenon (Kropf et al., 2007, Modolell et al., 2009).  This 
is illustrated in the physiological upregulation of arginase activity in human 
pregnancy (Kropf et al., 2007) and in the pathological upregulation of arginase 
activity in experimental murine leishmaniasis (Kropf et al., 2005, Modolell et al., 
2009).   
 
In this chapter, the frequency of arginase expressing LDGs was measured in the 
PBMC fraction.  This was sampling the level of LDGs in the peripheral blood.  
However, the anatomical reservoirs of HIV are defined by the tissue distribution of 
target cells, i.e. the gastrointestinal tract during acute HIV infection and other 
peripheral lymphoid organs during the chronic phase (Stebbing et al., 2004).  
Therefore, it is likely that the increase of LDGs detected in the PBMCs of untreated 
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HIV+ patients is merely a reflection of strongly increased LDG induction in local 
sites of HIV reservoirs such as the gastrointestinal track or the lymph nodes.  Indeed, 
it could be that, the LDGs detected in the PBMC fraction are cells that have re-entered 
circulation after having had their main suppressive effect at the site of pathology.   
This concept is supported by the work on solid cancer patients by Brandau et al. who 
found that the immature MDSCs which co-purified in the PBMC fraction expressed 
increased CXCR4 expression, required for migration out of the bone marrow, plus 
reduction in chemtoaxis and expression of CXCR1 and CXCR2 required for 
migration to sites of pathology.  This suggested that these MDSCs are immature and 
remain in the peripheral blood rather than migrating into the tumour 
microenvironment (Brandau et al., 2011).  In the peripheral blood, MDSCs might 
contribute to peripheral immunosuppression (Brandau et al., 2011).   On the other 
hand, it could be that the mature LDGs that become activated in circulation migrate to 
the site of inflammation.  Once at the site of pathology these activated LDGs exert 
their suppressive effects, a phenomenom that may not be observed or is only observed 
weakly whist they are in peripheral circulation.      
 
5.4.5.4.  Other potential functions of LDGs  
In SLE, the suppressive function of proinflammatory neutrophils was not assessed.  
However, it was found that proinflammatory neutrophils have decreased ability to 
phagocytose S. aureus compared to NDGs (Denny et al., 2010).  This could be 
relevant as, if a similar decrease in phagocytosis would be found in patients with HIV 
infection it might contribute to the increase in bacterial opportunistic infections seen 
in the later stages of the disease.  In addition, proinflammatory neutrophils had 
comparable: bactericidal activity; intracellular MPO expression; magnitude of 
respiratory burst (as assessed by H2O2 production following PMA or immune 
complex stimulation) when compared to NDGs (Denny et al., 2010). 
Further, in this model, it was shown that, via production of type I IFNs, 
proinflammatory neutrophils contribute to SLE pathology by causing dysfunctional 
blood vessel repair.  This is relevant to HIV infection as it is now apparent that, since 
patients with HIV are living longer, complications associated with an aging 
population such as atherosclerosis are becoming more apparent (Lekakis and 
Ikonomidis, 2010).  Therefore, it is tempting to hypothesise that LDGs may be 
playing a role in the increased cardiovascular disease risk seen in patients with HIV.   
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5.5.6.  The lifespan of LDGs compared to NDGs 
Until recently there was a scientific paradigm that neutrophils were short lived cells 
that have a life span of less than 24 hours in vitro and a circulatory half-life of 
approximately 8 hours in humans (Dancey et al., 1976).  Consequently, it was 
assumed that neutrophils were only of fundamental importance in inflammation where 
they: were recruited to the site of pathology; became activated (phagocytosed 
pathogens and degranulated to release the preformed effector molecule contained 
within their intracellular granules) and, once the danger had been cleared, underwent 
apoptosis marking a phase of resolution (Theilgaard-Monch et al., 2006, Borregaard 
et al., 2007, Witko-Sarsat et al., 2011).  Due to this assumed short life span, their role 
as immuneregulators was largely ignored.   More recently, using 2H2O, it was shown 
that the original estimate of neutrophil life span was a vast underestimate.  Pillay et al. 
showed that human neutrophils had an average circulatory lifespan of 5.4 days (Pillay 
et al., 2010).  It has not been investigated, but it is possible, that tissue neutrophils in 
the marginated pool have an even longer lifespan in which to exert an influence on 
other cells of the immune system.    
The rate of LDG and NDG apoptosis as an indirect measure of lifespan was not 
measured in this study; however, it would be interesting to do so and it has been 
measured in other activated neutrophils that co-purify in the PBMC fraction.  
Rodriguez et al. found that in RCC there was no increase in apoptosis, as measured by 
annexin V expression, in LDGs compared to NDGs from healthy controls (Rodriguez 
et al., 2009).  In contrast, NDGs activated with PMA in vitro had an increase in 
annexin V expression suggesting that LDGs have a lower rate of apoptosis than would 
be expected of activated neutrophils (Rodriguez et al., 2009).  This suggests that in 
situations of chronic inflammation, such as HIV infection and cancer, where the 
immune system fails to eliminate chronic antigenic stimulation and immune 
activation, neutrophils are activated and become LDGs.  These activated LDGs 
degranulate releasing arginase 1 which suppresses T cell function.  In addition, LDGs 
show an increased resistance to apoptosis so live longer than NDGs and exert their 
suppressive effects on T cells for an increased period of time resulting in T cell 
immune dysfunction. 
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5.4.7. Conclusion 
The experiments presented here have identified, in untreated HIV+ patients, a novel 
population of arginase 1 expressing cells that co-purify in the PBMC fraction 
following density gradient centrifugation.  These cells have been called LDGs.  LDGs 
share certain features with, but are phenotypically different from, other populations of 
granulocytic cells that have been found to co-purify in the PBMC fraction in a range 
of other pathologies.  I believe that they represent a predominantly mature activated 
granulocyte as: the cells are swollen; have an increase in the activation markers CD63 
and CD66b and have a reduced arginase 1 expression suggesting that it has been 
released upon activation.  However, there is probably a minority of immature cells 
that, due to their reduced density, also co-purify in the PBMC fraction and this 
probably accounts for the increased CD33 expression.  The frequency of LDGs 
increases with HIV disease severity.  Therefore, it can be hypothesised that the 
frequency of LDGs is affected by the virus or the chronic inflammation caused by the 
virus.  
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Chapter VI: Conclusions 
 
6.1.  Summary 
In this thesis I have demonstrated that:  
 
1. Human T cells have an absolute requirement for L-arginine and the absence of 
L-arginine causes reduction in T cell proliferation and CD3! expression. 
 
2. Patients with advanced HIV infection have increased arginase activity in the 
PBMC fraction of their blood.  In untreated HIV+ patients, PBMC arginase 
activity is associated with three clinically accepted markers of HIV disease 
severity: (i) CD4+ T cell count; (ii) plasma viral load and (iii) the level of 
immune activation as measured by CD38 and HLA-DR expression.  
Antiretroviral therapy abrogates the association between PBMC arginase 
activity and HIV disease severity.  
 
3. The cells that express arginase 1 in the PBMC are a population of LDGs that 
are defined as being CD15+ CD14lo CD1a-.  In addition, LDGs are positive for 
CD11b, CD13, CD16, CD33 and CD66b. 
 
4. LDG frequency is associated with PBMC arginase activity and markers of 
HIV disease severity (CD4+ T cell count and plasma viral load).  
 
5. LDGs are significantly different from NDGs as they have:  
1. increased FSC and SSC (size and granularity);  
2. increased expression of CD15;  
3. increased expression of the activation markers CD63 and CD66b;  
4. increased expression of the granulocyte progenitor marker CD33;  
5. decreased expression of arginase 1 and CD16. 
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6.2.  Concluding remarks 
The purpose of this study was to investigate the role of arginase mediated L-arginine 
depletion in HIV infection.  
Arginase enzymatic activity has been shown to be highly conserved throughout 
evolution from single-celled organisms to humans (Bronte and Zanovello, 2005).  It is 
likely that, in addition to metabolising the semi-essential amino acid L-arginine, 
organisms evolved to produce their own arginase as it gave a survival advantage by 
depleting L-arginine, thus, preventing other organisms trying to occupy the same 
biological niche.  However, its adaptation into immune regulation was probably in the 
context of an acute inflammatory reaction.  In this context, cells initially express NOS 
leading to the production of reactive nitrogen intermediates that assist in destroying 
the source of the inflammation (i.e. invading pathogen).  Then later, during the course 
of the inflammation, once the source of the inflammation has been neutralised, cells 
express arginase leading to L-arginine depletion that dampens down adaptive immune 
responses by rendering T cell hyporesponsive.  In addition, arginase metabolism 
produces L-proline and polyamines that are required for collagen synthesis and cell 
division - both key components of a healing response.  This is an attractive model of 
acute inflammation followed by a controlled and appropriate contraction of the 
immune response.  However, I propose that in situations where the immune system 
fails to eliminate the source chronic antigenic stimulation, such as HIV infection, 
immune activation persists resulting in chronic inflammation.  In an attempt to 
counteract this chronic inflammation and immune activation, counter regulatory 
mechanisms are upregulated in an attempt to limit tissue damage.  I propose that 
arginase-induced L-arginine depletion is one of the counter regulatory mechanisms 
responsible for T cell dysfunction in patients with advanced HIV infection. 
In the present study, I have indentified that the source of arginase in the PBMC 
fraction in HIV infection is a population of neutrophils that are activated and become 
LDGs (manuscript in preparation).   To my knowledge this is the first time that 
arginase 1+ LDGs have been described in patients with HIV infection.  
HIV infection is associated with chronic immune activation and it has been proposed 
that this directly affects the T cells of the adaptive immune system, eventually causing 
their exhaustion (Appay and Sauce, 2008).  It is tempting to speculate that the 
immune activation, seen in HIV and other chronic pathologies, has effects on both the 
adaptive and the innate immune responses.  One such consequence of this innate 
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activation could be the generation of suppressive LDGs that attempt to return the 
immune system to its homeostatic limits (or as suggested in the introduction – retune 
that string!).  However, these cells are unable to dampen down the immune response 
as HIV is not cleared from the body, and so, the activation continues leading to a 
vicious cycle which increases the frequency of LDGs and contributes to T cell 
dysfunction.  
LDGs in HIV are distinct from other granulocytes that have been found to co-purify 
in the PBMC fraction following density gradient centrifugation in other chronic 
pathologies such as renal cell carcinoma and trauma.  It is possible that this occurs 
because the inflammatory environment is likely to be unique in each pathology and, 
as such, will induce different kinds of LDGs.  I would expect that there are not, 
defined subpopulations of LDGs, but rather a heterogeneous spectrum of LDGs 
induced in different conditions, depending on the inflammatory environment.  
However, we have reason to believe that expression of LDGs in some form is a 
common feature of chronic inflammatory conditions.  Recently, we have been 
working on studies in Ethiopia on patients with tuberculosis, visceral leishmaniasis 
and visceral leishmaniasis/HIV co-infection and in all these cohorts we find the level 
of CD15+ CD14lo arginase1+ LDGs in the PBMC fraction is associated with PBMC 
arginase activity and disease progression (unpublished, personal communication P 
Kropf, I Müller and T Cloke).  These are three chronic inflammatory conditions and 
therefore these findings support the concept that LDGs are a common feature of 
chronic inflammation.  
Identifying the mechanistic pathway that is inducing LDG development in HIV 
infection and other inflammatory conditions is an important focus for future research.  
Once complete, potential therapeutic avenues will become open to inhibit this 
process, boost host immune responses and theoretically reverse the immune 
dysfunction seen in HIV infection and other inflammatory conditions.  
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6.3.  What causes neutrophil activation and increases in the percentage of LDGs? 
The answer to this question is unresolved at present.  However, I would like to 
consider the potential factors that may be playing a role.  
  
6.3.1.  A humoral factor? 
Back in 1986, Hacbarth et al. investigated what might be inducing low-density 
neutrophils in patients with rheumatic conditions (Hacbarth and Kajdacsy-Balla, 
1986).  They found that plasma from patients with SLE was able to increase the level 
of low-density neutrophils in blood from healthy patients (Hacbarth and Kajdacsy-
Balla, 1986).  In addition, activation of complement, by the classical and alternative 
pathways by addition of aggregated human gamma globulin and inulin (naturally 
occurring polysaccharides that activate the alternative complement pathway) led to a 
complement dependent increase in low-density neutrophils (Hacbarth and Kajdacsy-
Balla, 1986).  It was also found that in normal granulocytes treated with SLE plasma 
or plasma activated by inulin an increase in cell volume is induced (Hacbarth and 
Kajdacsy-Balla, 1986).  Therefore, it can by hypothesised that the inflammatory 
environments induced by the disease cause the release of one or more humoral factors 
into the plasma, that in turn, cause or contribute to a reduction in neutrophil buoyant 
density resulting in an accumulation of LDGs.  
 
6.3.2.  A role for reactive oxygen species? 
The work by Schmielau et al. stating that activated granulocytes in patients with 
adenocarcinomas suppressed T cell function in a hydrogen peroxide (H2O2) dependent 
manner (Schmielau and Finn, 2001), seemed to disagree with the proposed hypothesis 
here that T cell suppression is mediated by arginase mediated L-arginine metabolism.  
That is until it is considered that neutrophil derived H2O2 is causing oxidative 
modifications to plasma proteins that then further induce neutrophil activation.  This 
is what was proposed and demonstrated by Körmöczi et al. in 2001 (Körmöczi et al., 
2001).  They showed that upregulation of the markers of neutrophil activation 
(CD11b, CD35, CD66b) occurred when oxidative burst was stimulated by Fc receptor 
ligation, but only in the presence of selected serum proteins (for example purified 
human C4, C5 or human serum albumin). The neutrophil activation could be inhibited 
by using antioxidants or induced by adding exogenous H2O2 in a plasma protein 
dependent manner.  After exposure to H2O2, plasma proteins showed signs of 
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oxidative modification (increased carbonyl formation).  The modified plasma proteins 
were shown to bind to neutrophils, thus suggesting they have a feedback mechanism 
that leads to further activation.  This was confirmed by taking supernatants from 
neutrophils, stimulated by FcR ligation, to release H2O2 (consequently oxidizing the 
plasma proteins) and using it to culture resting neutrophils. This resulted in activation 
of the resting neutrophils. By adding anti-oxidatant when creating the conditioned 
supernatant, the activation of resting neutrophils was inhibited.  They concluded that, 
neutrophil derived reactive oxygen intermediates (H2O2) modified selective serum 
proteins, which then act as proinflammatory mediators of neutrophil stimulation.  
 
I would like to propose a model of neutrophil activation.  First, an initial 
inflammatory stimulus is required to activate the neutrophils.  This could be through 
FcR ligation, as proposed by Körmöczi et al., for example, due to immune complex 
formation.  Alternatively, it could be due to danger signals derived from the pathogen 
or as a result of inflammation accompanying the pathology.  For example, in HIV, 
there is massive T cell depletion in the gastrointestinal tract, which renders it 
increasingly permeable to bacterial translocation and consequently an increase in 
plasma LPS levels.  LPS has been shown to induce neutrophil activation via TLR4 
signalling so it is possible that this could be activating neutrophils in HIV infection.  
This initial activation would stimulate an oxidative burst within the neutrophils 
resulting in reactive oxygen intermediate generation and H2O2 release.  The H2O2 
would cause oxidative modifications to the surrounding plasma proteins enabling 
them to bind to neutrophils, thus leading to increased neutrophil activation, as 
proposed by Körmöczi et al.   This increased activation of the neutrophils may lead to 
the expression of molecules that direct them to the site of pathology and cause 
extravasation and degranulation.  The process of extravasation, in which L-selectin is 
shed, may induce further activation of the neutrophils. Once at the site of pathology, 
they degranulate releasing arginase 1 which reduces free L-arginine in the micro-
milieu, ultimately resulting in T cell dysfunction.  This process of multiple 
stimulations resulting in escalating levels of activation may be responsible for LDG 
generation and a reduction in neutrophil density causing the cells to co-purify in the 
PBMC fraction following density gradient centrifugation.  As initial neutrophil 
activation causes ROI generation that induces further activation, this is likely to be an 
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exponential process that once started is difficult to halt or reverse.  The concept of 
LDG generation requiring two or more activating signals is summarised in figure 6.1. 
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Figure 6.1:  Model of neutrophil activation and LDG induction 
 
 
 
Proposed model of neutrophil activation requiring: 
1) Neutrophil activation by pathological process stimulating the production of 
H2O2 
2) Release of H2O2 causing oxidative modification of plasma proteins 
3) Binding of modified plasma proteins to neutrophils causing further activation, 
extravasation and degranulation releasing arginase 1.   
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Chapter VII:  Future work 
 
7.1.  Longitudinal study investigating LDG frequency, PBMC and plasma 
arginase activity and plasma L-arginine levels 
The work presented in this thesis has been entirely performed on a cross-sectional 
cohort.  For future work, I suggest to further investigate the role of LDGs and 
arginase mediated L-arginine depletion in HIV infection by recruiting a cohort of 
HIV-1 positive patients and monitoring: peripheral blood LDG frequency; PBMC 
arginase activity and plasma L-arginine level over a period of time. This longitudinal 
data could be used to assess the association between: LDG frequency; arginase 
activity and L-arginine with markers of HIV disease progression (CD4+ T cell count, 
plasma viral load and markers of immune activation) and markers of inflammation 
such as: CRP; erythrocyte sedimentation rate (ESR) and plasma LPS levels.  
HIV seropositive patients that are not taking anti-retroviral therapy and have a CD4+ 
cell count above 200 cells/µL will be recruited.  From each patient a panel of clinical 
data and 20 mL of blood will be collected on 6-8 time points over a two year period. 
 
This blood will be used to determine:  
• Arginase activity in the serum and PBMCs;  
• Plasma levels of amino acids (particularly L-arginine and ornithine);  
• Frequency and phenotype of LDGs and NDGs by flow cytometry; 
• Cytokine production by luminex.   
 
From this data it should be possible to see if there is a temporal relationship between 
LDG frequency and HIV disease severity.  It should answer the question whether an 
increase in LDG frequency precedes disease progression, as measured by CD4+ T cell 
count and plasma viral load.  Also, as there is likely to be significant individual 
variation between each LDG response due to genetic and environmental factors, using 
longitudinal data, where comparisons are made over time in the same individual 
rather than between different individuals, will provide cleaner data as to the role of 
LDGs and arginase in HIV infection.  Furthermore, as individuals are likely to 
commence therapy whilst enrolled in the study, it may be possible to collect data on 
the effect of a reduction in viral load and immune reconstitution on LDG frequency 
and arginase activity.  Together, this data should provide justification for pursuing 
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therapy which targets LDGs and immune dysfunction due to arginase mediated L-
arginine depletion.     
  
7.2.  Further characterisation of LDG phenotype and morphology 
In order to further the phenotypic analysis of LDGs and NDGs performed in this 
thesis I would suggest to look at:  
1. The expression of CD10. This would be a useful marker to investigate as it is 
only expressed on mature segmented neutrophils and not on cells during the 
earlier stages of granulopoiesis.  Therefore, if detected on LDGs, it would 
strengthen the hypothesis that they are mature activated neutrophils. 
2. The expression of CD49d as a marker of immature granulocytes.  CD49d, the 
#4 integrin subunit, expression is maintained until the metamyelocytic stage of 
granulopoiesis.  However, CD49d is virtually absent on band and segmented 
neutrophils and therefore measuring its expression would help distinguish 
immature from mature the LDGs.  
3. The expression of L-selectin. L-selectin is shed following extravasation,so, if 
its levels were decreased, it would suggest that LDGs were activated and had 
migrated out of peripheral circulation. 
In addition to these phenotypic markers, I would also suggest to look at the 
morphology of the cells by performing cytospin followed by Wright-Giemsa staining 
on purified LDGs and NDGs.   
 
7.3.  Suppressive function of LDGs compared to NDGs 
Furthermore, I would suggest comparing the ability of LDGs and NDGs to suppress T 
cell function in vitro.  
In order to do this, I would purify LDGs, NDGs and CD3+ T cells from the blood of 
patients with untreated HIV infection.  I would then culture the T cell with LDGs or 
NDGs at various ratios (2:1, 1:1, 1:2) in medium with physiological levels of L-
arginine for 48 hours.  These T cells would be polyclonally activated with anti-CD3 
anti-CD28 beads.  To account for T cell dysfunction occurring in the patient due to 
other mechanisms, I would also do this experiment in tandem, replacing T cells with 
an immortalized T cell line such as Jurkat cells.   In order to establish that the 
suppression was arginase dependent I would use the following culture conditions:  
1. T cells and LDGs/NDGs alone  
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2. T cells and LDGs/NDGs + competitive arginase inhibitor (nor-NOHA) 
3. T cells and LDGs/NDGs + excess L-arginine 
As a read out for T cell suppression, I would measure T cell proliferation (measured 
by BrdU incorporation) and CD3! expression by flow cytometry.  I would also test for 
the determination of the level of L-arginine and the cytokine profile produced by 
luminex in the supernatants collected after 48 hours.  Finally, I would compare the 
ability of LDGs to suppress T cell functions from patients with CD4+ T cell count * 
350 and patients with CD4+ T cell count < 350 to see if disease severity affects the 
level of suppression observed.  
 
7.4.  Proteomic analysis of LDGs compared to NDGs  
To further characterise the differences between LDGs and NDGs in patients with HIV 
infection, I propose to perform a comparative proteomic study.  LDGs and NDGs 
(4x105 per sample) from the same patient will be purified, lysed and a total protein 
extract will be prepared, separated on a C18-capillary column and analysed online 
using nano-electrospray mass spectrometry.  Due to the fact that proteins are the 
functional components of the cell, I believe this form of unbiased analysis will 
provide interesting insights into the differences between these two populations of 
neutrophils.  I would favour this form of analysis over a genomic or transcriptomic 
approach because I believe that it is difficult to interpret these forms of analysis as 
cells have multiple levels of regulation between genes, mRNA and production of 
proteins.  
 
7.5.  Testing neutrophil degranulation  
Neutrophil degranulation can either be tested by investigating the presence of granule 
membrane markers on the cell surface membrane, as has been performed in this 
thesis, or by examining the extracellular fluid (normally plasma) for the presence of 
granule contents.  Here, I propose to measure plasma levels for:  
1. Arginase protein levels by ELISA (Biovendor); 
2. Myeloperoxidase activity, an indicator of azurophil degranulation, using 
InnoZyme activity kit (Calbiochem / EMD biosciences);   
3. Gelatinase A and B protein levels, as an indicator of gelatinase (tertiary) 
degranulation, using ELISA kits by R&D systems. 
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These experiments would act to confirm that patients with HIV infection had greater 
neutrophil degranulation and activation.   
 
7.6.  Testing the ability of neutrophils to clear infections  
It was noted by Denny et al. that proinflammatory neutrophils in patients with SLE 
had decreased ability for phagocytosis.  If, a similar finding occurred as HIV disease 
progressed, it might help to explain the increased rate of opportunistic bacterial 
infections.  In order to test the anti-microbial effector function of neutrophils, I 
propose to compare LDGs and NDGs from untreated HIV patients with the following 
assays: 
1. Phagocytosis assay;  
2. Microbicidal activity;  
3. Intracellular myeloperoxidase concentration;  
4. Generation of H2O2  
 
7.7.  Determining LDG and NDG life span by measuring the level of apoptosis 
longitudinally in vitro  
Initially, expression of the annexin V as a marker of apoptosis will be measured in 
freshly isolated LDGs and NDGs from untreated HIV+ patients.  Then, LDGs and 
NDGs will be co-cultured with autologous T cells in a transwell system. The 
expression of annexin V/propidium iodide will be tested at different times (t= 6, 12, 
24 hours) using an Annexin V-FITC Apoptosis detection kit as described by 
Rodriguez et al. (Rodriguez et al., 2009).   
 
7.8.  Is a plasma factor inducing neutrophil activation and causing an increase in 
the frequency of LDGs in HIV+ patients?  
The objective of this proposed experiment is to begin to investigate whether a plasma 
factor is contributing to the induction of LDGs, as suggested in section 6.3 and by 
Körmöczi et al.(Körmöczi et al., 2001).   
In order to test this, filtered plasma would be taken from untreated HIV+ patients with 
a high frequency of LDGs in the PBMC fraction.  This plasma would then be used to 
culture NDGs from uninfected control subjects or HIV+ patients with low frequencies 
of LDGs.  The cells would then be compared to NDGs cultured in autologous plasma 
to see if the NDGs have been activated and are expressing markers associated with 
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LDGs (CD11b, CD63 and CD66b) by flow cytometry.  In addition, the level of 
arginase expression will be measured in the cells by flow cytometry and the level of 
arginase protein will be measured in the supernatant by ELISA.  
To test the hypothesis that H2O2 (ROI) is inducing oxidative changes in the plasma 
proteins that then bind to the neutrophils and activate them, the levels of carbonyls in 
the plasma of patients should be measured to see if it is associated with LDG 
frequency. 
 
7.9.  Is arginase activity upregulated at the site of pathology in the gut associated 
lymphoid tissue of patients with HIV infection? 
To test this question would require histological staining and examination of gut 
biopsies from untreated HIV+ patients.  It would be interesting to stain for arginase 1 
and for neutrophils.  This would give an indication of the level of this immune 
regulatory mechanism at the local site of pathology in HIV infection.   
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Chapter IX:  Appendix 
Figure 9.1:  Arginine metabolism in mammals  
  
Abbreviations:  
ADC arginine decarboxylase, AGA agmatinase, AGAT arginine:glycine 
amidinotransferase, ASL argininosuccinate lyase, ASS argininosuccinate synthase, AS 
argininosuccinate, Asp aspartate, BH 4 (6R)-5,6,7,8-tetrahydro-L-biopterin, CP 
carbamoylphosphate, CPS-I carbamoylphosphate synthetase-I (ammonia), DCAM 
decarboxylated S-adenosylmethionine, Glu glutamate, Gln glutamine, GDH glutamate 
dehydrogenase, GA guanidinoacetate, GMAT guanidinoacetate N-methyltransferase, 
CK creatine kinase, Cr–P creatine-phosphate, "-KG #-ketoglutarate, MTA 
methylthioadenosine, NAG N-acetylglutamate, NAGS N-acetylglutamate synthase, NO 
nitric oxide, NOS nitric oxide synthase, OAT ornithine aminotransferase, OCT 
ornithine carbamoyltransferase, ODC ornithine decarboxylase, PO proline oxidase, 
P5CD pyrroline-5-carboxylate dehydrogenase, P5CR pyrroline-5-carboxylate 
reductase, P5CS pyrroline-5-carboxylate synthase, PUT putrescine, SAM S-
adenosylmethionine, SAMD S-adenosylmethionine decarboxylase, SAHC S-
adenosylhomocysteine, SPDS spermidine synthase 
From: Arginine metabolism and nutrition in growth, health and disease Wu, G. et al. 
Amino Acids (2009) 37:153-168 
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Table 9.1: Cohort 1 - Patient data: Treated patients 
 
ND = Viral load not detectable (<50 copies/mL) 
 
Summary:  
Male:Female    20:2 
CD4+ T cell count >350 16 
CD4+ T cell count "350 6 
 
 
 
 
Patient 
Code Sex  Age  
CD4+ 
count   
(cells/µL) 
CD8+ 
count 
cells/µL 
Viral load 
(copies/mL)  
Log10 
viral 
load/mL 
Treatment regimen 
T1 M 37 90 390 ND ND ABC 3TC NVP   
T2 M 40 510 1000 ND ND ABC 3TC LPV/R   
T3 M 46 720 980 ND ND TDF FTC EFV   
T4 M 34 460 410 ND ND ABC 3TC EFV   
T5 M 52 330 560 ND ND ABC 3TC SQV/R   
T6 M 45 870 870 ND ND TDF   LPV/R NVP 
T7 F 37 650 550 ND ND TDF 3TC ATV/R   
T8 M 54 540 900 ND ND DDI ABC ATV/R   
T9 M 32 250 1000 ND ND TDF FTC DRV/R RTG 
T10 M 39 560 1060 ND ND TDF FTC DRV/R   
T11 M 28 420 740 ND ND ABC 3TC EFV   
T12 F 35 600 990 ND ND ABC 3TC ATV/R   
T13 M 66 590 740 ND ND TDF DDI ATV/R   
T14 M 35 710 1040 136 2.13 TDF DDI LPV/R   
T15 M 47 400 1180 ND ND TDF FTC DRV/R   
T16 M 42 100 1170 ND ND TDF FTC AZT DRV/R 
T17 M 47 210 280 ND ND TDF FTC DRV/R   
T18 M 43 490 1120 ND ND TDF FTC DRV/R   
T19 M 54 760 810 ND ND 3TC AZT NVP   
T20 M 34 420 1010 ND ND TDF FTC DRV/R   
T21 M 47 330 1000 ND ND TDF FTC ATV/R   
T22 M 65 420 480 ND ND ETV LPV/R RTG   
Mean  43.6         
S.D. 10.1         
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Drug  Class Abbreviation  
Atazanavir / ritonavir ATV/r 
Darunavir / ritonavir DRV/r 
Lopinavir / ritonavir LPV/r 
Saquinavir / ritonavir 
Boosted Protease Inhibitor 
SQU/r 
Raltegravir Integrase inhibitor RTG 
Efavirenz EFV 
Etravirine ETV 
Nevirapine 
Non-nucleoside reverse-
transcriptase inhibitors 
NVP 
Abacavir ABC 
Didanosine DDI 
Emtricitabine FTC 
Lamivudine 3TC 
Zidovudine 
Nucleoside analog 
reverse-transcriptase 
inhibitors 
ZDU 
Tenofovir 
Nucleotide analog 
reverse-transcriptase 
inhibitors 
TDF 
 
Summary of treatment status:  
20/22  Dual Nucleotide analog reverse-transcriptase inhibitors (NRTI)/ Nucleotide 
analog reverse-transcriptase inhibitors backbone (NtRTI) 
5/20  Non-nucleoside reverse-transcriptase inhibitors (NNRTI) 
16/20 Boosted Protease Inhibitor (bPI) 
1  NNRTI / bPI / integrase inhibitor 
1 NtRTI / bPI / NNRTI 
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Table 9.2: Cohort 1 - Patient data: HAART naïve patients  
 
Patient 
code  Sex  Age  
CD4+ 
count   
(cells/µL) 
CD8+ 
count 
cells/µL 
Viral load 
(copies/mL)  
Log10 viral 
load/mL 
UT1 M 44 800 1180 455 2.66 
UT2 M 45 280 520 122419 5.09 
UT3 M 37 560 1370 36199 4.56 
UT4 M 32 330 1200 500000 5.70 
UT5 F 35 280 490 7771 3.89 
UT6 M 39 270 1860 63522 4.80 
UT7 M 40 160 420 500000 5.70 
UT8 M 65 520 720 237403 5.38 
UT9 M 25 230 660 128837 5.11 
UT10 M 27 320 2310 5447 3.74 
UT11 M 37 420 1520 29185 4.47 
UT12 M 47 380 970 9828 3.99 
UT13 M 62 10 330 93339 4.97 
UT14 M 45 20 560 116329 5.07 
UT15 M 50 10 240 467723 5.67 
UT16 F 40 70 440 474213 5.68 
UT17 M 42 10 370 226006 5.35 
UT18 M 66 270 440 364798 5.56 
UT19 F 34 100 300 399692 5.60 
UT20 M 52 90 760 139226 5.14 
UT21 M 41 0 340 236940 5.37 
UT22 F 34 0 60 500000 5.70 
Mean  42.7     
S.D. 11.1     
ND = Viral load not detectable (<50 copies/mL) 
Summary:  
Male:Female    19:3 
CD4+ T cell count >350 5 
CD4+ T cell count "350 17 
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 Table 9.3:  Cohort 2 - Patient data  
 
Patient 
Code Sex  Age  
CD4+ 
count   
(cells/µL) 
CD8+ 
count 
(cells/µL) 
Viral load 
(copies/mL)  
Log10 
viral 
load/mL 
H107 M 23 760 1520 421 2.6 
H108 F 31 270 1620 13844 4.1 
H109 M 64 820 860 971 3.0 
H114 M 52 350 1080 8999 4.0 
H115 M 42 290 400 12614 4.1 
H116 M 22 560 710 2236 3.3 
H117 M 25 830 1310 4804 3.7 
H118 M 48 750 1090 2190 3.3 
H119 M 28 240 850 139809 5.1 
H123 M 32 600 510 ND ND 
H124 M 40 470 770 43901 4.6 
H125 M 38 650 1100 ND ND 
H126 M 28 360 900 83860 4.9 
H130 M 39 20 250 105575 5.0 
H132 M 37 250 2270 54136 4.7 
H136 M 44 16 208 92264 5.0 
H137 M 27 24 242 90270 5.0 
H138 M 42 60 430 35028 4.5 
H139 M 30 300 1680 60012 4.8 
H140 M 23 270 1510 205787 5.3 
H141 M 42 340 1370 94267 5.0 
H142 M 29 340 1440 31633 4.5 
H143 M 43 40 238 500000 5.7 
H144 M 29 290 930 64650 4.8 
H145 M 44 110 900 13424 4.1 
Mean  36.1     
S.D. 10.3     
ND = Viral load not detectable (<50 copies/mL) 
 
Summary:  
Male:Female    24:1 
CD4+ T cell count >350 9 
CD4+ T cell count "350 16 
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Table 9.4:  Cohort 3 - Patient data 
 
Patient 
Code Sex  Age  
CD4+ 
count   
(cells/µL) 
CD8+ 
count 
(cells/µL) 
Viral load 
(copies/mL)  
Log10 
viral 
load/mL 
N4 M 66 122 1116 33334 4.52 
N5 F 51 7 452 118429 5.07 
N10 M 49 330 660 - - 
N13 F 33 76 410 80210 4.90 
N14 M 53 150 1650 225184 5.35 
N15 M 40 560 1520 3118 3.49 
N16 M 36 560 890 255 2.41 
N17 M 38 230 410 10156 4.01 
N18 M 23 400 1480 59475 4.77 
N19 F 44 219 669 36540 4.56 
N20 M 59 200 1190 283072 5.45 
N28 M 51 300 690 372820 5.57 
N30 M 38 780 4880 91542 4.96 
N31 M 60 540 920 1450 3.16 
N32 M 48 330 750 61697 4.79 
N33 M 23 520 540 9815 3.99 
N34 M 33 680 1180 22398 4.35 
N35 M 42 540 950 34899 4.54 
N36 M 27 580 750 247 2.39 
N37 M 44 20 122 500000 5.70 
N38 F 27 25 269 374269 5.57 
Mean 42.1     
S.D. 12.2     
 
Summary:  
Male:Female    17:4 
CD4+ T cell count >350 9 
CD4+ T cell count "350 12 
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Table 9.5:  Summary table of arginase activity calculation for cohort 1: patients 
on HAART)  
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Table 9.6:  Summary table of arginase activity calculation for cohort 1:  HAART 
naïve patients  
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Table 9.7:  Summary table of arginase activity calculation for cohort 2  
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Table 9.8:  Surface marker expression during different stages of granulopoiesis 
 
 
 
From: Elghetany, M. T., Surface antigen changes during normal neutrophilic 
development: a critical review. Blood Cells Mol Dis 28 (2), 260 (2002). 
 
 
 
 
 
 
 
 
 
 268 
Chapter X: Publications arising from this thesis  
 
At the date of submission two publications have arisen from the work conducted in 
this thesis.  They are: 
Cloke, T. E. et al., Increased level of arginase activity correlates with disease 
severity in HIV-seropositive patients. J Infect Dis 202 (3), 374.  
Cloke, T. E. et al., Antiretroviral therapy abrogates association between 
arginase activity and HIV disease severity. Trans R Soc Trop Med Hyg 104 
(11), 746.  
A copy of these publications has been appended to the end of this thesis.  In addition, 
a manuscript encompassing the data produced in chapter V is in preparation for 
submission.  
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Increased Level of Arginase Activity Correlates
with Disease Severity in HIV-Seropositive Patients
T. E. Cloke,1 L. Garvey,2 B.-S. Choi,1 T. Abebe,4 A. Hailu,4 M. Hancock,3 U. Kadolsky,1 C. R. M. Bangham,1 M. Munder,5
I. Mu¨ller,1 G. P. Taylor,2 and P. Kropf1
1Department of Immunology, Faculty of Medicine, and 2Department of Genito-Urinary Medicine and Communicable Diseases, Imperial College
London, and 3Department of Clinical Biochemistry, Imperial College Healthcare National Health Service Trust, Charing Cross Hospital, London,
United Kingdom; 4Department of Microbiology, Parasitology, and Immunology, University of Addis Ababa, Addis Ababa, Ethiopia; 5Department
of Hematology, Oncology, and Rheumatology, University of Heidelberg, Heidelberg, Germany
Infection with human immunodeficiency virus (HIV) results in a chronic infection that progressively impairs
the immune system. Although depletion of CD4+ T cells is frequently used to explain immunosuppression,
chronicity of infection and progressive loss of CD4+ T cells are not sufficient to fully account for immune
dysregulation. Arginase-induced L-arginine deprivation is emerging as a key mechanism for the down-regu-
lation of immune responses. Here, we hypothesized that the level of arginase activity increases with disease
severity in HIV-seropositive patients. We determined the levels of arginase activity in peripheral blood mono-
nuclear cells from HIV-seropositive patients and uninfected control participants. Our results show that pe-
ripheral blood mononuclear cells from HIV-seropositive patients with low CD4+ T cell counts expressed
statistically significantly higher levels of arginase activity, compared with patients with high CD4+ T cell counts
or uninfected control participants. Furthermore, we found a statistically significant correlation between high
level of arginase activity and high viral load in HIV-seropositive patients.
The pandemic of human immunodeficiency virus
(HIV) infection is not declining; more than 39 million
people are living with HIV infection and over 2.1 mil-
lion people died of HIV infection in 2007, according
to estimates of the Joint United Nations Programme
on HIV/AIDS and the World Health Organization.
Major advances have been made in the development
of life-prolonging highly active antiretroviral therapy
(ART). ART provides substantial benefit to HIV-in-
fected individuals by reducing opportunistic infec-
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tions and hospitalization and improving quality and
duration of life.
Chronic HIV infection progressively impairs the im-
mune system. The progressive quantitative and quali-
tative impairment of CD4+ T cells is well established,
and the loss of activated CD4+ T cells starts in the early
phases of HIV infection and is accompanied by reduced
proliferative responses and altered cytokine secretion
[1]. Although the depletion of CD4+ T cells explains
much of the immunosuppression, the precise reasons
for the onset of immunopathology during HIV infec-
tion have not yet been resolved [2]. In particular, al-
though there are ample population-based data corre-
lating clinical outcomes with absolute CD4+ T cell
counts, it is also apparent that individual outcomes vary
widely at any given CD4+ T cell count. A variety of
explanations, ranging from immunological factors to
genetic, behavioral, and environmental factors, con-
tribute to the rate of HIV disease progression [3].
The metabolism of l-arginine by arginase is emerging
as a crucial mechanism for the regulation of immune
responses [4–8]. Arginase 1 impairs T cell responses by
modulating the bioavailability of l-arginine. Human
 at Im
perial College London Library on July 26, 2011
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peripheral blood polymorphonuclear cells constitutively ex-
press high amounts of arginase 1; when released from periph-
eral blood polymorphonuclear cells, arginase 1 profoundly
suppressed the T cell activation [9]. Whereas arginase 1 is con-
stitutively expressed in human peripheral blood polymorpho-
nuclear cells, it is an inducible enzyme in murine granulocytes,
as well as in macrophages and dendritic cells [9]. In mouse
myeloid cells, high levels of arginase activity coincide with the
transport of extracellular l-arginine into the cells, thereby caus-
ing a reduction of l-arginine in the microenvironment. In turn,
this decrease in l-arginine results in impaired T cell responses
[4–6, 9–14]. This T cell dysfunction is directly attributed to l-
arginine starvation, which arrests cells in the G0–G1 phase of
the cell cycle [13]. Arginase-mediated l-arginine deprivation
has been shown to cause T cell hyporesponsiveness in a variety
of physiological and pathological conditions [6, 15, 16]. More-
over, high levels of arginase expression have been reported in
a variety of infectious diseases, including schistosomiasis [17],
trypanosomiasis [18], tuberculosis [19], and leishmaniasis [20].
Arginase hydrolyzes l-arginine to urea and ornithine, the
latter being further metabolized into polyamines. Homeostasis
of l-arginine depends on dietary arginine intake, protein turn-
over, l-arginine synthesis, and catabolism.
In the present study, we have investigated the levels of ar-
ginase activity in peripheral blood mononuclear cells (PBMCs)
isolated from the blood of HIV-seropositive patients.
MATERIALS AND METHODS
Subjects. The study protocol was approved by the National
Research Ethics Service (Centre of Research: Ethical Campaign
[COREC] reference 05/Q0410/93). An initial cohort of 38 HIV-
seropositive patients (mean age ! standard deviation [SD],
years) were recruited from St Mary’s Hospital, fol-42.5! 1.6
lowed by an additional 31 HIV-seropositive patients (mean age
! SD, years). From the patient’s hospital records38.5! 2.0
it was determined whether the patient was receiving ART. The
22 patients who were receiving treatment were receiving either
2-class or 3-class combination ART. These treatments com-
prised a dual nucleoside or nucleotide analogue reverse tran-
scriptase inhibitor backbone with either a non-nucleoside an-
alogue reverse transcriptase inhibitor (5 patients) or a boosted
protease inhibitor (14 patients), or a nucleoside or nucleotide
analogue reverse transcriptase inhibitor and a boosted protease
inhibitor backbone with either a nonnucleoside analogue re-
verse transcriptase inhibitor (1 patient) or an integrase inhibitor
(2 patients). The only exclusion criterion was that the patients
must be at least 18 years old. Eleven healthy, age-matched vol-
unteers (mean age ! SD, years) were recruited as45.9! 5.0
control subjects. All study subjects gave written, informed con-
sent before participation.
Laboratory evaluation. Plasma HIV type 1 RNAwas quan-
tified by real-time polymerase chain reaction (Bayer Quantiplex
assay [branched DNA] polymerase chain reaction test; lower
detection level, 50 copies/mL). Levels of the standard T lym-
phocyte markers CD3, CD4, and CD8 were determined by flow
cytometry.
Samples. Twenty milliliters of anticoagulated peripheral
blood was collected in edetic acid tubes, and PBMCs were
isolated by density gradient centrifugation with Histopaque-
1077 solution (Sigma). Cells were washed in phosphate-buf-
fered saline and resuspended in lysis buffer (0.1% Triton X-
100, 25 mmol/L Tris–hydrogen chloride, and 10 mmol/L man-
ganese chloride [Sigma]) and then frozen until further use. Se-
rum was isolated by centrifuging 1 mL of blood at 200 g for
10 min and was then frozen until further use.
Determination of PBMC level of arginase activity and pro-
tein level and seruml-arginine concentrations. The level of
enzymatic activity of arginase was measured as described else-
where [6]. A bicinchoninic acid protein assay (Pierce) was used
to determine the protein concentration. Concentrations of l-
arginine were determined in the serum samples. Free amino
acids were separated by ion-exchange chromatography and
quantified by postcolumn ninhydrin derivatization by use of
an amino acid analyzer (AminoTac JLC-500/V).
Western blot analyses and flow cytometry. CD3z protein
expression levels were measured as described elsewhere [21].
Intracellular arginase levels were determined as described else-
where [6]. The following antibodies were used: anti-CD4, anti-
CD15, anti-CD1a, anti-CD14 (BD Pharmingen), anti-CD38
monoclonal antibody (eBioscience), anti-CD3z (Santa Cruz),
and anti-HLA-DR monoclonal antibody (Beckman Coulter);
samples were analyzed using a CyAn ADP analyzer (Dako) and
Summit software (version 4.3; Dako).
Statistical analyses. Data were evaluated for statistical dif-
ferences by use of a 2-tailed Mann-Whitney U test and for
correlation by use of a Spearman rank test, with Prism software
(version 5.0; GraphPad).
RESULTS
Levels of arginase activity in PBMCs isolated from HIV-se-
ropositive patients. In the present study, we tested the hy-
pothesis that the level of arginase activity is increased in HIV-
seropositive patients, which might contribute to immune dys-
function and disease progression. First, we tested the levels
of arginase activity in the PBMCs of HIV-seropositive patients
and age-matched uninfected control participants. As shown in
Figure 1A, there were similar levels of arginase activity in
PBMCs isolated from HIV-seropositive patients and in PBMCs
isolated from uninfected control participants (median concen-
trations ! SEM, vs mU/mg of protein;14.2! 3.1 12.1! 1.5
). To investigate the effect of disease progression on thePp .17
level of arginase activity, we subdivided our cohort of HIV-
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Figure 1. Levels of arginase activity in peripheral blood mononuclear
cells (PBMCs) from control participants and human immunodeficiency virus
(HIV)–seropositive patients. PBMCs from control participants ( ) andnp 11
HIV-seropositive patients ( ) were isolated by Ficoll gradient, and thenp 44
activity level of arginase was measured by enzymatic assay (A). HIV-se-
ropositive patients were classified according to their CD4+ T cell counts as
high–CD4 cell count patients (CD4 cell count, 1350 cells/mL; ) andnp 21
low–CD4 cell count patients (CD4 cell count, !350 cells/mL; ); thenp 23
activity level of arginase in the PBMCs was measured by enzymatic assay
(B ). ** ; *** . NS, not significant.Pp .004 P ! .001
seropositive patients into 2 groups on the basis of their CD4+
T cell count: 1350 cells/mL (high–CD4 cell count patients) and
!350 cells/mL (low–CD4 cell count patients), this being the
value below which differences in clinical outcome increasingly
appear [22] and the initiation of ART is recommended [23].
The levels of arginase activity measured in PBMCs isolated from
HIV-seropositive patients with a high CD4 T cell count and in
PBMCs isolated from control participants were similar (median
concentrations ! SEM, vs mU/mg of10.7! 1.5 12.1! 1.5
protein; ) (Figure 1B). However, the levels of arginasePp .61
activity were statistically significantly higher inHIV-seropositive
patients with a low CD4 T cell count than those in control
participants (median concentrations ! SEM, vs21.9! 5.2
mU/mg of protein; ). Moreover, there were12.1! 1.5 Pp .004
statistically significantly higher levels of arginase activity in
PBMCs from HIV-seropositive patients with a low CD4 T cell
count, compared with HIV-seropositive patients with a high
CD4 T cell count (median concentrations ! SEM, 10.7!
vs mU/mg of protein; ). To exclude the1.5 21.9! 5.2 P ! .001
possibility that the increased levels of arginase activity observed
in the PBMCs of HIV-seropositive patients with low CD4+ T
cell counts (Figure 1) could be due to a switch in the ratio of
T cells to arginase-expressing cells, we also calculated the level
of arginase activity as milliunits of arginase per milliliter of
blood: there were also statistically significantly higher levels of
arginase activity in PBMCs fromHIV-seropositive patients with
a low CD4 T cell count than those in PBMCs from HIV-
seropositive patients with a high CD4 T cell count (median
concentrations ! SEM, vs mU/mL;1.4! 0.1 2.2! 0.3 P !
; data not shown)..001
High levels of arginase activity are correlated with low T
cell counts in untreated HIV-seropositive patients. To ana-
lyze further the strength of this association in HIV-seropositive
patients, we plotted the levels of arginase activity against the
absolute CD4+ T cell counts. As shown in Figure 2A, there was
a highly statistically significant inverse correlation between the
level of arginase activity and CD4+ T cell counts in the PBMCs
fromHIV-seropositive patients ( ; ; Spearmanrp"0.60 P ! .001
rank test). To assess the effect of ART on the level of arginase
activity, we stratified the cohort further into 2 groups, that is,
patients who were receiving ART (treated patients) and patients
who were not receiving ART (untreated patients). Interestingly,
a highly statistically significant inverse correlation was found
between CD4+ T cell counts and levels of arginase activity in
PBMCs isolated from the untreated patients ( ;rp"0.80 P !
) (Figure 2B) but not in PBMCs isolated from the treated.001
patients ( ; ) (Figure 2C). Similar results wererp"0.25 Pp .25
obtained when the CD4+ T cell counts were plotted against the
levels of arginase activity, expressed as milliunits of arginase
per milliliter of blood, with an inverse correlation found in
PBMCs from the untreated patients ( ; ) butrp"0.68 P ! .001
not in PBMCs from the treated patients ( ; ;rp"0.23 Pp .30
data not shown).
Because CD8+ T cells are important in the immune response
against HIV infection, we asked whether there was a similar
association between CD8+ T cell count and the level of arginase
activity. Figure 3A shows a statistically significant inverse cor-
relation between CD8+ T cell counts and levels of arginase
activity in the HIV-seropositive cohort ( ; ).rp"0.51 P ! .001
Similar to the findings for CD4+ T cell counts, there was a
statistically significant inverse correlation in the group of un-
treated patients between CD8+ T cell count and the level of
arginase activity, as measured both in milliunits of arginase per
milligram of protein ( ; ) and in milliunits ofrp"0.73 P ! .001
 at Im
perial College London Library on July 26, 2011
jid.oxfordjournals.org
Downloaded from
 
Arginase in HIV-Seropositive Patients • JID 2010:202 (1 August) • 377
Figure 2. Correlation between the level of arginase activity in peripheral blood mononuclear cells and CD4+ T cell counts, among human immunodeficiency
virus (HIV)–seropositive patients ( ) (A), HIV-seropositive patients who were not receiving antiretroviral therapy ( untreated patients) (B ), andnp 44 np 22
HIV-seropositive patients who were receiving antiretroviral therapy ( treated patients) (C ).np 22
arginase per milliliter of blood ( ; ; data notrp!0.51 Pp .02
shown) (Figure 3B); however, this correlation was not found
in the group of treated patients, neither for milliunits of ar-
ginase per milligram of protein ( ; ) nor forrp 0.09 Pp .70
milliunits of arginase per milliliter of blood ( ;rp!0.03 Pp
; data not shown) (Figure 3C). A similar association was.89
observed between the level of arginase activity and CD3+ T cell
count (data not shown).
High level of arginase activity correlates with high viral
load. Viral load is another marker of HIV disease severity.
Therefore, we tested whether viral load (measured as HIV type
1 RNA copies per milliliter of plasma [Bayer Diagnostics])
correlates with the level of arginase activity in PBMCs from
HIV-seropositive patients. Our results reveal a statistically sig-
nificant correlation between viral load and the level of arginase
activity in PBMCs isolated from HIV-seropositive patients
( ; ) (Figure 4A). The cohort of HIV-seropos-rp 0.38 Pp .01
itive patients was subdivided into treated patients and untreated
patients; as expected, no correlation was observed among the
treated patients, as nearly all patients who receive ART have
an undetectable viral load ( ; ) (Figure 4C).rp 0.26 Pp .25
However, the correlation between viral load and the level of
arginase activity was statistically significant in the untreated
patients ( ; ) (Figure 4B). Similar results wererp 0.53 Pp .01
obtained when the viral loads were plotted against the levels
of arginase activity expressed as milliunits of arginase per mil-
liliter of blood: a correlation was seen in the untreated patients
( ; ) but not in the treated patients ( ;rp 0.47 Pp .03 rp 0.25
; data not shown). These results show that high viralPp .27
load correlates with high levels of arginase activity in untreated
HIV-seropositive patients.
Lower levels of l-arginine in serum samples from HIV-
seropositive patients. High levels of arginase activity have
been associated with lower levels of l-arginine in the plasma
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Figure 3. Correlation between the level of arginase activity in peripheral blood mononuclear cells and CD8+ T cell counts, among human immunodeficiency
virus (HIV)–seropositive patients ( ) (A), HIV-seropositive patients who were not receiving antiretroviral therapy ( untreated patients) (B ), andnp 44 np 22
HIV-seropositive patients who were receiving antiretroviral therapy ( treated patients) (C ).np 22
[19]. Here, we tested the hypothesis that the increased levels
of arginase activity that were measured in HIV-seropositive
patients with low CD4+ T cell counts (Figure 1B) were accom-
panied by decreased l-arginine concentrations. To test this hy-
pothesis, we first compared l-arginine concentrations in the
serum samples from HIV-seropositive patients with a high CD4
T cell count with those in the serum samples from HIV-se-
ropositive patients with a low CD4 T cell count. As shown in
Figure 5A, l-arginine levels in the serum samples from low–
CD4 cell count, HIV-seropositive patients were lower than in
those from high–CD4 cell count, HIV-seropositive patients, but
this difference was not statistically significant (median concen-
trations ! SEM, vs mmol/L; ).65.0! 6.7 87.0! 4.7 Pp .17
No differences were observed when the cohort of HIV-sero-
positive patients was subdivided into treated patients and un-
treated patients (median concentrations! SEM, vs71.0! 5.8
mmol/L; ) (Figure 5B). We then assessed the79.5! 5.2 Pp .68
correlation between serum l-arginine level and the level of
PBMC arginase activity. As shown in Figure 5C, no statistically
significant correlation was observed between l-arginine level
and the level of arginase activity ( ; ) (Figurerp!0.14 Pp .43
5C) or when the cohort of patients was subdivided into treated
patients ( ; ) (Figure 5E) and untreated patientsrp 0.17 Pp .54
( ; ) (Figure 5D). We recruited HIV-seropos-rp!0.19 Pp .42
itive patients from 2 sources: outpatients and inpatients; the
latter had AIDS-defining illnesses. Although all inpatients were
recruited prior to commencing ART, they were receiving other
therapeutic and/or nutritional interventions. Interestingly, when
the inpatients ( ; ) (Figure 5F) were removedrp!0.14 Pp .78
from the cohort of untreated patients, a correlation between the
level of arginase activity and the l-arginine level was observed
( ; ) (Figure 5G), whereby as the level of ar-rp!0.59 Pp .03
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Figure 4. Correlation between the level of arginase activity in peripheral blood mononuclear cells and viral load among human immunodeficiency virus
(HIV)–seropositive patients ( ) (A), HIV-seropositive patients who were not receiving antiretroviral therapy ( untreated patients) (B ), and HIV-np 44 np 22
seropositive patients who were receiving antiretroviral therapy ( treated patients) (C ).np 22
ginase activity in the PBMC fraction increases, the level of l-
arginine in the serum samples decreases.
Relationship between the level of arginase activity and the
level of expression of the CD3z chain in PBMCs from un-
treated HIV-seropositive patients. Arginase-induced l-argi-
nine depletion has been associated with profound T cell dys-
function, and the expression level of CD3z in T cells is widely
used as a marker of T cell hyporesponsiveness [4, 6–8]. Because
we have shown that a higher level of arginase activity is ex-
pressed in PBMCs of HIV-seropositive patients with a low CD4
T cell count (Figure 1), we asked whether the enhanced arginase
levels coincide with decreased levels of CD3z expression. To
test this hypothesis, we measured the levels of CD3z expression
in PBMCs from treated HIV-seropositive patients anduntreated
HIV-seropositive patients by means of Western blot analysis.
Figure 6 shows that the expression levels of CD3z were low-
er in untreated patients (lanes 5–8) than in treated patients
(lanes 1–4). Furthermore, higher levels of arginase expression
in PBMCs from HIV-seropositive patients were associated with
decreased levels of CD3z expression (Figure 6). To characterize
further the association between the level of CD3z expression
and the level of arginase activity, we recruited an additional 18
patients and measured the mean fluorescence intensity (MFI)
of CD3z in CD4+ and CD8+ T cells by means of flow cytometry.
The results in Figures 6B and 6C show that although the ex-
pression levels of CD3z in both CD4+ and CD8+ T cells de-
crease with increasing levels of arginase activity (rp!0.41
and , respectively), the correlations were not statis-rp!0.43
tically significant ( and , respectively).Pp .09 Pp .07
To assess the percentages of CD38-expressing and HLA-DR–
expressing CD4+ and CD8+ T cells, we recruited an additional
25 HIV-seropositive patients for whom we measured the fre-
quency of these 2 activation markers by means of flow cytom-
etry. As shown in Figures 6D and 6E, we found a statistically
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Figure 5. Levels of L-arginine in serum samples from human immunodeficiency virus (HIV)–seropositive patients. HIV-seropositive patients were classified
according to their CD4+ T cell counts as high–CD4 cell count patients (CD4 cell count, 1350 cells/mL; ) and low–CD4 cell count patients (CD4 cellnp 13
count, !350 cells/mL; ) (A). HIV-seropositive patients were also classified according to their treatment status as patients receiving antiretroviralnp 17
therapy (ART; treated patients) and patients not receiving ART ( untreated patients) (B ). Levels of arginase activity in peripheral bloodnp 15 np 20
mononuclear cells are plotted against serum sample L-arginine levels for all HIV-seropositive patients ( ) (C ), untreated HIV-seropositive patientsnp 35
( ) (D ), treated HIV-seropositive patients ( ) (E ), untreated HIV-seropositive inpatients ( ) (F ), and untreated HIV-seropositive outpatientsnp 20 np 15 np 7
( ) (G ).np 13
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Figure 6. Levels of arginase activity and CD3z expression in peripheral blood mononuclear cells (PBMCs) from human immunodeficiency virus (HIV)–
seropositive patients. PBMCs were isolated by Ficoll gradient from the blood of treated HIV-seropositive patients (mean CD3+ T cell count [! standard
deviation], cells/mL; lanes 1–4 ) and untreated HIV-seropositive patients (mean CD3+ T cell count [! standard deviation],1250.0! 107.2 1152.5!
cells/mL; lanes 5–8 ) (A). Levels of arginase activity were measured by enzymatic assay, and CD3z expression levels were measured by Western228.9
blot analysis. PBMCs were isolated by density gradient from the blood of HIV-seropositive patients. The mean fluorescence intensity (MFI) of CD3z was
determined by flow cytometry and is plotted against the level of arginase activity for CD4+ T cells ( patients) (B ) and CD8+ T cells ( patients)np 18 np 18
(C ). The percentage of CD38+ cells was determined by flow cytometry and is plotted against the level of arginase activity for CD4+ T cells ( patients)np 25
(D ) and CD8+ T cells ( patients) (E ). The percentage of HLA-DR+ cells was determined by flow cytometry and is plotted against the level of arginasenp 25
activity for CD4+ T cells ( patients) (F ) and CD8+ T cells ( patients) (G ).np 25 np 25
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significant correlation between the levels of arginase activity
and the frequency of CD38 on CD8+ T cells ( ;rp 0.43 Pp
) but not between the levels of arginase activity and the.03
frequency of CD38 on CD4+ T cells ( ; ). An-rp 0.27 Pp .19
other statistically significant correlation was observed between
the level of arginase activity and the frequency of HLA-DR on
CD4+ T cells ( ; ) (Figure 6F) but not betweenrp 0.70 P ! .001
the level of arginase activity and the frequency of HLA-DR on
CD8+ T cells ( ; ) (Figure 6G).rp 0.10 Pp .65
The cells that express arginase in the PBMC fraction are
CD15+CD145. We have shown that higher levels of arginase
are expressed in PBMCs from HIV-seropositive patients (Figure
1). In humans, the main arginase-expressing cell types are neu-
trophils [9], alternatively activated macrophages [6], and my-
eloid-derived suppressor cells [8]. Here, we identified the phe-
notype of arginase-expressing cells in PBMCs of HIV-seropos-
itive patients. As shown in Figure 7A, 95.1% (9.7% of 10.2%)
of arginase-expressing cells are CD15 positive. PBMCs from an
additional 5 patients were tested, and a mean (! SD) of
of arginase-expressing cells were found to be93.5%! 1.6%
CD15 positive (data not shown). These CD15+ cells did not
express CD14. Furthermore, !1% of CD14+ cells and !0.1%
of CD1a+ cells expressed arginase (data not shown). We also
measured the MFI of arginase 1 by means of flow cytometry.
As shown in Figure 7B, there was no correlation between the
levels of arginase activity as measured by enzymatic assay and
the MFI ( ; ). Next, we tested whether the fre-rp 0.17 Pp .41
quency of CD15+ cells in the PBMC fraction differs between
HIV-seropositive patients with a high CD4 T cell count and
HIV-seropositive patients with a low CD4 T cell count and
found a strong correlation between the levels of arginase activity
and the frequency of CD15+ cells in PBMCs ( ;rp 0.75 Pp!
)..001
DISCUSSION
Amino acid starvation is increasingly recognized as a potent
immunoregulatory mechanism. For example, cysteine deple-
tion leads to cell cycle arrest in human T cells, due to intra-
cellular glutathione reduction and altered redox regulation [24].
Reduction of the levels of another amino acid, tryptophan, by
the enzymatic activity of indoleamine 2,3-dioxygenase in the
kynurenine pathway suppresses maternal T cell responses dur-
ing pregnancy and thereby contributes to the tolerance of al-
logeneic fetuses [25]. The catabolism of the semi-essential
amino acid l-arginine by arginase is also emerging as a potent
mechanism for the regulation of T cell responses. Depletion of
l-arginine by arginase-expressing myeloid cells has been pre-
viously shown in vitro [5, 20, 26, 27], and high levels of arginase
activity coincide with reduced levels of l-arginine in the plasma
of patients who have active tuberculosis [19].
Our study reveals that PBMCs from HIV-seropositive pa-
tients with a low–CD4 T cell count express statistically signif-
icantly higher levels of arginase activity than PBMCs fromHIV-
seropositive patients with a high CD4 T cell count. Moreover,
we found a statistically significant association between high
levels of arginase activity and high viral load in untreated HIV-
seropositive patients. These results show that high levels of
arginase activity in PBMCs from HIV-seropositive patients
correlate with 2 well-described markers of disease progression,
high plasma viremia and low CD4+ T cell counts. Immune dys-
function leading to AIDS is characterized by a profound decline
in the number and effector functions of CD4+ T cells [1, 3].
Here, we propose that the higher levels of arginase activity
observed in PBMCs from HIV-seropositive patients with a low
CD4 T cell count result in lower levels of l-arginine, thereby
causing dysregulation of CD4+ T cell responses.
We measured the expression levels in PBMCs of CD3z, a
marker commonly used to assess T cell responsiveness [4, 28,
29] and show down-regulation of the CD3z chain in untreated
HIV-seropositive patients, as measured by Western blot anal-
ysis. Although our data obtained by flow cytometry suggest
that the expression levels of CD3z decrease with increasing
levels of arginase activity, the correlation was not statistically
significant. HIV-associated down-modulation of the CD3z
chain in T cells has previously been shown to correlate with
disease severity [30, 31]. In contrast, we did not find a statis-
tically significant correlation between CD3z MFI and CD4+ T
cell counts or viral load (data not shown). These apparent
contradictions between the results of Geertsma et al [30] and
our results are likely due to differences in the numbers of CD4+
T cells in HIV-seropositive patients: there were considerably
more patients with low CD4+ T cell counts in the study by
Geertsma et al [30] than there were in the present study.
We report for the first time, to our knowledge, that the level
of arginase, an enzyme that catabolizes l-arginine (an amino
acid that is essential for T cell effector functions), is statistically
significantly increased in PBMCs of untreated HIV-seropositive
patients. The central role played by l-arginine in the regulation
of T cell responses has already been described elsewhere [4, 7–
9]. The molecular basis for this T cell dysfunction induced by
l-arginine deprivation has recently been identified: the ab-
sence of l-arginine arrests T cells in the G0–G1 phase of the
cell cycle [13].
We have previously shown that in uncomplicated preg-
nancies, remarkably high levels of arginase were selectively
expressed in the placenta; although higher levels of arginase
activity were observed in the PBMCs of pregnant women
compared with those of control subjects, these levels were
still notably lower compared with the levels in the placenta.
Furthermore, the expression levels of the CD3z chain were
statistically significantly lower in T cells from the placenta bi-
opsy specimens than in T cells from the peripheral blood sam-
 at Im
perial College London Library on July 26, 2011
jid.oxfordjournals.org
Downloaded from
 
Arginase in HIV-Seropositive Patients • JID 2010:202 (1 August) • 383
Figure 7. Evidence that arginase-expressing cells in human immunodeficiency virus (HIV)–seropositive patients are neutrophils. Peripheral blood mono-
nuclear cells were isolated by density gradient from the blood of HIV-seropositive patients. The phenotype of arginase-expressing cells was determined
by flow cytometry (isotype control, 1.1%). Data are the results of 1 representative experiment of 6 independent experiments (A). The arginase 1 (ARG1)
mean fluorescence intensity (MFI) in CD15+ cells ( patients) is plotted against the level of arginase activity (B ). The percentage of CD15+ cells isnp 25
plotted against the level of arginase activity ( patients) (C ).np 25
ples. These results suggest that arginase-induced T cell hypo-
responsiveness is most pronounced locally. In the present study,
we measured the levels of arginase activity in PBMCs. The
anatomical reservoirs of HIV are defined by the tissue distri-
bution of target cells, that is, the gastrointestinal tract during
acute HIV infection and other peripheral lymphoid organs dur-
ing the chronic phase [32]. There are many more HIV-infected
cells in the lymph nodes than in the blood. Therefore, it is
possible that in our study, the enhanced levels of arginase ac-
tivity observed in the PBMCs of untreated HIV-seropositive
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patients are merely a reflection of strongly increased levels of
expression in local sites of HIV reservoirs such as the gastro-
intestinal track or the lymph nodes.
We identified the arginase-expressing cells in the PBMC frac-
tion as neutrophils. Activated granulocytes have been shown
to copurify with the PBMC fraction in peripheral blood samples
and are therefore called low-density granulocytes [33]. Their
sedimentation with PBMCs is likely due to in vivo activation
because it has been shown that receptor-mediated granulocyte
activation leads to changes in their sedimentation [33]. We had
also shown that the majority of arginase-expressing cells from
placentae are neutrophils that copurify with placental cells [6].
Human peripheral blood neutrophils constitutively express
high amounts of arginase 1 [9], and once liberated, this arginase
can profoundly suppress T cell activation in vitro [5]. In this
study, we found a clear correlation between the levels of argi-
nase activity and the frequency of CD15+ T cells, which suggests
that the enhanced levels of arginase activity observed in the
PBMC fraction of HIV-seropositive patients with high CD4+ T
cell counts might be due to higher frequencies of CD15+ cells.
We cannot exclude the possibility that a switch in the ratio of
T cells to neutrophils, rather then an absolute increase in the
number of neutrophils, could be responsible for the increase
in the level of arginase activity; however, when we exclude the
number of cells as a factor in the calculation of the levels of
arginase activity, our results clearly show that the levels of ar-
ginase activity are statistically significantly higher in HIV-se-
ropositive patients with low CD4+ T cell counts, compared with
HIV-seropositive patients with high CD4+ T cell counts. An
impairment of T cell functions by neutrophils has already been
demonstrated in HIV-seropositive patients [34].
Myeloid-derived suppressor cells have been extensively de-
scribed in mouse and human cancer; they also express high levels
of arginase and have been shown to have strong immunomod-
ulatory properties [4, 7, 8, 35, 36]. Interestingly, myeloid-derived
suppressor cells in renal cell carcinomas have recently been iden-
tified as a subpopulation of activated granulocytes [37], and it
is not clear whether myeloid-derived suppressor cells and low-
density granulocytes can be clearly functionally and phenotyp-
ically distinguished from normal human polymorphonuclear
cells.
The findings presented here suggest that high levels of arginase
activity might contribute to T cell dysfunction in HIV-seropos-
itive patients. A better understanding of the events that result in
the up-regulation of arginase and the subsequent down-regula-
tion of T cell responsiveness will improve our understanding of
the complex mechanisms that lead to progressive immune dys-
functions in patients with HIV infection and AIDS and provide
new targets to improve the efficacy of therapy.
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a b s t r a c t
Arginase-induced L-arginine deprivation is emerging as a keymechanism for the downreg-
ulationof immune responses.Wehypothesised that arginase activity increaseswithdisease
severity in HIV-seropositive patients. Our results show that peripheral blood mononuclear
cells (PBMCs) from23HIV-seropositive patientswith lowCD4+ T cell counts (≤350 cells/!l)
expressed significantly more arginase compared with 21 patients with high CD4+ T cell
counts. Furthermore,we founda significant associationbetween the twoprincipal prognos-
ticmarkers used tomonitor HIV disease (CD4+ T cell count and plasma viral load) and PBMC
arginase activity in antiretroviral therapy naïve patients but not in patients undergoing
therapy.
Crown Copyright © 2010 Published by Elsevier Ltd on behalf of Royal Society of
 Tropical Medicine and Hygiene. All rights reserved.
1. Introduction
HIV results in a chronic infection that progressively
impairs the immune system. Although depletion of CD4+ T
cells explainsmuch of the immunosuppression, the precise
mechanisms involved in the onset of immunopathology
during HIV infection have not yet been resolved.1
The metabolism of L-arginine by arginase is emerg-
ing as a crucial mechanism for the regulation of immune
responses. L-arginine has two principal metabolic fates;
either it can be metabolised by nitric oxide synthase
into nitric oxide or by arginase into ornithine and urea.
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Arginase has been shown to impair T cell responses by
reducing the bioavailability of L-arginine: high arginase
activity expressed by myeloid cells results in reduced
availability of extracellular L-arginine in themicroenviron-
ment. In turn, this decrease in L-arginine results in T cell
hyporesponsiveness.2–4
To test the hypothesis that arginase activity is increased
in HIV-seropositive (HIV+) patients and might contribute
to immune dysfunction and disease progression we mea-
sured the levels of arginase activity in peripheral blood
mononuclear cells (PBMCs) isolated from the blood of HIV+
patients.
2. Materials and methods
The duration of the study was from February 2008 to
December 2009 and a cohort of 44 HIV+ patients was
recruited from St Mary’s Hospital, London UK. Inclusion
criteria were (i) HIV+ by standard laboratory tests and (ii)
older than 18 years. From the patient’s hospital records
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it was determined whether the patient was receiving
antiretroviral therapy (ART). All subjects gave written,
informed consent before participation.
Plasma HIV-I viral RNA was quantified (Bayer Quan-
tiplex assay; Bayer Diagnostics, East Walpole, MA, USA).
The standard T lymphocyte markers, CD3, CD4 and CD8
were determined by flow cytometry.
Twenty millilitres of anticoagulated peripheral blood
was collected in EDTA tubes and PBMCs were isolated
by density gradient centrifugation on Histopaque®-1077
(Sigma Chemical Co., St. Louis, MO, USA).
The enzymatic activity of arginase was measured by
a colorimetric enzymatic assay as previously described.5
Arginase activity is expressed as mU per ml of blood.
Data were evaluated for statistical differences using a
two-tailed Mann-Whitney U test and for correlation using
Spearman’s rank test with GraphPad PRISM version 5.0
(Prism, San Diego, CA, USA).
3. Results
We subdivided our cohort of HIV+ patients into two
groups based on their CD4+ T cell count. Arginase activ-
ity in PBMCs isolated from 23 HIV+ patients with low
CD4+ T cell counts (≤350 cells/!l) was significantly
higher than that in 21 HIV+ patients with high CD4+ T
cell counts (median± SEM: 2.2±0.3 vs. 1.4±0.1 mU/ml
blood, respectively, P<0.001; Figure 1A). Moreover, we
founda statistically significant inverse correlationbetween
arginase activity andCD4+ T cell count (r=−0.59, P<0.001).
In addition, our results show that high viral load correlates
with high arginase activity (r=0.43, P=0.003).
Toassess the impactofARTonarginaseactivitywestrat-
ified the cohort into two groups. The 22 patients on ART
had a median (range) CD4+ T cell count of 475 (90–870)
and 21 of themhad an undetectable plasma viral load (<1.7
log10 copies/ml). The 22 patients not on ART had amedian
(range) CD4+ T cell count of 250 (0–800) and a median
(range) plasmaviral loadof 5.1 (2.66-5.67) log10 copies/ml.
Interestingly, a highly significant inverse correlation
was found between CD4+ T cell count and PBMC arginase
activity in untreated but not in treated patients (untreated:
r=−0.676, P<0.001 vs. treated: r=−0.231, P=0.301;
Figures 1B and C). In addition, a positive association
between plasma viral load and PBMC arginase activity was
found in untreated patients (r=0.47, P=0.03). As 21 of the
22 patients receiving ART had viral loads below detection
limits association between arginase activity and viral load
in these patients could not be calculated.
These results show that both low CD4+ T cell count
and high viral load correlate with high arginase activity in
untreated but not treated HIV+ patients.
4. Discussion
Our study reveals that arginase activity is significantly
higher in PBMCs from HIV+ patients with a low CD4+ T cell
count, compared with that in HIV+ patients with a high
CD4+ T cell count. Moreover, we found that in ART naïve
patients there is a significant association between high
PBMC arginase activity and both of the principal markers
Figure 1. Arginase activity in peripheral bloodmononuclear cells isolated
from44HIV-seropositivepatients. (A)Arginaseactivity in21patientswith
CD4+ T cell count >350 cells/!l and 23 patients with CD4+ T cell count
≤350 cells/!l; ***P<0.001. (B) Arginase activity and CD4+ T cell counts for
22 patients not on antiretroviral therapy (ART). (C) Arginase activity and
CD4+ T cell counts for 22 patients on ART.
of HIV disease progression, namely low CD4+ T cell count
and high plasma viral load. Therefore, we propose that the
higher arginase activity detected in PBMCs from advanced
untreated HIV+ patients may result in lower levels of L-
arginine, thereby causing dysregulation of T cell responses.
One potential consequence of L-arginine starvation is
altered T cell proliferation as it has been shown that
sub-physiological levels of L-arginine lead to G0-G1 cell
cycle arrest.4 A better understanding of the events result-
ing in the upregulation of arginase and the subsequent
downregulation of T cell responsiveness will improve our
understanding of the complex mechanisms leading to
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progressive immune dysfunction in HIV/AIDS and may
provide new targets to improve the efficacy of therapy.
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